WorldWideScience

Sample records for 7-days moxifloxacin based

  1. Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial

    Tomić Monika; Bakula Vinko; Kućišec Nastja; Belošić-Halle Željka; Majstorović Karolina; Bago Josip; Bago Petra; Troskot Rosana

    2010-01-01

    Abstract Introduction Antibiotic resistance decreases success of Helicobacter pylori (Hp) eradication. Recently published results show low rate of resistance and better compliance with moxifloxacin based regiments. Aims&methods Whether 7 days moxifloxacin with lansoprasole and amoxycillin can be compared with 10 days moxifloxacin with lansoprasole and amoxycillin according to moxifloxacin resistance. Patients with non-ulcer dyspepsia who had culture and histology positive Hp infection (n = 15...

  2. Moxifloxacin

    ... moxifloxacin, other quinolone or fluoroquinolone antibiotics such as ciprofloxacin (Cipro), gatifloxacin (Tequin) (not available in the U.S.), ... your doctor immediately or get emergency medical help: rash hives itching peeling or blistering of the skin ...

  3. Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis?

    Rosenthal, Ian M; Zhang, Ming; Almeida, Deepak; Jacques H Grosset; Eric L Nuermberger

    2008-01-01

    Rationale: Recent studies have demonstrated that combined substitutions of rifapentine for rifampin and moxifloxacin for isoniazid in the standard, daily, short-course regimen of rifampin, isoniazid, and pyrazinamide produces stable cure in 12 weeks or less. This study was designed to more precisely evaluate the contribution of moxifloxacin and isoniazid to rifapentine-based regimens.

  4. Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients

    Zvada, Simbarashe P.; Denti, Paolo; Sirgel, Frederick A.; Chigutsa, Emmanuel; Hatherill, Mark; Charalambous, Salome; Mungofa, Stanley; Wiesner, Lubbe; Simonsson, Ulrika S. H.; Jindani, Amina; Harrison, Thomas; McIlleron, Helen M.

    2014-01-01

    Pharmacokinetic exposure and the MIC of fluoroquinolones are important determinants of their efficacy against Mycobacterium tuberculosis. Population modeling was used to describe the steady-state plasma pharmacokinetics of moxifloxacin in 241 tuberculosis (TB) patients in southern Africa. Monte Carlo simulations were applied to obtain the area under the unbound concentration-time curve from 0 to 24 h (fAUC0–24) after daily doses of 400 mg or 800 mg moxifloxacin and 800 mg ofloxacin. The MIC d...

  5. Moxifloxacin Ophthalmic

    Moxifloxacin ophthalmic solution is used to treat bacterial conjunctivitis (pink eye; infection of the membrane that covers ... the eyeballs and the inside of the eyelids). Moxifloxacin is in a class of antibiotics called fluoroquinolones. ...

  6. Moxifloxacin Injection

    ... moxifloxacin, other quinolone or fluoroquinolone antibiotics such as ciprofloxacin (Cipro), gatifloxacin (Tequin) (not available in the U.S.), ... your doctor immediately or get emergency medical help: rash hives itching peeling or blistering of the skin ...

  7. Moxifloxacin Bayer.

    Barrett, J F

    2000-09-01

    Bayer has launched the fluorinated oxoquinolone, moxifloxacin, as a treatment for bacterial infection. It was launched in Germany for the treatment of respiratory tract infections in September 1999, and regulatory approval in the other EU member states was expected to be completed early in 2000, with marketing throughout the EU by the end of 2000 [336340,340358]. Moxifloxacin received FDA approval in December 1999 and it was launched in the same month [350407,350415,365913]. By July 2000, the drug had been launched in Japan [375976]. In February 1999, Lehman Brothers predicted 95% probabilities that moxifloxacin would reach the US and ex-US markets, and launch onto these market in 1999. Peak annual sales of US $500 million in 2005 (US) and US $800 million in 2007 (ex-US) are predicted [319225]. PMID:11249594

  8. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials

    G. Zhang

    2013-08-01

    Full Text Available Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitro and in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pylori treatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263. Pooled H. pylori eradication rates were 79.03% (95%CI: 75.73-82.07 and 68.33% (95%CI: 64.44-72.04 for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis. The odds ratio (OR was 1.82 (95%CI: 1.17-2.81, the occurrence of total side effects was 15.23% (95%CI: 12.58-18.20 and 27.17% (95%CI: 23.64-30.92 for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI: 0.26-0.77. In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR: 1.78, 95%CI: 1.16-2.73, P<0.001. However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection.

  9. Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations▿

    Dooley, Kelly; Flexner, Charles; Hackman, Judith; Peloquin, Charles A.; Nuermberger, Eric; Chaisson, Richard E.; Dorman, Susan E.

    2008-01-01

    Moxifloxacin- and rifapentine-based regimens are under investigation for the treatment of tuberculosis. However, rifapentine may induce enzymes that metabolize moxifloxacin, resulting in decreased moxifloxacin concentrations. In this phase I, two-period, sequential-design study, 13 subjects received 400 mg moxifloxacin daily for 4 days followed by daily moxifloxacin coadministered with 900 mg rifapentine thrice weekly. Pharmacokinetic analyses were performed after the 4th and 19th doses of mo...

  10. Moxifloxacin-warfarin interaction

    Ji, Yan; Hokayem, Youssef

    2012-01-01

    Two case reports presented here show elevated prothrombin time/international normalized ratios (PT/INR) following coadministration of warfarin and moxifloxacin. Although the underlying mechanism of this interaction still remains unclear, health care providers should be careful when prescribing moxifloxacin to patients on warfarin therapy, especially to patients with low albumin levels. More frequent monitoring of INR in these patients may be warranted.Keywords: warfarin; moxifloxacin; PT/INR;...

  11. Increased Moxifloxacin Utilization Associated with an Unrestricted Addition to a Drug Reimbursement Formulary: A Population-Based Analysis

    Alissa Jade Wright

    2014-01-01

    Full Text Available OBJECTIVES:To determine whether utilization of moxifloxacin, a broad-spectrum fluoroquinolone antibiotic, has changed since its addition to the British Columbia provincial formulary in 2009 and to determine whether utilization was guideline concordant.

  12. In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model▿

    Grossi, Olivier; Caillon, Jocelyne; Arvieux, Cedric; Jacqueline, Cedric; Bugnon, Denis; Potel, Gilles; Hamel, Antoine

    2007-01-01

    We investigated the efficacies of moxifloxacin, cloxacillin, and vancomycin in a rabbit model of Staphylococcus aureus arthritis. No significant difference between therapeutic regimens was observed after a 7-day treatment. Oral moxifloxacin could be a suitable alternative to standard parenteral therapy for S. aureus arthritis.

  13. Moxifloxacin-warfarin interaction

    Yan Ji

    2012-01-01

    Full Text Available Two case reports presented here show elevated prothrombin time/international normalized ratios (PT/INR following coadministration of warfarin and moxifloxacin. Although the underlying mechanism of this interaction still remains unclear, health care providers should be careful when prescribing moxifloxacin to patients on warfarin therapy, especially to patients with low albumin levels. More frequent monitoring of INR in these patients may be warranted.

  14. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

    Marcus B Conde

    Full Text Available The combination of rifapentine and moxifloxacin administered daily with other anti-tuberculosis drugs is highly active in mouse models of tuberculosis chemotherapy. The objective of this phase 2 clinical trial was to determine the bactericidal activity, safety, and tolerability of a regimen comprised of rifapentine, moxifloxacin, isoniazid, and pyrazinamide administered daily during the first 8 weeks of pulmonary tuberculosis treatment.Adults with sputum smear-positive pulmonary tuberculosis were randomized to receive either rifapentine (approximately 7.5 mg/kg plus moxifloxacin (investigational arm, or rifampin (approximately 10 mg/kg plus ethambutol (control daily for 8 weeks, along with isoniazid and pyrazinamide. The primary endpoint was sputum culture status at completion of 8 weeks of treatment.121 participants (56% of accrual target were enrolled. At completion of 8 weeks of treatment, negative cultures using Löwenstein-Jensen (LJ medium occurred in 47/60 (78% participants in the investigational arm vs. 43/51 (84%, p = 0.47 in the control arm; negative cultures using liquid medium occurred in 37/47 (79% in the investigational arm vs. 27/41 (66%, p = 0.23 in the control arm. Time to stable culture conversion was shorter for the investigational arm vs. the control arm using liquid culture medium (p = 0.03, but there was no difference using LJ medium. Median rifapentine area under the concentration-time curve (AUC0-24 was 313 mcg*h/mL, similar to recent studies of rifapentine dosed at 450-600 mg daily. Median moxifloxacin AUC0-24 was 28.0 mcg*h/mL, much lower than in trials where rifapentine was given only intermittently with moxifloxacin. The proportion of participants discontinuing assigned treatment for reasons other than microbiological ineligibility was higher in the investigational arm vs. the control arm (11/62 [18%] vs. 3/59 [5%], p = 0.04 although the proportions of grade 3 or higher adverse events were similar (5/62 [8%] in the

  15. Moxifloxacin: Clinically compatible contrast agent for multiphoton imaging

    Wang, Taejun; Jang, Won Hyuk; Lee, Seunghun; Yoon, Calvin J.; Lee, Jun Ho; Kim, Bumju; Hwang, Sekyu; Hong, Chun-Pyo; Yoon, Yeoreum; Lee, Gilgu; Le, Viet-Hoan; Bok, Seoyeon; Ahn, G.-One; Lee, Jaewook; Gho, Yong Song; Chung, Euiheon; Kim, Sungjee; Jang, Myoung Ho; Myung, Seung-Jae; Kim, Myoung Joon; So, Peter T. C.; Kim, Ki Hean

    2016-06-01

    Multiphoton microscopy (MPM) is a nonlinear fluorescence microscopic technique widely used for cellular imaging of thick tissues and live animals in biological studies. However, MPM application to human tissues is limited by weak endogenous fluorescence in tissue and cytotoxicity of exogenous probes. Herein, we describe the applications of moxifloxacin, an FDA-approved antibiotic, as a cell-labeling agent for MPM. Moxifloxacin has bright intrinsic multiphoton fluorescence, good tissue penetration and high intracellular concentration. MPM with moxifloxacin was demonstrated in various cell lines, and animal tissues of cornea, skin, small intestine and bladder. Clinical application is promising since imaging based on moxifloxacin labeling could be 10 times faster than imaging based on endogenous fluorescence.

  16. Evaluation of moxifloxacin-induced biochemical changes in mice

    Grace E Ukpo

    2012-01-01

    Full Text Available The aim of the present study was to investigate the toxicological effects of moxifloxacin in mice to determine the toxicological implications. Forty mice of both sexes were divided into four groups of 10 mice each, designated as A, B, C and D. Group A served as the control and received 2 ml of distilled water, while Groups B, C and D were orally administered 12.5, 25 and 50 mg/kg body weight of moxifloxacin once daily for 7 days, respectively. The weights of the mice were recorded before and throughout the duration of drug administration. Blood samples were collected for serum analysis. Total blood protein, cholesterol, triglyceride, creatinine, activities of aspartate transaminase, alanine transaminase and alkaline phosphatase, levels of high density lipoprotein-cholesterol and low density lipoprotein-cholesterol were assayed. There were significant ( P≤0.05 differences in the concentrations of serum creatinine, urea, aspartate transaminase, alanine transaminase and alkaline phosphatase, levels of high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, cholesterol and triglyceride of mice administered moxifloxacin. Serum level of total bilirubin in low dose treated animals was not significantly different from that of the control group animals, but there were significant dose dependent decrease in the animals treated with 25 mg/kg as well as 50 mg/kg. Data of the study indicate there was a dose dependent reduction in the protein metabolites, lipid profile and liver enzyme activities of mice administered moxifloxacin.

  17. Update on the Cardiac Safety of Moxifloxacin

    Haverkamp, Wilhelm; Kruesmann, Frank; Fritsch, Anna; van Veenhuyzen, David; Arvis, Pierre

    2012-01-01

    Cardiac safety was compared in patients receiving moxifloxacin and other antimicrobials in a large patient population from Phase II–IV randomized active-controlled clinical trials. Moxifloxacin 400 mg once-daily monotherapy was administered orally (PO) or sequentially (intravenous/oral, IV/PO). Across 64 trials, 21,298 patients received PO therapy (10,613 moxifloxacin, 10,685 comparators) while 6846 received sequential IV/PO therapy (3431 moxifloxacin, 3415 comparators). Treatment-emergent ca...

  18. Moxifloxacin Induced Acute Delirium with Visual Hallucinations

    Karagoz, Ergenekon; Ulcay, Asim; Budakli, Asil; Tutuncu, Recep

    2015-01-01

    AbstractA few reports accuse and implicate moxifloxacin as a contributor to delirium state.Here, we report the A 60-year-old female patient, who developed acute delirium with visual hallucinations following treatment with moxifloxacin for atypical pneumonia.   Key Words: Moxifloxacin, delirium, hallucination 

  19. Sustained Uptake of a Hospital-Based Handwashing with Soap and Water Treatment Intervention (Cholera-Hospital-Based Intervention for 7 Days [CHoBI7]): A Randomized Controlled Trial.

    George, Christine Marie; Jung, Danielle S; Saif-Ur-Rahman, K M; Monira, Shirajum; Sack, David A; Rashid, Mahamud-Ur; Mahmud, Toslim; Mustafiz, Munshi; Rahman, Zillur; Bhuyian, Sazzadul Islam; Winch, Peter J; Leontsini, Elli; Perin, Jamie; Begum, Farzana; Zohura, Fatema; Biswas, Shwapon; Parvin, Tahmina; Sack, R Bradley; Alam, Munirul

    2016-02-01

    Diarrhea is the second leading cause of death in children under 5 years of age globally. The time patients and caregivers spend at a health facility for severe diarrhea presents the opportunity to deliver water, sanitation, and hygiene (WASH) interventions. We recently developed Cholera-Hospital-Based Intervention for 7 days (CHoBI7), a 1-week hospital-based handwashing with soap and water treatment intervention, for household members of cholera patients. To investigate if this intervention could lead to sustained WASH practices, we conducted a follow-up evaluation of 196 intervention household members and 205 control household members enrolled in a randomized controlled trial of the CHoBI7 intervention 6 to 12 months post-intervention. Compared with the control arm, the intervention arm had four times higher odds of household members' handwashing with soap at a key time during 5-hour structured observation (odds ratio [OR]: 4.71, 95% confidence interval [CI]: 2.61, 8.49) (18% versus 50%) and a 41% reduction in households in the World Health Organization very high-risk category for stored drinking water (OR: 0.38, 95% CI: 0.15, 0.96) (58% versus 34%) 6 to 12 months post-intervention. Furthemore, 71% of observed handwashing with soap events in the intervention arm involved the preparation and use of soapy water, which was promoted during the intervention, compared to 9% of control households. These findings demonstrate that the hospital-based CHoBI7 intervention can lead to significant increases in handwashing with soap practices and improved stored drinking water quality 6 to 12 months post-intervention. PMID:26728766

  20. Heterogeneous photocatalysis of moxifloxacin in water: chemical transformation and ecotoxicity.

    Van Doorslaer, Xander; Haylamicheal, Israel Deneke; Dewulf, Jo; Van Langenhove, Herman; Janssen, Colin R; Demeestere, Kristof

    2015-01-01

    This work provides new insights on the impact of TiO2/UV catalyzed chemical transformation of moxifloxacin on ecotoxicity effects towards the green alga Pseudokirchneriella subcapitata. The moxifloxacin median effect concentration (EC-50=0.78 [0.56, 1.09] mg L(-1)), determined in accordance to the OECD 72-h growth inhibition test guideline, was 7 times lower than that of the older and widely used fluoroquinolone ciprofloxacin (EC-50=5.57 [4.86, 6.38] mg L(-1)). Applying heterogeneous photocatalysis as an advanced oxidation technique to degrade moxifloxacin in aqueous solution decreased the average growth inhibition from 72% to 14% after 150 min of treatment. No significant carbon mineralization was observed and liquid chromatography mass spectrometry analysis revealed the formation of 13 degradation products for which a chemical structure could be proposed based on accurate mass determination. Combined chemical and ecotoxicological analysis showed that as long as moxifloxacin is present in the reaction solution, it is the main compound affecting algal growth inhibition. However, also the contribution of the degradation products to the observed ecotoxicity cannot be neglected. Photocatalytically induced modifications of moxifloxacin mainly occur at the diazobicyclo-substituent as ring opening, oxidation into carbonyl groups, and hydroxylation. This results into the formation of more hydrophilic compounds with a decreased biological activity compared with moxifloxacin. The change in lipophilicity, and possibly a modified acid-base speciation, most probably also affect the cell membrane permeation of the degradation products, which might be another factor explaining the observed lower residual ecotoxicity of the photocatalytically treated reaction solutions. PMID:24735961

  1. Moxifloxacin Induced Seizures -A Case Report.

    Jiana Shi

    2014-09-01

    Full Text Available A 73-year-old female patient developed a generalized tonic-clonic seizure on the 6th day after treatment with moxifloxacin 400 mg daily intravenously for appendicitis. This patient had atrial fibrillation and history of a surgery for intracerebral hemorrhage, with impaired renal function and liver function, but without history of seizures. Moxifloxacin was discontinued and switched to cefuroxime. The patient remained seizure-free at discharge four days later. The naranjo adverse drug reaction probability scale score was 4, indicating a possible adverse reaction to moxifloxacin. The potential risk factors related to moxifloxacin-induced seizures are discussed. It highlights that preexisting central nervous system disease, elderly female with lower bodyweight and severe renal impairment may be the risk factors involved in moxifloxacin-induced seizures.

  2. In vivo 3D measurement of moxifloxacin and gatifloxacin distributions in the mouse cornea using multiphoton microscopy

    Lee, Seunghun; Lee, Jun Ho; Park, Jin Hyoung; Yoon, Yeoreum; Chung, Wan Kyun; Tchah, Hungwon; Kim, Myoung Joon; Kim, Ki Hean

    2016-05-01

    Moxifloxacin and gatifloxacin are fourth-generation fluoroquinolone antibiotics used in the clinic to prevent or treat ocular infections. Their pharmacokinetics in the cornea is usually measured from extracted ocular fluids or tissues, and in vivo direct measurement is difficult. In this study multiphoton microscopy (MPM), which is a 3D optical microscopic technique based on multiphoton fluorescence, was applied to the measurement of moxifloxacin and gatifloxacin distribution in the cornea. Intrinsic multiphoton fluorescence properties of moxifloxacin and gatifloxacin were characterized, and their distributions in mouse cornea in vivo were measured by 3D MPM imaging. Both moxifloxacin and gatifloxacin had similar multiphoton spectra, while moxifloxacin had stronger fluorescence than gatifloxacin. MPM imaging of mouse cornea in vivo showed (1) moxifloxacin had good penetration through the superficial corneal epithelium, while gatifloxacin had relatively poor penetration, (2) both ophthalmic solutions had high intracellular distribution. In vivo MPM results were consistent with previous studies. This study demonstrates the feasibility of MPM as a method for in vivo direct measurement of moxifloxacin and gatifloxacin in the cornea.

  3. Moxifloxacin Induced Seizures -A Case Report

    Jiana Shi; Huimin Xu

    2014-01-01

    Abstract A 73-year-old female patient developed a generalized tonic-clonic seizure on the 6th day after treatment with moxifloxacin 400 mg daily intravenously for appendicitis. This patient had atrial fibrillation and history of a surgery for intracerebral hemorrhage, with impaired renal function and liver function, but without history of seizures. Moxifloxacin was discontinued and switched to cefuroxime. The patient remained seizure-free at discharge four days later. The naranjo adverse drug...

  4. Safety and tolerability of moxifloxacin in the treatment of respiratory tract infections: a post-marketing surveillance conducted in Indonesia

    Arini Setiawati

    2005-03-01

    Full Text Available Moxifloxacin 400 mg tablet has been marketed in Indonesia for several indications, i.e. acute exacerbation of chronic bronchitis (AECB, community-acquired pneumonia (CAP, and acute bacterial sinusitis (ABS. To assess the safety and tolerability of moxifloxacin, a post-marketing surveillance study was conducted in the year 2001 involving 589 physicians. Clinical efficacy was also evaluated, both by physicians and patients, using a 6-symptom total score, which was scaled 0-12. A total of 1715 patients with acute sinusitis, CAP, AECB, and other infections were treated with oral moxifloxacin 400 mg once daily. There were 151 (8.8% patients with adverse events (AEs and 5 (0.29% patients with serious adverse events (SAEs that were considered related to moxifloxacin treatment. The most common adverse reactions were nausea (4.96%, dizziness (1.52%, vomiting (0.64%, headache (0.47%, and weakness (0.47%. Twenty three (1.34% patients discontinued treatment due to adverse events. Tolerance to treatment was rated very good and good by 647 (37.7% and 919 (53.6% of patients, respectively. Based on physicians’ clinical assessment, 57.7% of patients were cured and 39.9% were improved at the end of treatment. Mean total symptom score, as assessed by the patients, decreased from 6.43 on day-1 to 2.76 on day-3. Totally, 95.3% of patients felt better after receiving moxifloxacin and 97.6% of patients had good impression on moxifloxacin treatment. In conclusion, treatment of respiratory tract infections, mainly AECB, CAP and ABS, with moxifloxacin 400 mg once daily in this post-marketing surveillance was shown to be safe and well tolerated. Moxifloxacin was also shown to be highly effective in the treatment of these infections with rapid improvement of symptoms. (Med J Indones 2005; 14: 11-19Keywords : post-marketing survtillance, PMS, moxifloxacin, respiratory tract infections

  5. Moxifloxacin

    ... if it becomes available.See the FDA Drug Safety Communication (see http://1.usa.gov/1TdvrCk) for a ... BACKGROUND: The safety issues described in the Drug Safety Communication were also discussed at an FDA Advisory Committee ( ...

  6. Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy▿

    Pardillo, Fe Eleanor F.; Burgos, Jasmin; Fajardo, Tranquilino T.; Cruz, Eduardo Dela; Abalos, Rodolfo M.; Paredes, Rose Maria D.; Andaya, Cora Evelyn S.; Gelber, Robert H.

    2008-01-01

    In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P ≤ 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, sk...

  7. Bacteriostatic and Bactericidal Activities of Moxifloxacin against Coxiella burnetii

    Rolain, Jean-Marc; Maurin, Max; Raoult, Didier

    2001-01-01

    The in vitro activity of moxifloxacin against Coxiella burnetii was compared to those of pefloxacin, ofloxacin, and doxycycline. MICs of moxifloxacin ranged from 0.5 to 1 μg/ml for the Nine Mile, Priscilla, and Q212 strains. Moxifloxacin was not bactericidal against C. burnetii at 4 μg/ml.

  8. In vivo 3D measurement of moxifloxacin and gatifloxacin distributions in the mouse cornea using multiphoton microscopy

    Seunghun Lee; Jun Ho Lee; Jin Hyoung Park; Yeoreum Yoon; Wan Kyun Chung; Hungwon Tchah; Myoung Joon Kim; Ki Hean Kim

    2016-01-01

    Moxifloxacin and gatifloxacin are fourth-generation fluoroquinolone antibiotics used in the clinic to prevent or treat ocular infections. Their pharmacokinetics in the cornea is usually measured from extracted ocular fluids or tissues, and in vivo direct measurement is difficult. In this study multiphoton microscopy (MPM), which is a 3D optical microscopic technique based on multiphoton fluorescence, was applied to the measurement of moxifloxacin and gatifloxacin distribution in the cornea. I...

  9. Development and Validation of First Derivative Spectrophotometric Method for Simultaneous Estimation of Cefixime and Moxifloxacin in Synthetic Mixture

    Bhakti Patel

    2012-09-01

    Full Text Available A simple and economical first derivative spectrophotometric method has been developed for the simultaneous estimation of cefixime and moxifloxacin in their synthetic mixture. The method involved determination of Zero Crossing points (ZCP in their respective derivative spectra. By scanning first derivative spectra of cefixime and moxifloxacin, ZCP for cefixime was found to be at 289 nm and for moxifloxacin at 316.4 nm. For cefixime 316.4 nm and for moxifloxacin 289 nm was chosen as an analytical wavelength. The method involved solving of an equation based on measurement of absorbances at wavelengths 289 and 316.4 nm. The proposed method was found to be simple, economical, accurate, and reproducible for routine analysis of both drugs in tablet dosage form.

  10. Severe QT interval prolongation associated with moxifloxacin: a case report

    Koide, Tetsuro; Shiba, Masato; Tanaka, Katsuhiro; Muramatsu, Masatoshi; Ishida, Satoshi; Kondo, Yoshihiro; Watanabe, Keiko

    2008-01-01

    Introduction The QT interval prolongation is an adverse effect associated with moxifloxacin. This adverse effect can lead to potentially life-threatening arrhythmias such as Torsades de pointes. We describe a case of severe QT interval prolongation associated with moxifloxacin which may cause the development of Torsades de pointes. There have been no reported case of severe corrected QT interval prolongation caused by moxifloxacin in the patient of normal heart rate. Case presentation In an 8...

  11. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

    Nijland, H.M.J.; Ruslami, R.; Suroto, A.J.; Burger, D. M.; Alisjahbana, B.; van Crevel, R.; Aarnoutse, R E

    2007-01-01

    BACKGROUND: The long duration of the current tuberculosis (TB) treatment is demanding and warrants the development of new drugs. Moxifloxacin shows promising results and may be combined with rifampicin to shorten the duration of TB treatment. Rifampicin induces the phase II metabolic enzymes that are involved in the biotransformation of moxifloxacin. Therefore, the interaction between rifampicin and moxifloxacin should be investigated. PATIENTS AND METHODS: Nineteen Indonesian patients with p...

  12. HERG Protein Plays a Role in Moxifloxacin-Induced Hypoglycemia

    Hai-Yan Qiu; Sha-Sha Yuan; Fang-Yuan Yang; Ting-Ting Shi; Jin-Kui Yang

    2016-01-01

    The purpose of this study was to investigate the effect of moxifloxacin on HERG channel protein and glucose metabolism. HERG expression was investigated using immunohistochemistry. The whole-cell patch clamp method was used to examine the effect of moxifloxacin on HERG channel currents. A glucose tolerance test was used to analyze the effects of moxifloxacin on blood glucose and insulin concentrations in mice. Results show that HERG protein was expressed in human pancreatic β-cells. Moxifloxa...

  13. Penetration of Moxifloxacin into Peripheral Compartments in Humans

    Müller, Markus; Staß, Heino; Brunner, Martin; Möller, Jan G.; Lackner, Edith; Eichler, Hans G.

    1999-01-01

    To characterize the penetration of moxifloxacin (BAY 12-8039) into peripheral target sites, the present study aimed at measuring unbound moxifloxacin concentrations in the interstitial space fluid by means of microdialysis, an innovative clinical sampling technique. In addition, moxifloxacin concentrations were measured in cantharides-induced skin blisters, saliva, and capillary plasma and compared to total- and free-drug concentrations in venous plasma. For this purpose, 12 healthy volunteer...

  14. IR Camera Report for the 7 Day Production Test

    Holloway, Michael Andrew [Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

    2016-02-22

    The following report gives a summary of the IR camera performance results and data for the 7 day production run that occurred from 10 Sep 2015 thru 16 Sep 2015. During this production run our goal was to see how well the camera performed its task of monitoring the target window temperature with our improved alignment procedure and emissivity measurements. We also wanted to see if the increased shielding would be effective in protecting the camera from damage and failure.

  15. IR Camera Report for the 7 Day Production Test

    The following report gives a summary of the IR camera performance results and data for the 7 day production run that occurred from 10 Sep 2015 thru 16 Sep 2015. During this production run our goal was to see how well the camera performed its task of monitoring the target window temperature with our improved alignment procedure and emissivity measurements. We also wanted to see if the increased shielding would be effective in protecting the camera from damage and failure.

  16. Chitosan gel-embedded moxifloxacin niosomes: An efficient antimicrobial hybrid system for burn infection.

    Sohrabi, Shohreh; Haeri, Azadeh; Mahboubi, Arash; Mortazavi, Alireza; Dadashzadeh, Simin

    2016-04-01

    The purpose of this study was to prepare and characterize a hybrid system of moxifloxacin loaded niosomes incorporated into chitosan gel as a potential carrier for topical antimicrobial delivery. The prepared system was characterized regarding entrapment efficiency, particle size, zeta potential, in vitro drug release kinetics, morphology, FTIR analysis, bioadhesive strength and rheological behavior. The effect of different formulation parameters (surfactant type, surfactant to drug ratio, cholesterol percentage and loading methodology) on moxifloxacin entrapment and drug release was evaluated. The antibacterial effectiveness of various formulations was also assessed by measuring the minimal inhibitory concentrations, minimal bactericidal concentrations and agar diffusion assay using Pseudomonas aeruginosa and Staphylococcus aureus as model pathogens. The optimized niosomal formulation showed 73% drug entrapment, 47% drug release in 8h and was ∼290 nm in particle diameter and negatively charged (ζ∼-23 mV). The gel-embedded niosomes exhibited pseudo-plastic flow behavior and more sustained drug release profile compared to niosomes. The niosomal formulation of moxifloxacin was the most efficient system against P. aeruginosa, while gel based formulations were superior against S. aureus. Taken together, moxifloxacin-in-niosomes-in-gels hold great promise for topical microbial infections. PMID:26794314

  17. Moxifloxacin (Avelox) Induced Thrombotic Thrombocytopenic Purpura

    Surana, Sikander P.; Zahily Sardinas; Multz, Alan S.

    2012-01-01

    We report a case of a 66-year-old African-American female who presented with complaints of progressively worsening weakness, shortness of breath on minimal exertion, lethargy for the last few days, and short episodes of aphasia lasting 20–30 seconds. Prior to presentation, she was treated with two courses of moxifloxacin for sinusitis. Laboratory examination was remarkable for anemia and thrombocytopenia with elevated lactate dehydrogenase and no evidence of renal failure. Peripheral smear sh...

  18. Pharmacokinetics of Moxifloxacin in an Infant with Mycoplasma hominis Meningitis

    Watt, Kevin M; Massaro, Matthew M; Smith, Brian; Cohen-Wolkowiez, Michael; Benjamin, Daniel K; Laughon, Matthew M

    2012-01-01

    Treatment of Mycoplasma hominis meningitis in infants is limited by a lack of consensus regarding therapy and limited pharmacokinetic data for agents to which M. hominis is susceptible. We report the successful treatment of a premature infant with M. hominis meningitis with doxycycline and moxifloxacin and provide a pharmacokinetic profile of moxifloxacin.

  19. Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA

    Trieu, Lisa; Proops, Douglas C.; Shama D. Ahuja

    2015-01-01

    Contacts of persons infected with multidrug-resistant tuberculosis (MDR TB) have few prophylaxis options. Of 50 contacts of HIV- and MDR TB–positive persons who were treated with moxifloxacin, 30 completed treatment and 3 discontinued treatment because of gastrointestinal symptoms. Moxifloxacin was generally well-tolerated; further research of its efficacy against MDR TB is needed.

  20. Plasma Disposition of Conventional and Long-Acting Moxifloxacin in Sheep after Intravenous Administration

    C. M. Modi; S. K. Mody; Modi, F. D.; Patel, H. B.

    2012-01-01

    This study describes disposition of long-acting moxifloxacin and conventional formulations of moxifloxacin in sheep after intravenous administration in five male sheep. Long acting moxifloxacin solution (10% moxifloxacin in solution with L-arginine, N-butyl alcohol, and benzyl alcohol) and conventional moxifloxacin (10%) were injected in jugular vein. Blood samples were collected from contralateral jugular vein in test tubes containing 30–50 IU heparin (anticoagulant) periodically from 0.083 ...

  1. Skin Microcirculatory Dysfunction Induced by 7 Days of Dry Immersion

    Navasiolava, N. M.; Tsvirkun, D. V.; Pastushkova, L. Kh.; Larina, I. M.; Dobrokhotov, I. V.; Fortrat, J. O.; Gharib, G.; Gauquelin-Koch, G.; Custaud, M.-A.

    2008-06-01

    To study the effects of microgravity on the skin microcirculatory function, basal blood flow and stimulated vasodilation were determined at the calf level by laser Doppler flowmetry in 8 male subjects before, during and after 7 days of dry immersion. Endothelium-dependent and - independent vasodilation was assessed using iontophoresis of acetylcholine and sodium nitroprusside, respectively. Basal blood flow was significantly reduced on the third day of immersion (13 ± 1 arbitrary units (AU) vs. 33 ± 8 AU pre-immersion level, p Endothelium dependent vasodilation was significantly decreased on the seventh day of immersion in comparison with pre-immersion values (12 ± 6% vs. 29 ± 6% of max vasodilation, p < 0.05). Our results support the idea that dry immersion induces changes in skin microcirculation with impairment of endothelial functions. Microcirculatory impairment should be considered as an important factor of the cardiovascular deconditioning.

  2. Moxifloxacin in the Therapy of Experimental Pneumococcal Meningitis

    Schmidt, H.; Dalhoff, A.; Stuertz, K; Trostdorf, F.; Chen, V.; Schneider, O.; Kohlsdorfer, C.; BRÜCK, W.; Nau, R.

    1998-01-01

    The activity of moxifloxacin (BAY 12-8039) against a Streptococcus pneumoniae type 3 strain (MIC and minimum bactericidal concentration [MBC] of moxifloxacin, 0.06 and 0.25 μg/ml, respectively; MIC and MBC of ceftriaxone, 0.03 and 0.06 μg/ml, respectively) was determined in vitro and in a rabbit model of meningitis. Despite comparable bactericidal activity, 10 μg of moxifloxacin per ml released lipoteichoic and teichoic acids less rapidly than 10 μg of ceftriaxone per ml in vitro. Against exp...

  3. Drug-induced immune thrombocytopenia due to moxifloxacin

    Coker, Timothy J

    2013-01-01

    A 39-year-old woman with 1 day of oral petechiae, leg ecchymoses and epistaxis was found to have isolated thrombocytopenia. She had recently completed a 10-day course of moxifloxacin for an upper respiratory infection. On further questioning, she had developed thrombocytopenia 2 years earlier after a treatment course with moxifloxacin. After ruling out other causes, drug-induced immune thrombocytopenia due to moxifloxacin was diagnosed. Her platelets returned to normal range 15 days after fin...

  4. The role of moxifloxacin in tuberculosis therapy

    Stephen H. Gillespie

    2016-03-01

    Full Text Available Tuberculosis (TB remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate this treatment and discontinue therapy, increasing the risk of resistance. There is a growing tide of multidrug resistance and few effective antibiotics to tackle the problem. Since the turn of the millennium there has been a surge in interest in developing new therapies for TB and a number of new drugs have been developed. In this review the repurposing of moxifloxacin, an 8-methoxy-fluoroquinolone, for TB treatment is discussed. The evidence that underpins the development of this agent is reviewed. The results of the recently completed phase III trials are summarised and the reasons for the unexpected outcome are explored. Finally, the design of new trials that incorporate moxifloxacin, and that address both susceptible disease and multidrug resistance, is described.

  5. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI

    Chuchalin Alexander

    2013-01-01

    Full Text Available Abstract Background Acute exacerbations of chronic bronchitis (AECB, including chronic obstructive pulmonary disease (AECOPD, represent a substantial patient burden. Few data exist on outpatient antibiotic management for AECB/AECOPD in Eastern/South Eastern Europe, in particular on the use of moxifloxacin (Avelox®, although moxifloxacin is widely approved in this region based on evidence from international clinical studies. Methods AVANTI (AVelox® in Acute Exacerbations of chroNic bronchiTIs was a prospective, observational study conducted in eight Eastern European countries in patients > 35 years with AECB/AECOPD to whom moxifloxacin was prescribed. In addition to safety and efficacy outcomes, data on risk factors and the impact of exacerbation on daily life were collected. Results In the efficacy population (N = 2536, chronic bronchitis had been prevalent for > 10 years in 31.4% of patients and 66.0% of patients had concomitant COPD. Almost half the patients had never smoked, in contrast to data from Western Europe and the USA, where only one-quarter of COPD patients are non-smokers. The mean number of exacerbations in the last 12 months was 2.7 and 26.3% of patients had been hospitalized at least once for exacerbation. Physician compliance with the recommended moxifloxacin dose (400 mg once daily was 99.6%. The mean duration of moxifloxacin therapy for the current exacerbation (Anthonisen type I or II in 83.1%; predominantly type I was 6.4 ± 1.9 days. Symptom improvement was reported after a mean of 3.4 ± 1.4 days. After 5 days, 93.2% of patients reported improvement and, in total, 93.5% of patients were symptom-free after 10 days. In the safety population (N = 2672, 57 (2.3% patients had treatment-emergent adverse events (TEAEs and 4 (0.15% had serious TEAEs; no deaths occurred. These results are in line with the known safety profile of moxifloxacin. Conclusions A significant number of patients in this

  6. A comparison of 5 or 7 days of rabeprazole triple therapy for eradication of Helicobacter pylori

    Ari F. Syam

    2010-05-01

    Full Text Available Aim A combination of PPI and 1000 mg amoxicillin/500 mg clarithromycin twice daily for 2 weeks has been proven effective in the eradication of H. pylori. Most studies suggested that treatment for 7 and 10 days may be equally effective. Few data are available on the efficacy of 5-day triple therapy. Aim of this study was to compare 5-day and 7-day rabeprazole triple therapy for eradication of H. pylori infection.Methods We prospectively studied 60 consecutive H. pylori-infected patients who came to hospitals in six centres in Indonesia and who underwent upper endoscopy and biopsy. H. pylori infection was confirmed if two rapid urease tests (Pronto Dry and histology or urea breath test were positive. Patients were assigned to either an open-labelled 5-day or 7-day course of oral amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., and rabeprazole 10 mg b.i.d. (RAC. Four weeks after therapy, all patients had a repeated UBT for evaluation of the presence of H. pylori.Results Of the 60 patients (42 males and 18 females with mean age (± SD 47.63 ± 13.93 years, range 21–74 years, 25 patients (41.7% had 5-day treatment and 35 patients (58.3% had 7-day treatment. With 5-day treatment, 18 patients (72% and with 7-day treatment 32 patients (91.4% became negative for H. pylori infection. The eradication failure was found on 7 patients (28.0% in 5-day treatment and 3 patients (8.6% in 7-day treatment.Conclusions The study showed that the eradication of H. pylori infection by triple rabeprazole-based treatment in 7-day is still better than in 5-day. (Med J Indones 2010; 19:113-7Keywords: H. pylori, rabeprazole, triple therapy

  7. Cohort Study of Intracameral Moxifloxacin in Postoperative Endophthalmitis Prophylaxis

    Virgilio Galvis; Alejandro Tello; Mary Alejandra Sánchez; Paul Anthony Camacho

    2014-01-01

    We conducted a cohort study to evaluate post-cataract surgery endophthalmitis rates in relation to prophylactic intracameral moxifloxacin administration. A total of 2332 patients (2674 eyes) who underwent phacoemulsification by a single surgeon from January 2007 through December 2012 were included in the study. A total of 1056 eyes did not receive intracameral prophylactic moxifloxacin and the antibiotic was injected in 1618 eyes. The incidence of presumed postoperative endophthalmitis in the...

  8. Moxifloxacin in the treatment of skin and skin structure infections

    Guay, David RP

    2006-01-01

    Moxifloxacin is a recent addition to the fluoroquinolone class, differing from ciprofloxacin and other older agents in having much better in vitro activity against Gram-positive aerobes while retaining potent activity against Gram-negative aerobes. It is also active against the pathogens of human and animal bite wounds and those species of atypical mycobacteria associated with dermatologic infections. Its activity against anaerobes is quite variable. Moxifloxacin penetrates well into inflamma...

  9. Moxifloxacin: Clinically compatible contrast agent for multiphoton imaging

    Taejun Wang; Won Hyuk Jang; Seunghun Lee; Yoon, Calvin J.; Jun Ho Lee; Bumju Kim; Sekyu Hwang; Chun-Pyo Hong; Yeoreum Yoon; Gilgu Lee; Viet-Hoan Le; Seoyeon Bok; G-One Ahn; Jaewook Lee; Yong Song Gho

    2016-01-01

    Multiphoton microscopy (MPM) is a nonlinear fluorescence microscopic technique widely used for cellular imaging of thick tissues and live animals in biological studies. However, MPM application to human tissues is limited by weak endogenous fluorescence in tissue and cytotoxicity of exogenous probes. Herein, we describe the applications of moxifloxacin, an FDA-approved antibiotic, as a cell-labeling agent for MPM. Moxifloxacin has bright intrinsic multiphoton fluorescence, good tissue penetra...

  10. Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery.

    Zhou, Andrew Xingyu; Messenger, Wyatt Boyer; Sargent, Steven; Ambati, Balamurali Krishna

    2016-08-01

    The objective of this study is to evaluate the safety of undiluted 0.5 % intracameral moxifloxacin for postoperative endophthalmitis prophylaxis in cataract surgery patients without the use of additional postoperative topical antibiotics. All phacoemulsification cataract surgeries performed by a single surgeon (B.A.) at the John A. Moran Eye Center from June 2012 to May 2015 were reviewed retrospectively. From June 2012 to April 2014, patients were given topical 0.5 % moxifloxacin postoperatively. From May 2014 to May 2015, all patients were given moxifloxacin intracamerally with no antibiotics postoperatively. The follow-up period was 1 month after surgery. Preoperative visual acuity and postoperative visual acuity, corneal edema, and anterior chamber reaction were recorded and compared between the two groups. 384 cataract surgeries were performed during the study period. None of the 384 eyes in the study developed endophthalmitis. Of those 384 eyes, 222 were included in the study for analysis based on the inclusion and exclusion criteria. 131 were part of the topical antibiotic group and 91 were part of the intracameral group. The differences in uncorrected visual acuity at 1 day postoperatively (p = 0.595) and best corrected visual acuity at 1 month postoperatively (p = 0.099) were not statistically significant. Differences in corneal edema (p = 0.370) and anterior chamber reaction (p = 0.069) at 1 day postoperatively and corneal edema (p = 0.512) and anterior chamber reaction (p = 0.512) at 1 month postoperatively were also not statistically significant. Undiluted 0.5 % moxifloxacin can be safely injected intracamerally following cataract surgery without additional postoperative antibiotic prophylaxis to prevent endophthalmitis without adverse effects on patient outcomes. PMID:26577588

  11. Application of intracameral moxifloxacin to prevent endophthalmitis in cataract surgery

    Servet Cetinkaya

    2015-10-01

    Full Text Available AIM: To evaluate the safety and efficacy of intracameral moxifloxacin in preventing endophthalmitis after cataract surgery.METHODS:Sixty-five eyes of 65 patients underwent cataract surgery between January and June 2012. Some patients received intracameral moxifloxacin at the end of surgery, while others did not(controls. Pre- and postperative logarithm of the minimum angle of resolution(logMARbest corrected visual acuity(BCVA, intraocular pressure(IOP, corneal edema, and anterior chamber(ACstatus were examined.RESULTS: Thirty-three patients(19 males, 14 females; average age, 64.81±11.61y(range: 41-82yreceived moxifloxacin and 32 patients(15 males, 17 females; average age, 65.43±11.10y(range: 42-81ydid not. The differences in patient age(P=0.827and sex(P=0.396were insignificant. Preoperative BCVA was approximately 20/130 in both groups. After surgery, moxifloxacin and control patients had a BCVA of 20/25 and 20/23, respectively(P=0.160. Preoperative IOP was 14.93±2.77mmHg(range: 11-21mmHgin moxifloxacin patients and 15.06±2.42mm Hg(range: 12-21mmHgin controls(P=0.850. After surgery, IOP was not statistically different between two groups(moxifloxacin: 14.06±2.31(range: 10-19mmHg, controls: 14.03±2.36mmHg(range: 10-19mmHg, P=0.960. Slight differences in corneal edema(P=0.623and anterior chamber cell(P=0.726incidences between two groups were not statistically significant. CONCLUSION: Intracameral moxifloxacin is safe and effective in preventing endophtalmitis after cataract surgery.

  12. In Vitro Activities of Moxifloxacin, 127I-Moxifloxacin and 131I-Moxifloxacin Against Staphylococcus Aureus Biofilms

    Hasan Demiroğlu

    2015-02-01

    Full Text Available Objective: The aim of the study was to investigate the antimicrobial effect of Moxifloxacin (MXF, radio (Na131I and cold (K127I iodinated MXF on methicillin susceptible Staphylococcus aureus ATCC 35556 (MSSA biofilms. Methods: MXF was labeled with Na131I using the iodogen method. The optimum radiodination conditions for 131I-MXF was determined by thin-layer radio chromatography studies. Thin-layer radio chromatography (TLRC chromatograms were obtained by using Cyclone Plus Storage Phosphor System. The MICs of MXF, 127I-MXF and 131I-MXF were determined using the microdilution broth method according to CLSI criteria. Time kill curves were performed over 24 h using an inoculum of 2×105 (CFU/mL. Biofilms were grown in microtitre plates, dyed with crystal violet and the mean optical density (OD630 was used for quantification. Biofilms were incubated MXF, 127I-MXF and 131I-MXF at various concentration (0.03 to 64 µg/mL. Results: MXF was labeled with 131I iodogen method. 131I-MXF was obtained with high a yield 95±3%. The MIC values for MXF, 127I-MXF and 131I-MXF was 0.06 µg/mL. Bactericidal activity was demonstrated at 0.25 µg/mL 4 hour for MXF, 127I-MXF and 131I-MXF. At MIC levels, MXF, 127I-MXF and 131I-MXF was not showed a marked reduction of metabolic activity in the S. aureus biofilm. The ODs of biofilm after incubation with an increasing antibiotic concentration were significantly lower than the ODs of biofilms without antibiotic p≤005. The radiolabeled MXF was most effective than MXF, 127I-MXF in reducing the number of bacteria in biofilm. After 24 h incubation Log10 CFU/mL values for 32 µg/mL antibiotic concentration: Control, MXF, 127I-MXF and 131I-MXF were 9.5, 4.3, 4.8 and 3.1, respectively. Conclusion: 131I and 127I were used alone there was no penetration of the S. aureus biofilm and no damage. In contrast our results demonstrate that the radiolabeled Moxifloxacin (131I-MXF have potent anti-biofilm activity against S. aureus

  13. Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis

    Thee, Stephanie; Anthony J Garcia-Prats; Draper, Heather R.; McIlleron, Helen M.; Wiesner, Lubbe; Castel, Sandra; Schaaf, H Simon; Hesseling, Anneke C

    2014-01-01

    Moxifloxacin serum concentrations in children receiving multidrug-resistant tuberculosis treatment following an oral dose of 10 mg/kg were low. Human immunodeficiency virus infection was associated with lower moxifloxacin exposure. Moxifloxacin was generally well tolerated when taken for several months.

  14. Moxifloxacin Penetration in Bronchial Secretions of Mechanically Ventilated Patients with Pneumonia

    Leone, Marc; Albanèse, Jacques; Sampol-Manos, Emmanuelle; Simon, Nicolas; Lacarelle, Bruno; Bruguerolle, Bernard; Martin, Claude

    2004-01-01

    The pharmacokinetics of moxifloxacin was studied in 17 mechanically ventilated patients with pneumonia. Patients were given 400 mg of moxifloxacin intravenously. Blood samples and bronchial secretions were taken on days 1 and 4. A dose of 400 mg of moxifloxacin allows one to achieve efficient concentrations in bronchial secretions and plasma.

  15. Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine

    Zvada, Simbarashe P.; Denti, Paolo; Geldenhuys, Hennie; Meredith, Sandra; van As, Danelle; Hatherill, Mark; Hanekom, Willem; Wiesner, Lubbe; Simonsson, Ulrika S. H.; Jindani, Amina; Harrison, Thomas; McIlleron, Helen M.

    2012-01-01

    We described the population pharmacokinetics of moxifloxacin and the effect of high-dose intermittent rifapentine in patients with pulmonary tuberculosis who were randomized to a continuation-phase regimen of 400 mg moxifloxacin and 900 mg rifapentine twice weekly or 400 mg moxifloxacin and 1,200 mg rifapentine once weekly. A two-compartment model with transit absorption best described moxifloxacin pharmacokinetics. Although rifapentine increased the clearance of moxifloxacin by 8% during ant...

  16. Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin

    Koji Sugioka

    2009-10-01

    Full Text Available Koji Sugioka1, Masahiko Fukuda1, Shohei Komoto1, Motoki Itahashi1, Masakazu Yamada2, Yoshikazu Shimomura11Department of Ophthalmology, Kinki University School of Medicine, Osaka-Sayama City, Osaka, Japan; 2Division for Vision Research, National Institute of Sensory Organs, National Tokyo Medical Center, Tokyo, JapanPurpose: The objective of the study was to compare the intraocular penetration levels of the newer fluoroquinolones, moxifloxacin, gatifloxacin, and levofloxacin in the rabbit’s cornea, aqueous humor, and conjunctiva after topical instillation.Methods: 0.5% moxifloxacin, 0.3% gatifloxacin, and 0.5% levofloxacin were instilled in random sequence in both eyes of nine New Zealand White rabbits at two-minute intervals. Instillation was repeated every 15 minutes for a total of three drops of each fluoroquinolone per eye. Three additional animals had only moxifloxacin instilled bilaterally using the same schedule. Sixty minutes after the final instillation, the rabbits were sacrificed for determination of corneal, aqueous humor, and conjunctival fluoroquinolone concentrations using highperformance liquid chromatography.Results: Moxifloxacin achieved significantly higher concentrations than levofloxacin and gatifloxacin in the cornea (P = 0.0102 and P = 0.0006, respectively, aqueous humor (P = 0.0015 and P < 0.0001, respectively, and conjunctiva (P = 0.0191 and P = 0.0236, respectively. Conclusions: 0.5% moxifloxacin eyedrops provided superior intraocular penetration in rabbits’ eyes compared with the two other fluoroquinolones, 0.5% levofloxacin and 0.3% gatifloxacin.Keywords: fluoroquinolone, gatifloxacin, levofloxacin, moxifloxacin, penetration, rabbit

  17. Activity of and Resistance to Moxifloxacin in Staphylococcus aureus

    Ince, Dilek; Zhang, Xiamei; Hooper, David C.

    2003-01-01

    Moxifloxacin has enhanced potency against Staphylococcus aureus, lower propensity to select for resistant mutants, and higher bactericidal activity against highly resistant strains than ciprofloxacin. Despite similar activity against purified S. aureus topoisomerase IV and DNA gyrase, it selects for topoisomerase IV mutants, making topoisomerase IV the preferred target in vivo.

  18. Moxifloxacin dosing in post-bariatric surgery patients

    Colin, Pieter; Eleveld, Douglas J.; Struys, Michel M. R. F.; T'Jollyn, Huybrecht; Van Bortel, Luc M.; Ruige, Johannes; De Waele, Jan; Van Bocxlaer, Jan; Boussery, Koen

    2014-01-01

    Introduction Given the ever increasing number of obese patients and obesity related bypass surgery, dosing recommendations in the post-bypass population are needed. Using a population pharmacokinetic (PK) analysis and PK-pharmacodynamic (PD) simulations, we investigated whether adequate moxifloxacin

  19. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

    Nijland, H.M.J.; Ruslami, R.; Suroto, A.J.; Burger, D.M.; Alisjahbana, B.; Crevel, R. van; Aarnoutse, R.E.

    2007-01-01

    BACKGROUND: The long duration of the current tuberculosis (TB) treatment is demanding and warrants the development of new drugs. Moxifloxacin shows promising results and may be combined with rifampicin to shorten the duration of TB treatment. Rifampicin induces the phase II metabolic enzymes that ar

  20. Safety of Moxifloxacin following repeated intramuscular administration in Wistar rats

    K.A. Sadariya

    Full Text Available Moxifloxacin is a novel fourth generation fluoroquinolone with broad spectrum of antibacterial activity. The study was conducted to evaluate the safety of Moxifloxacin (5.0 mg/kg after repeated intramuscular administration at 24 h interval for 14 days in male and female wistar rats. Hematological (Haemoglobin, RBC, WBC, MCV, MCH, MCHC, HCT and DLC, blood biochemical parameters (AST, ALT, ALP, Total Bilirubin, Total Serum Protein, Serum Albumin, Globulin, Serum Creatinine, Urea, Uric acid and Blood glucose and histopathological examination of various tissues were carried out in the present study. Male and female animals of any group did not reveal any clinical symptoms and mortality attributable to the 14 days intramuscular administration of Moxifloxacin. The data were compared by unpaired two tail `t` test using Graph Pad Prism (Version 4.00. All above hematological and blood biochemical parameters were found to fluctuate within normal range during treatment period and the mean values were not significantly differ (p < 0.05 from corresponding control values. Moreover, no gross or microscopic changes were found in the liver, kidney, heart, spleen, stomach, intestine and joint cartilages of the treated wistar rats. Results indicate that daily administration of Moxifloxacin for 14 days seems to be safe and well tolerated in rats. [Veterinary World 2010; 3(10.000: 449-452

  1. Impairment of IFN-gamma response to synthetic peptides of Mycobacterium tuberculosis in a 7-day whole blood assay.

    Hannah Priyadarshini Gideon

    Full Text Available Studies on Mycobacterium tuberculosis (MTB antigens are of interest in order to improve vaccine efficacy and to define biomarkers for diagnosis and treatment monitoring. The methodologies used for these investigations differ greatly between laboratories and discordant results are common. The IFN-gamma response to two well characterized MTB antigens ESAT-6 and CFP-10, in the form of recombinant proteins and synthetic peptides, was evaluated in HIV-1 uninfected persons in both long-term (7 day and 24 hour, commercially available QuantiFERON TB Gold in Tube (QFT-GIT, whole blood assays. Our findings showed differences in the IFN-gamma response between 24 hour and 7 day cultures, with recombinant proteins inducing a significantly higher response than the peptide pools in 7 day whole blood assays. The activity of peptides and recombinant proteins did not differ in 24 hour whole blood or peripheral blood mononuclear cell (PBMC based assays, nor in the ELISpot assay. Further analysis by SELDI-TOF mass spectrometry showed that the peptides are degraded over the course of 7 days of incubation in whole blood whilst the recombinant proteins remain intact. This study therefore demonstrates that screening antigenic candidates as synthetic peptides in long-term whole blood assays may underestimate immunogenicity.

  2. DEVELOPMENT OF COMPOSITION OF INFUSION MEDICATION ON BASIS OF MOXIFLOXACIN

    Almakaeva L.G.

    2015-05-01

    Full Text Available Application of fluoroquinolones covers by experience of treatment more than 800 million patients, and presently they are one of basic classes in the antimicrobial arsenal of practical medicine. Such achievements became possible after the clear understanding of intercommunication of structure and activity of molecules of this class of antibiotics. This knowledge became the basis for the synthesis of new derivatives with a wide range, powerful activity and improved pharmacokinetic profile for the best clinical outcome. Moxifloxacin is 8-methoxyfluoroquinolon of wide spectrum which interacts mainly with DNA gyrase of gram-negative and with topoisomerase of IV type of gram-positive bacteria. He has the extended activity against gram-positive cocci, however keeps activity against gram-negative bacteria. Moxifloxacin also has good activity against atypical respiratory pathogens (Legionella of pneumophila, Chlamydia of pneumoniae and Mycoplasma of pneumoniae. Another his feature is high anti-anaerobic activity. Therefore development of domestic medication with Moxifloxacin - a fluoroquinolone 4 generations - is actual. Materials and methods Research material was a substance of Moxifloxacin hydrochloride, produced by firm «Sansh Biotech Pvt. Ltd.», India, a dosage form on the basis of Moxifloxacin - solution for infusion. Qqualitative and quantitative control of samples of the drug were conducted on parameters which characterize stability: рН, content of active substance, transparency, colour, related impurities, mechanical inclusions on methods, which are described in SPhU. Results and Discussion Proposed the drug is antibiotic of wide spectrum of action of fluoroquinolone. Moxifloxacin hydrochloride is powder pale yellow with slightly hygroscopic nature. He moderately dissolve in water and methanol, poorly will dissolve in hydrochloric acid and ethanol, and practically will not dissolve in an acetone and toluene. рН 0,2 % solution is in a range

  3. The Effects of Moxifloxacin on QTc Interval in Healthy Korean Male Subjects

    Moon, Seol Ju; Lee, Jongtae; An, Hyungmi; Yim, Dong-Seok; Chung, Jae-Yong; Yu, Kyung-Sang; Cho, Joo-Youn; Lim, Kyoung Soo

    2014-01-01

    Background and objective Moxifloxacin 400 mg is a widely used positive control in thorough QT (TQT) studies, but its QT-prolonging effects in Korean subjects have not been studied. The present study was conducted to collect pilot data in Korean subjects after moxifloxacin administration to evaluate the adequacy of moxifloxacin as a positive control. Methods Thirty-eight, healthy, Korean, male subjects were recruited for pharmacokinetic (PK) blood sampling and electrocardiography (ECG) recordi...

  4. Simultaneous determination of moxifloxacin and cefixime by first and ratio first derivative ultraviolet spectrophotometry

    Attimarad Mahesh; Al-Dhubiab Bander E; Alhaider Ibrahim A; Nair Anroop B; N Sree; K Mueen

    2012-01-01

    Abstract Background The new combination of moxifloxacin HCl and cefixime trihydrate is approved for the treatment of lower respiratory tract infections in adults. At initial formulation development and screening stage a fast and reliable method for the dissolution and release testing of moxifloxacin and cefixime were highly desirable. The zero order overlaid UV spectra of moxifloxacin and cefixime showed >90% overlapping. Hence, simple, accurate precise and validated two derivative spectropho...

  5. In Vitro Postantibiotic Effects of Rifapentine, Isoniazid, and Moxifloxacin against Mycobacterium tuberculosis

    Chan, Chiu-Yeung; Au-Yeang, Carrie; Yew, Wing-Wai; Leung, Chi-Chiu; Cheng, Augustine F. B.

    2004-01-01

    Postantibiotic effects (PAEs) of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis ATCC 27294 were studied using a radiometric culture system. Rifapentine at 20 mg/liter gave the longest PAE (104 h) among the drugs used alone. The combinations of rifapentine plus isoniazid, rifapentine plus moxifloxacin, and isoniazid plus moxifloxacin gave PAEs of 136.5, 59.0, and 8.3 h, respectively.

  6. Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study

    Pletz, Mathias W. R.; De Roux, Andres; Roth, Andreas; NEUMANN, Karl-Heinz; Mauch, Harald; Lode, Hartmut

    2004-01-01

    Moxifloxacin is the most active fluoroquinolone against Mycobacterium tuberculosis in vitro. However, data about the efficacy in patients are not available. We enrolled 17 patients with tuberculosis in a prospective, randomized study. After 5 days of monotherapy with either moxifloxacin or isoniazid, we detected significant decreases in mean CFU per milliliter in sputum in both groups. The calculated early bactericidal activities for isoniazid and moxifloxacin were 0.209 and 0.273 log10 CFU p...

  7. Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections

    Darlene Miller

    2008-01-01

    Darlene MillerAbrams Ocular Microbiology Laboratory, Bascom Palmer Eye Institute, Anne Bates Leach Eye Hospital, Miller School of Medicine-University of Miami, FL, USAAbstract: Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox®) is the ocular formulation/adaptation of moxifloxacin. Moxifloxacin is a broad spectrum 8-methoxyfluoroquinolone which terminates bacterial growth by binding to DNA gyrase (topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved ...

  8. Comparison of the In Vitro Efficacies of Moxifloxacin and Amoxicillin against Listeria monocytogenes▿ †

    Grayo, S.; Join-Lambert, O.; Desroches, M. C.; Le Monnier, A.

    2008-01-01

    Listeria monocytogenes is a facultative intracellular bacterium that causes severe infections associated with a high mortality rate. Moxifloxacin presents extended activity against gram-positive bacteria and has recently been suggested to be a potential alternative in the treatment of listeriosis. We evaluated the in vitro efficacy of moxifloxacin against L. monocytogenes using a combination of epidemiological and experimental approaches. The median MIC of moxifloxacin for a large collection ...

  9. In Vitro Activities of Moxifloxacin and Other Fluoroquinolones against Mycoplasma pneumoniae

    Hamamoto, Kumiko; Shimizu, Takashi; Fujimoto, Naoyuki; Zhang, Ye; Arai, Sumio

    2001-01-01

    A total of 105 isolates of Mycoplasma pneumoniae were evaluated for susceptibility to moxifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin. Moxifloxacin, a newly synthesized compound, showed the greatest activity. The MICs and MBCs at which 50 and 90% of isolates were affected were 0.15 (MIC50 and MBC50) and 0.3 μg/ml (MIC90 and MBC90) respectively. The results indicate that moxifloxacin might be promising an antimycoplasmal agent.

  10. Moxifloxacin Retains Antimycobacterial Activity in the Presence of gyrA Mutations

    McGrath, Marieta; Gey van Pittius, Nico C.; Sirgel, Frederick A.; van Helden, Paul D.; Warren, Robin M

    2014-01-01

    Moxifloxacin-resistant Mycobacterium tuberculosis mutants were selected in vitro using different concentrations of moxifloxacin. gyrA mutations at codons 88 and 94 were associated with resistance (defined as an MIC of ≥2 μg/ml) (P < 0.0001 and P = 0.0053, respectively). Despite the presence of gyrA mutations, moxifloxacin significantly impedes bacterial growth, supporting its use for the treatment of ofloxacin-resistant M. tuberculosis.

  11. Synthesis, characterization and antimicrobial investigation of some moxifloxacin metal complexes

    Sadeek, Sadeek A.; El-Shwiniy, Walaa H.; El-Attar, Mohamed S.

    2011-12-01

    The new complexes of moxifloxacin (MOX), with Ti(IV), Y(III), Pd(II) and Ce(IV) have been synthesized. These complexes were then characterized by melting point, magnetic studies and spectroscopic techniques involving infrared spectra (IR), UV-Vis, 1H NMR. C, H, N and halogen elemental analysis and thermal behavior of complexes also investigated. The results suggested that the molar ratio for all complexes is M: MOX = 1:2 where moxifloxacin acts as a bidentate via one of the oxygen atoms of the carboxylate group and through the ring carbonyl group and the complexes have the following formula [Ti(MOX) 2](SO 4) 2·7H 2O, [Y(MOX) 2Cl 2]Cl·12H 2O, [Pd(MOX) 2(H 2O) 2]Cl 2·6H 2O and [Ce(MOX) 2](SO 4) 2·2H 2O. The activation energies, E*, enthalpies, Δ H*, entropies, Δ S* and Gibbs free energies, Δ G*, of the thermal decomposition reactions have been derived from thermogravimetric (TGA) and differential thermogravimetric (DrTG) curves, using Coats-Redfern (CR) and Horowitz-Metzger (HM) methods. The antimicrobial activity of these complexes has been evaluated against three Gram-positive and three Gram-negative bacteria and compared with the reference drug moxifloxacin. The antibacterial activity of Ti(IV) complex is significant for E. coli K32 and highly significant for S. aureus K1, B. subtilis K22, Br. otitidis K76, P. aeruginosa SW1 and K. oxytoca K42 compared with free moxifloxacin.

  12. Evaluation of Moxifloxacin, a New 8-Methoxyquinolone, for Treatment of Meningitis Caused by a PenicillinResistant Pneumococcus in Rabbits

    Østergaard, Christian; Klitmøller Sørensen, Tina; Dahl Knudsen, Jenny; Frimodt-Møller, Niels

    1998-01-01

    Moxifloxacin is a new 8-methoxyquinolone with high activity against gram-positive bacteria, including penicillin-resistant pneumococci. In an experimental meningitis model, we studied the pharmacokinetics of moxifloxacin in infected and uninfected rabbits and evaluated the antibiotic efficacies of moxifloxacin, ceftriaxone, and vancomycin against a penicillin-resistant Streptococcus pneumoniae strain (penicillin, ceftriaxone, vancomycin, and moxifloxacin MICs were 1, 0.5, 0.5, and 0.125 μg/ml...

  13. Susceptibilities of Campylobacter jejuni Isolates from Germany to Ciprofloxacin, Moxifloxacin, Erythromycin, Clindamycin, and Tetracycline

    Wagner, Jutta; Jabbusch, Miriam; Eisenblätter, Martin; Hahn, Helmut; Wendt, Constanze; Ignatius, Ralf

    2003-01-01

    To elucidate Campylobacter jejuni resistance to antibiotics in Germany, MICs of ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline were determined (using agar dilution) for 144 clinical isolates. The data indicate a considerable ciprofloxacin resistance (45.1%) without a clonal relationship of the strains and a greater in vitro activity of moxifloxacin, erythromycin, and clindamycin.

  14. Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and Levofloxacin

    Li, Xinying; Zhao, Xilin; Drlica, Karl

    2002-01-01

    With Streptococcus pneumoniae, moxifloxacin was 4- and 10-fold more effective than levofloxacin at restricting selection of resistant mutants and at killing resistant mutants, respectively. The selection frequency for first-step topoisomerase mutants was 1,000 times lower for moxifloxacin than for levofloxacin; this difference was lost when second-step mutants were selected.

  15. Moxifloxacin Lethality against Mycobacterium tuberculosis in the Presence and Absence of Chloramphenicol

    Malik, Muhammad; Drlica, Karl

    2006-01-01

    The C-8-methoxy fluoroquinolone moxifloxacin was more lethal against chloramphenicol-treated Mycobacterium tuberculosis than Bay y3114, a C-8-H cognate of moxifloxacin, and two C-8-methoxy fluoroquinolones, gatifloxacin and BMS-433368, which have different C-7 substituents. Thus, an optimal combination of C-7 and C-8 substituents is likely to be important for killing nongrowing M. tuberculosis.

  16. Effects of Subinhibitory Concentrations of Antibiotics on Colonization Factor Expression by Moxifloxacin-Susceptible and Moxifloxacin-Resistant Clostridium difficile Strains▿

    Denève, Cécile; Bouttier, Sylvie; Dupuy, Bruno; Barbut, Frédéric; Collignon, Anne; Janoir, Claire

    2009-01-01

    Recent outbreaks of Clostridium difficile infection have been related to the emergence of the NAP1/027 epidemic strain. This strain demonstrates increased virulence and resistance to the C-8-methoxyfluoroquinolones gatifloxacin and moxifloxacin. These antibiotics have been implicated as major C. difficile infection-inducing agents. We investigated by real-time reverse transcription-PCR the impact of subinhibitory concentrations of ampicillin, clindamycin, ofloxacin, and moxifloxacin on the ex...

  17. Simultaneous determination of moxifloxacin and cefixime by first and ratio first derivative ultraviolet spectrophotometry

    Attimarad Mahesh

    2012-09-01

    Full Text Available Abstract Background The new combination of moxifloxacin HCl and cefixime trihydrate is approved for the treatment of lower respiratory tract infections in adults. At initial formulation development and screening stage a fast and reliable method for the dissolution and release testing of moxifloxacin and cefixime were highly desirable. The zero order overlaid UV spectra of moxifloxacin and cefixime showed >90% overlapping. Hence, simple, accurate precise and validated two derivative spectrophotometric methods have been developed for the determination of moxifloxacin and cefixime. Methods In the first derivative spectrophotometric method varying concentration of moxifloxacin and cefixime were prepared and scanned in the range of 200 to 400 nm and first derivative spectra were calculated (n = 1. The zero crossing wavelengths 287 nm and 317.9 nm were selected for determination of moxifloxacin and cefixime, respectively. In the second method the first derivative of ratio spectra was calculated and used for the determination of moxifloxacin and cefixime by measuring the peak intensity at 359.3 nm and 269.6 nm respectively. Results Calibration graphs were established in the range of 1–16 μg /mL and 1–15 μg /mL for both the drugs by first and ratio first derivative spectroscopic methods respectively with good correlation coefficients. Average accuracy of assay of moxifloxacin and cefixime were found to be 100.68% and 98 93%, respectively. Relative standard deviations of both inter and intraday assays were less than 1.8%. Moreover, recovery of moxifloxacin and cefixime was more than 98.7% and 99.1%, respectively. Conclusions The described derivative spectrophotometric methods are simple, rapid, accurate, precise and excellent alternative to sophisticated chromatographic techniques. Hence, the proposed methods can be used for the quality control of the cited drugs and can be extended for routine analysis of the drugs in formulations.

  18. Uptake and Intracellular Activity of Moxifloxacin in Human Neutrophils and Tissue-Cultured Epithelial Cells

    Pascual, Alvaro; García, Isabel; Ballesta, Sofía; Perea, Evelio J.

    1999-01-01

    The penetration by moxifloxacin of human neutrophils (polymorphonuclear leukocytes [PMN]) and tissue-cultured epithelial cells (McCoy cells) was evaluated by a fluorometric assay. At extracellular concentrations of 5 mg/liter, the cellular-to-extracellular concentration ratios (C/E) of moxifloxacin in PMN and McCoy cells were 10.9 ± 1.0 and 8.7 ± 1.0, respectively (20 min; 37°C). The uptake of moxifloxacin by PMN was rapid, reversible, nonsaturable (at extracellular concentrations ranging fro...

  19. Orally administered moxifloxacin prolongs QTc in healthy Chinese volunteers: a randomized, single-blind, crossover study

    Chen, Qian; Liu, Yan-Mei; Liu, Yun; Mendzelevski, Boaz; Chanter, Dennis; Pu, Hua-hua; Liu, Gang-yi; Weng, Onglee; Hu, Chao-Ying; Wang, Wei; Yu, Chen; Jia, Jing-Ying

    2015-01-01

    Aim: To investigate the QT/QTc effects of orally administered moxifloxacin in healthy Chinese volunteers. Methods: This was a single-blinded, randomized, single-dose, placebo-controlled, two-period cross-over study. A total of 24 healthy Chinese volunteers were enrolled, randomly assigned to two groups: one group received moxifloxacin (400 mg, po) followed by placebo with a 7-d interval, another group received placebo followed by moxifloxacin with a 7-d interval. On the days of dosing, 12-lea...

  20. Reproductive and Developmental Effects of Moxifloxacin on Female Mice and Embryos

    Hanaa M. Roshdy

    2004-01-01

    Moxifloxacin (Avelox®) is a fluoroquinolone antibiotic with a broad spectrum of activity and bactericidal action. Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative organisms. The safe use of moxifloxacin in human pregnancy has not been established. In order to evaluate the genotoxic and embryo toxic effects of (Avelox)® during pregnancy, Avelox was administrated orally to female mice with doses (8.7, 17 and 26 mg/kg/day) from 1 to 17 days of pregnancy....

  1. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.

    Saravolatz, Louis D; Leggett, James

    2003-11-01

    Gatifloxacin, gemifloxacin, and moxifloxacin are the newest fluoroquinolones and show excellent in vitro activity against a wide variety of respiratory tract pathogens, many gram-negative aerobic organisms, and Bacteroides fragilis. These agents may be administered as oral and/or intravenous formulations with excellent bioavailability. The pharmacodynamics of these 3 new fluoroquinolones is more favorable than that of levofloxacin or ciprofloxacin for Streptococcus pneumoniae. All 3 agents are approved for the treatment of acute exacerbation of chronic bronchitis and community-acquired pneumonia. In addition, gatifloxacin and moxifloxacin are approved for the treatment of sinusitis. The toxicity of these 3 agents appears to be similar to that of the other fluoroquinolones in terms of gastrointestinal and central nervous system disturbances. All 3 agents have a low risk of phototoxicity, but gemifloxacin is associated with an increased risk of skin rash that is not a photoreaction. These agents can be useful for treatment of bacterial respiratory tract infections in patients who are allergic to beta-lactams, but caution must be exercised to avoid the potential for selection of widespread resistance, which may occur with indiscriminate use. PMID:14557966

  2. Huge congenital cervical immature teratoma mimicking lymphatic malformation in a 7-day-old male neonate

    Jihoon Jang; Jinyoung Park

    2016-01-01

    Most cervical teratomas are benign. However, because of their location and size, these neoplasms cause airway obstruction, and the prognosis of patients is poor if left untreated. Early diagnosis by antenatal ultrasound, airway management, and a multidisciplinary team approach to treatment are therefore necessary. This report describes a 7-day-old male neonate who presented at our institution with a huge neck mass that was treated by surgical excision.

  3. Influence of dose per fraction on 7 days per week fractionation in radiotherapy

    To evaluate the effect of the dose per fraction in a radiotherapy schedule of 7 fractions per week and compare it with a conventional one of 5fr/w, 2Gy/fr, we use computer simulations methods taking into account the tumor proliferation. We have a significant increase of TCP with regard to the conventional schedule for 7 days per week programmes in which the dose per fraction is =1.7 Gy. (author)

  4. Huge congenital cervical immature teratoma mimicking lymphatic malformation in a 7-day-old male neonate

    Jihoon Jang

    2016-05-01

    Full Text Available Most cervical teratomas are benign. However, because of their location and size, these neoplasms cause airway obstruction, and the prognosis of patients is poor if left untreated. Early diagnosis by antenatal ultrasound, airway management, and a multidisciplinary team approach to treatment are therefore necessary. This report describes a 7-day-old male neonate who presented at our institution with a huge neck mass that was treated by surgical excision.

  5. In vitro function of random donor platelets stored for 7 days in composol platelet additive solution

    Gupta Ashish

    2011-01-01

    Full Text Available Background and Aim: Platelets are routinely isolated from whole blood and stored in plasma for 5 days. The present study was done to assess the in vitro function of random donor platelets stored for 7 days in composol platelet additive solution at 22°C. Materials and Methods: The study sample included 30 blood donors of both sex in State Blood Bank, CSM Medical University, Lucknow. Random donor platelets were prepared by platelet rich plasma method. Whole blood (350 ml was collected in anticoagulant Citrate Phosphate Dextrose Adenine triple blood bags. Random donor platelets were stored for 7 days at 22°C in platelet incubators and agitators, with and without additive solution. Results: Platelet swirling was present in all the units at 22°C on day 7, with no evidence of bacterial contamination. Comparison of the mean values of platelet count, platelet factor 3, lactate dehydrogenase, pH, glucose and platelet aggregation showed no significant difference in additive solution, whereas platelet factor 3, glucose and platelet aggregation showed significant difference (P < 0.001 on day 7 without additive solution at 22°C. Conclusion: Our study infers that platelet viability and aggregation were best maintained within normal levels on day 7 of storage in platelet additive solution at 22°C. Thus, we may conclude that in vitro storage of random donor platelets with an extended shelf life of 7 days using platelet additive solution may be advocated to improve the inventory of platelets.

  6. A Case Report of Severe Corneal Toxicity following 0.5% Topical Moxifloxacin Use

    A.P. Vignesh

    2015-02-01

    Full Text Available Moxifloxacin is a widely used topical antibiotic in various bacterial infections of the eye. Its safety and efficacy have been proved by many studies. We report a case of a rare adverse effect following its use. A 10-year-old female who had presented with acute bacterial conjunctivitis in both eyes with no corneal involvement was started on preservative-free 0.5% topical moxifloxacin four times a day. The child developed a severe form of corneal toxicity in both eyes with circumcorneal congestion and corneal edema following its use. The child's visual acuity had dropped from 20/20 to 20/400 in both the eyes. Topical moxifloxacin was discontinued, following which the cornea cleared dramatically and the visual acuity became normal. This case indicates that though rare, topical moxifloxacin can cause severe keratitis and that more studies need to be conducted to evaluate its safety.

  7. Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections

    Darlene Miller

    2008-03-01

    Full Text Available Darlene MillerAbrams Ocular Microbiology Laboratory, Bascom Palmer Eye Institute, Anne Bates Leach Eye Hospital, Miller School of Medicine-University of Miami, FL, USAAbstract: Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox® is the ocular formulation/adaptation of moxifloxacin. Moxifloxacin is a broad spectrum 8-methoxyfluoroquinolone which terminates bacterial growth by binding to DNA gyrase (topoisomerase II and topoisomerase IV, essential bacterial enzymes involved in the replication, translation, repair and recombination of deoxyribonucleic acid. Affinity for both enzymes improves potency and reduces the probability of selecting resistant bacterial subpopulations. Vigamox is a bactericidal, concentration dependent, anti-infective. It is preservative free, and well tolerated with minimal ocular side effects. It provides increased penetration into ocular tissues and fluids with improved activity against Streptococci and Staphylococci species and moderate to excellent activity against clinically relevant, gram- negative ocular pathogens.Keywords: moxifloxacin, vigamox, pharmacodynamic indices, minimal inhibitory concentrations

  8. Toxicity and bioconcentration of the pharmaceuticals moxifloxacin, rosuvastatin, and drospirenone to the unionid mussel Lampsilis siliquoidea.

    Gilroy, Eve A M; Klinck, Joel S; Campbell, Sheena D; McInnis, Rodney; Gillis, Patricia L; de Solla, Shane R

    2014-07-15

    Pharmaceuticals and personal care products (PPCPs) and their metabolites are continually released from wastewater treatment plants into the aquatic environment; however, their impact on aquatic biota is poorly understood. This study examined the toxicity and bioconcentration of three pharmaceuticals: moxifloxacin, rosuvastatin, and drospirenone to the unionid mussel Lampsilis siliquoidea. Effects of moxifloxacin and rosuvastatin were assessed through aqueous 21-d static-renewal tests using 2-year-old mussels, at 0.01, 0.1, 1, 10 and 100mg/L (nominal concentrations). Following exposure, survival, behavior, algal clearance rate, hemocyte viability and density, and glutathione S-transferase (GST) activity were assessed. In addition, the acute (48 h) toxicity of moxifloxacin (0-100mg/L) and drospirenone (0-3mg/L) to glochidia (larval mussels) were examined. In 21 day exposures (2-yr old mussels), there were no differences in survival, oxygen consumption, hemocyte density, or GST activity over the range of concentrations examined; however, the proportion of time mussels spent filtering, and consequently the algal clearance rate, decreased at the higher moxifloxacin and rosuvastatin concentrations. Bioconcentration factors (BCFs) ranged between 0.03 and 70 for moxifloxacin, and between 0 and 0.05 for rosuvastatin for exposures up to 100mg/L. The BCF for moxifloxacin at the highest exposure concentration was lower than that at the mid-level concentrations, likely due to decreased filtering activity at the higher exposure levels. The feeding rates declined and the amount of time the subadult mussels spent with their valves closed increased at the higher moxifloxacin and rosuvastatin exposures. Glochidia viability did not vary with exposure to drospirenone, but declined at the highest moxifloxacin concentration, resulting in an EC50 of 120 mg/L. Overall, observed sublethal and lethal effects occurred at concentrations which exceed expected environmental concentrations

  9. Effect of moxifloxacin administration on pharmacokinetics of tolfenamic acid in rats

    Satish D. Patel; Sadariya, Kamlesh A.; Anil K. Gothi; Urvesh D. Patel; Pradhuman A. Gohil; Jain, Mukul R.; Bhavsar, Shailesh K.; Thaker, Aswin M.

    2011-01-01

    Pharmacokinetics of tolfenamic acid as a single drug (4 mg/kg, intramuscularly) and its co-administration with moxifloxacin (5 mg/kg, intramuscularly) in wistar rats were studied. The plasma drug concentration of tolfenamic acid was assayed by LC-MS/MS. Following intramuscular administration of tolfenamic acid as single drug and in combination with moxifloxacin in male rats, the mean values of observed peak plasma drug concentration (Cmax), area under plasma drug concentration-time curve (AUC...

  10. Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans

    Joukhadar, Christian; Stass, Heino; Müller-Zellenberg, Ulrike; Lackner, Edith; Kovar, Florian; Minar, Erich; Müller, Markus

    2003-01-01

    The present study addressed the ability of moxifloxacin to penetrate into healthy and inflamed subcutaneous adipose tissues in 12 patients with soft tissue infections (STIs). Penetration of moxifloxacin into the interstitial space fluid of healthy and inflamed subcutaneous adipose tissues was measured by use of in vivo microdialysis following administration of a single intravenous dosage of 400 mg in six diabetic and six nondiabetic patients with STIs. For the entire study population, the mea...

  11. Rapid Eradication of Listeria monocytogenes by Moxifloxacin in a Murine Model of Central Nervous System Listeriosis▿

    Grayo, Solène; Lott-Desroches, Marie-Catherine; Dussurget, Olivier; Respaud, Renaud; Fontanet, Arnaud; Join-Lambert, Olivier; Singlas, Eric; Le Monnier, Alban

    2008-01-01

    Listeriosis is a rare but life-threatening infection. A favorable outcome is greatly aided by early administration of antibiotics with rapid bactericidal activity against Listeria monocytogenes. Moxifloxacin, a new-generation fluoroquinolone with extended activity against gram-positive bacteria, has proved its effectiveness in vitro against intracellular reservoirs of bacteria. The efficacies of moxifloxacin and amoxicillin were compared in vivo by survival curve assays and by studying the ki...

  12. Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: a case report

    Verma, Rajanshu; Dhamija, Radhika; Batts, Donald H.; Stephen C Ross; Loehrke, Mark E

    2009-01-01

    Moxifloxacin is a newer-generation synthetic fluoroquinolone that is used for treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia, intra-abdominal infections and skin/skin structure infections. We describe a case of fatal hepatotoxicity caused by Moxifloxacin in a 72-year-old man. He presented with jaundice and epigastric tenderness that started one week after being treated for acute exacerbation of his chronic bronchitis with Moxiflo...

  13. Effects of Moxifloxacin on Human Neutrophil and T-Lymphocyte Functions in Vitro

    Ronald Anderson; Riana Cockeran; Charles Feldman; Theron, Annette J.; Moliehi Potjo

    2010-01-01

    Moxifloxacin is useful in the treatment of respiratory infections, including community-acquired pneumonia, and also shows promise in the treatment of tuberculosis, a clinical setting which necessitates extended administration of this agent. Relatively little is known, however, about the effects of this agent on the antimicrobial and proliferative activities of human neutrophils and T-lymphocytes, respectively. In the current study, we have investigated the effects of moxifloxacin at therapeut...

  14. Potentiometric determination of moxifloxacin in some pharmaceutical formulation using PVC membrane sensors

    Hefnawy, Mohammed M; Homoda, Atef M; Abounassif, Mohammed A; Alanazi, Amer M; Al-Majed, Abdulrahaman; Mostafa, Gamal A

    2014-01-01

    Background The construction and electrochemical response characteristics of Poly (vinyl chloride) membrane sensors for moxifloxacin HCl (MOX) are described. The sensing membranes incorporate ion association complexes of moxifloxacin cation and sodium tetraphenyl borate (NaTPB) (sensor 1), phosphomolybdic acid (PMA) (sensor 2) or phosphotungstic acid (PTA) (sensor 3) as electroactive materials. Results The sensors display a fast, stable and near-Nernstian response over a relative wide moxiflox...

  15. Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes

    Lee, Jinwoo; Lee, Chang-Hoon; Kim, Deog Kyeom; Yoon, Ho Il; Kim, Jae Yeol; Lee, Sang-Min; Yang, Seok-Chul; Lee, Jae Ho; Yoo, Chul-Gyu; Lee, Choon-Taek; Chung, Hee Soon; Kim, Young Whan; Han, Sung Koo; Yim, Jae-Joon

    2011-01-01

    Background/Aims To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). Methods A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). Results The median age of the patients was 42.0 years. Approximate...

  16. In vitro function of random donor platelets stored for 7 days in composol platelet additive solution

    Gupta Ashish

    2011-01-01

    Full Text Available Background and Aim: Platelets are routinely isolated from whole blood and stored in plasma for 5 days. This study was done to assess the in vitro function of random donor platelets stored for 7 days in composol platelet additive solution at 22°C. Materials and Methods: The study sample included 30 blood donors of both sex in State Blood Bank, C S M Medical University, Lucknow. Random donor platelets were prepared by the platelet-rich plasma method. Whole blood (350 ml was collected in anticoagulant Citrate Phosphate Dextrose Adenine triple blood bags. Random donor platelets were stored for 7 days at 22°C in platelet incubators and agitators with and without additive solution. Results: Platelet swirling was present in all the units at 22°C on day 7 with no evidence of bacterial contamination. Comparison of the mean values of platelet count, platelet factor 3, lactate dehydrogenase, pH, glucose and platelet aggregation showed no significant difference in additive solution while platelet factor 3, glucose and platelet aggregation showed significant difference (P < 0.001 on day 7 without additive solution at 22°C. Conclusion: Our study infers that the platelet viability and aggregation were the best maintained within normal levels on day 7 of storage in platelet additive solution at 22°C. Thus, we may conclude that in vitro storage of random donor platelets with an extended shelf life of 7 days using platelet additive solution may be advocated to improve the inventory of platelets.

  17. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction

    Stass, H; Bührmann, S; Mitchell, A.; Kubitza, D; Möller, J-G; Kribben, A; Wenzel, R R; Schäfers, R F

    2007-01-01

    What is already known about this subjectAlthough renal excretion is one important route of excretion of moxifloxacin and its metabolites, moxifloxacin pharmacokinetics are similar in patients with varying degrees of renal impairment (but not on dialysis) and in healthy subjects.What this study addsThis study showed that moxifloxacin pharmacokinetics are comparable in patients with severe renal failure requiring haemodialysis and in healthy subjects and patients with impaired renal function no...

  18. 莫西沙星与左氧氟沙星治疗社区获得性肺炎的临床研究%The Clinical stady of moxifloxacin and levofloxacin in the treatment of community-acquired pneumonia for the treatment community-acquired pneumonia

    曾峰; 林雅; 肖靖华; 廖美玲

    2011-01-01

    目的 探讨莫西沙星和左氧氟沙星治疗社区获得性肺炎的疗效.方法 选择社区获得性肺炎患者120例,随机分成莫西沙星组60例和左氧氟沙星组60例,分别给予治疗7d,运用药物经济学的成本-效果分析方法进行评价.结果 莫西沙星组和左氧氟沙星组治疗有效率分别为98.33%和71.67%,细菌清除率分别为91.67和65.57%,不良反应发生率分别为8.33%和13.33%,成本-效果比分别为21.87%和10.26%.结论 莫西沙星组的治疗有效率和细菌清除率明显优于左氧氟沙星组(P<0.01),莫西沙星治疗社区获得性肺炎在临床治疗中是优选方案.%Objective To study the clinical Value in moxifloxacin and levofloxacin for the treatment of community-acquired pneumonia (CAP). Methods 120 patients of CAP were chosen and divided randomly into team of moxifloxacin and team of levofloxacin. These two categories of patients were given separate treatments for 7 days which were analyzed and appraised by the cost-effect method in pharmacoeconomic research. Results The Overall clinical effective rate for team of moxifloxacin was 98.33% and for team of levofloxcine was 71. 67% ; the bacterial clearance rate for team of moxifloxacin wag 91. 67% and for team of levofloxcine was 65. 57% ; Occurrence of the adverse reaction for team moxifloxacin was 8. 33% and for team levofloxcine was 13.33% , and the cost-effectiveness ratios were 21. 87 and 10. 26. Conclusion The overall clinical effective rate and the bacterial clearance rate of team moxifloxacin is better than that of team levofloxcine. Moxifloxacin for the treatment CAP is the preferred plan in the clinic.

  19. In vitro function of random donor platelets stored for 7 days in composol platelet additive solution

    Gupta, Ashish; Chandra, Tulika; Kumar, Ashutosh

    2011-01-01

    Background and Aim: Platelets are routinely isolated from whole blood and stored in plasma for 5 days. The present study was done to assess the in vitro function of random donor platelets stored for 7 days in composol platelet additive solution at 22°C. Materials and Methods: The study sample included 30 blood donors of both sex in State Blood Bank, CSM Medical University, Lucknow. Random donor platelets were prepared by platelet rich plasma method. Whole blood (350 ml) was collected in antic...

  20. In vitro function of random donor platelets stored for 7 days in composol platelet additive solution

    Gupta, Ashish; Chandra, Tulika; Kumar, Ashutosh

    2011-01-01

    Background and Aim: Platelets are routinely isolated from whole blood and stored in plasma for 5 days. This study was done to assess the in vitro function of random donor platelets stored for 7 days in composol platelet additive solution at 22°C. Materials and Methods: The study sample included 30 blood donors of both sex in State Blood Bank, C S M Medical University, Lucknow. Random donor platelets were prepared by the platelet-rich plasma method. Whole blood (350 ml) was collected in antico...

  1. Eccentric and concentric muscle performance following 7 days of simulated weightlessness

    Hayes, Judith C.; Roper, Mary L.; Mazzocca, Augustus D.; Mcbrine, John J.; Barrows, Linda H.; Harris, Bernard A.; Siconolfi, Steven F.

    1992-01-01

    Changes in skeletal muscle strength occur in response to chronic disuse or insufficient functional loading. The purpose of this study was to examine changes in muscle performance of the lower extremity and torso prior to and immediately after 7 days of simulated weightlessness (horizontal bed rest). A Biodex was used to determine concentric and eccentric peak torque and angle at peak torque for the back, abdomen, quadriceps, hamstring, soleus, and tibialis anterior. A reference angle of 0 degrees was set at full extension. Data were analyzed by ANOVA.

  2. Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis

    Miyazaki, Eishi; Miyazaki, Miki; Chen, Jong Min; Chaisson, Richard E.; Bishai, William R.

    1999-01-01

    Moxifloxacin (BAY12-8039) is a new 8-methoxyquinolone shown to be active against Mycobacterium tuberculosis in vitro. We tested moxifloxacin for activity in mice against M. tuberculosis CSU93, a highly virulent, recently isolated clinical strain. The MIC of moxifloxacin for the CSU93 strain was 0.25 μg/ml. The serum moxifloxacin concentration after oral administration in mice peaked within 0.25 h, reaching 7.8 μg/ml with doses of 100 mg/kg of body weight; the maximum concentration and the ana...

  3. Changes of human serum proteome profile during 7-day “dry” immersion

    Pakharukova, N. A.; Pastushkova, L. Kh.; Larina, I. M.; Grigoriev, A. I.

    2011-05-01

    The aim of this study was to characterize changes of serum proteome profile during 7-day "dry" immersion (DI). The experiment with DI consisted of three series: control group without countermeasures (10 men), with using mechanical stimulation (6 men) and low-frequency myostimulation (5 men) as preventive means. Serum samples were fractionated using ClinProt robot (Bruker Daltonics) on magnetic beads (weak cation exchange magnetic beads—MB WCX) prior to mass-spectral profiling. It was obtained 170 peaks after fractionation of serum samples in each group. On 7th immersion day peak areas of fibrinopeptide A ( m/ z=1206; 1464), angiotensin II ( m/ z=1051), high molecular mass kininogen fragment ( m/ z=2133 Da) and C3-fragment of the complement system ( m/ z=1350 Da) were significantly decreased comparing with pre-experimental values of all experimental series. Peak areas of apolipoprotein C III ( m/ z=9419) and C4a fragment of the complement system ( m/ z=3206 Da) were increased. On 7th day of the recovery peak areas of all changed peaks were not close to pre-experimental values. This fact provided evidence of incomplete recovery of an organism after DI. The depth of the alterations had considerable individual variability. Thereby the detected changes of serum proteome profile in the experiment. They indicated a reorganization of the hormonal, immune systems and lipid metabolism. The use of myostimulation and mechanical stimulation as countermeasures partly compensated adverse effects of 7-day dry immersion on the parameters of coagulation system (fibrinopeptide A) and lipid metabolism (apolipoprotein CIII).

  4. The time course of altered brain activity during 7-day simulated microgravity

    Yang eLiao

    2015-05-01

    Full Text Available Microgravity causes multiple changes in physical and mental levels in humans, which can induce performance deficiency among astronauts. Studying the variations in brain activity that occur during microgravity would help astronauts to deal with these changes. In the current study, resting-state functional magnetic resonance imaging (rs-fMRI was used to observe the variations in brain activity during a 7-day head down tilt (HDT bed rest, which is a common and reliable model for simulated microgravity. The amplitudes of low frequency fluctuation (ALFF of twenty subjects were recorded pre-head down tilt (pre-HDT, during a bed rest period (HDT0, and then each day in the HDT period (HDT1–HDT7. One-way analysis of variance of the ALFF values over these 8 days was used to test the variation across time period (P<0.05, corrected. Compared to HDT0, subjects presented lower ALFF values in the posterior cingulate cortex and higher ALFF values in the anterior cingulate cortex during the HDT period, which may partially account for the lack of cognitive flexibility and alterations in autonomic nervous system seen among astronauts in microgravity. Additionally, the observed improvement in function in CPL during the HDT period may play a compensatory role to the functional decline in the paracentral lobule to sustain normal levels of fine motor control for astronauts in a microgravity environment. Above all, those floating brain activities during 7 days of simulated microgravity may indicate that the brain self-adapts to help astronauts adjust to the multiple negative stressors encountered in a microgravity environment.

  5. Efficacy of Ciprofloxacin and Moxifloxacin against Nocardia brasiliensis In Vitro and in an Experimental Model of Actinomycetoma in BALB/c Mice▿

    Chacon-Moreno, Brenda Edith; Welsh, Oliverio; Cavazos-Rocha, Norma; de la Luz Salazar-Cavazos, Maria; Garza-Lozano, Hector Gerardo; Said-Fernandez, Salvador; Ocampo-Candiani, Jorge; Vera-Cabrera, Lucio

    2008-01-01

    The efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis was evaluated by applying 25 mg of each drug/kg subcutaneously every 8 h in BALB/c mice infected with N. brasiliensis. A statistically significant difference was observed only with moxifloxacin. A moxifloxacin-trimethoprim-sulfamethoxazole combination was as active as when each compound was used alone.

  6. 荧光分析法检测牛奶中的残留莫西沙星%Determination of Moxifloxacin Residues in Milk by Fluorimetry Method

    席会平; 师兆忠

    2012-01-01

    目的:建立测定牛奶中莫西沙星残留量的方法.方法:基于在pH 6.50的硼酸缓冲溶液中,莫西沙星可使硫化镉-牛血清白蛋白体系的荧光强度显著猝灭的原理建立了荧光分析法测定莫西沙星残留量的新方法,其中激发波长和发射波长分别为372、536 nm.结果:莫西沙星检测浓度线性范围为50~400 μg·L-1(r=0.9991),最低检测限为13.6 μg· L-1;平均回收率为93.51%,RSD均不超过1.74%(n=5).结论:该方法简便、快捷、准确,可用于残留莫西沙星的检测.%OBJECTIVE: To establish the method for the determination of moxifloxacin residues in milk. METHODS: Based on quenching acting of moxifloxacin on the fluorescence intensity emitted by the reaction of cadmium sulfide and bovine serum albumin in a B-R buffer solution (pH 6.50), new fluorimetry method for the determination of moxifloxacin residues was established. The excitation wavelength and emission wavelength were 372 nm and 536 nm. RESULTS: The linear range of moxifloxacin was 50~400 μg·L-1 (r=0.999 1) with average recovery of 93.51% (RSD≤l.74%, n=5). The detection limit was 13.6 ug·L-1. CONCLUSIONS: The method is simple, rapid and accurate, and it is suitable for the determination of moxifloxacin residues.

  7. SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease

    Bermudez, Luiz E.; Kolonoski, Peter; Seitz, Lianne E.; Petrofsky, Mary; Reynolds, Robert; Wu, Martin; Young, Lowell S.

    2004-01-01

    Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone.

  8. Modeling In Vivo Pharmacokinetics and Pharmacodynamics of Moxifloxacin Therapy for Mycobacterium tuberculosis Infection by Using a Novel Cartridge System

    Ginsburg, Amy Sarah; Lee, Jin; Woolwine, Samuel C.; Jacques H Grosset; Hamzeh, Fayez M.; Bishai, William R.

    2005-01-01

    To study the efficacy of moxifloxacin treatment for tuberculosis, we utilized a novel cartridge system to simulate in vivo pharmacokinetics. We found this system to be a robust method for modeling in vivo pharmacokinetics and present data supporting the utility of intermittent moxifloxacin treatment as a component of antituberculosis chemotherapy.

  9. No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block

    Thomsen, Morten Bækgaard; Beekman, J D M; Attevelt, N J M;

    2006-01-01

    The therapeutically available quinolone antibiotic moxifloxacin has been used as a positive control for prolonging the QT interval in both clinical and non-clinical studies designed to assess the potential of new drugs to delay cardiac repolarization. Despite moxifloxacin prolonging QT, it has not...

  10. Supramolecular interaction of Moxifloxacin and β-cyclodextrin spectroscopic characterization and analytical application

    Dsugi, Nuha Fathi Ali; Elbashir, Abdalla A.

    2015-02-01

    The supramolecular interaction of Moxifloxacin (Moxi) and β-cyclodextrin (β-CD) has been examined by UV-VIS, FTIR, H1NMR, SEM and fluorescence spectroscopy. The formation of inclusion complex has been confirmed on the base of changes of spectroscopy properties. The results showed that β-CD reacted with Moxi to form an inclusion complex. The Moxi and β-CD complex formed a host-guest complex in 1:1 stoichiometry and inclusion constant (K = 3.95 × 102 L mol-1) was ascertained by the typical double reciprocal plots. Furthermore, the thermodynamic parameters (ΔH°, ΔS° and ΔG°) associated with the inclusion process were also determined. Based on the significant enhancement of the fluorescence intensity of Moxi produced through complex formation, a simple, accurate, rapid and highly sensitive spectrofluorometric method for the determination of Moxi in pharmaceutical formulation was developed. The measurement of relative fluorescence intensity was carried out at 464 nm with excitation at 289 nm. The factors affecting the inclusion complex formation were studied and optimized. Under the optimum reaction conditions, linear relationships with good correlation coefficients (0.99973) were in the concentration range of 10-60 ng/mL for spectrofluorimetry. The limit of detection (LOD) was found to be 1.6 ng/mL. The proposed method was successfully applied to the analysis of Moxi in pharmaceutical preparation.

  11. Efficacy of Clindamycin Vaginal Ovule (3-Day Treatment vs. Clindamycin Vaginal Cream (7-Day Treatment in Bacterial Vaginosis

    Charles P. Wajszczuk

    2001-01-01

    Full Text Available Objective: To compare the efficacy and safety of a 3-day regimen of clindamycin vaginal ovules with a 7-day regimen of clindamycin vaginal cream for the treatment of bacterial vaginosis (BV

  12. Pyruvate ingestion for 7 days does not improve aerobic performance in well-trained individuals

    Morrison, M. A.; Spriet, L. L.; Dyck, D. J.

    2000-01-01

    The purposes of the present studies were to test the hypotheses that lower dosages of oral pyruvate ingestion would increase blood pyruvate concentration and that the ingestion of a commonly recommended dosage of pyruvate (7 g) for 7 days would enhance performance during intense aerobic exercise in well-trained individuals. Nine recreationally active subjects (8 women, 1 man) consumed 7, 15, and 25 g of pyruvate and were monitored for a 4-h period to determine whether blood metabolites were altered. Pyruvate consumption failed to significantly elevate blood pyruvate, and it had no effect on indexes of carbohydrate (blood glucose, lactate) or lipid metabolism (blood glycerol, plasma free fatty acids). As a follow-up, we administered 7 g/day of either placebo or pyruvate, for a 1-wk period to seven, well-trained male cyclists (maximal oxygen consumption, 62.3 +/- 3.0 ml. kg(-1). min(-1)) in a randomized, double-blind, crossover trial. Subjects cycled at 74-80% of their maximal oxygen consumption until exhaustion. There was no difference in performance times between the two trials (placebo, 91 +/- 9 min; pyruvate, 88 +/- 8 min). Measured blood parameters (insulin, peptide C, glucose, lactate, glycerol, free fatty acids) were also unaffected. Our results indicate that oral pyruvate supplementation does not increase blood pyruvate content and does not enhance performance during intense exercise in well-trained cyclists.

  13. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.

    Ackermann, G; Tang, Y J; Kueper, R; Heisig, P; Rodloff, A C; Silva, J; Cohen, S H

    2001-08-01

    Clostridium difficile is the etiological agent of antibiotic-associated colitis and the most common cause of hospital-acquired infectious diarrhea. Fluoroquinolones such as ciprofloxacin are associated with lower risks of C. difficile-associated diarrhea. In this study, we have analyzed 72 C. difficile isolates obtained from patients with different clinical courses of disease, such as toxic megacolon and relapses; the hospital environment; public places; and horses. They were investigated for their susceptibilities to moxifloxacin (MXF), metronidazole (MEO), and vancomycin (VAN). Mutants highly resistant to fluoroquinolones were selected in vitro by stepwise exposure to increasing concentrations of MXF. The resulting mutants were analyzed for the presence of mutations in the quinolone resistance-determining regions of DNA gyrase (gyrA), the production of toxins A and B, and the epidemiological relationship of these isolates. These factors were also investigated using PCR-based methods. All strains tested were susceptible to MEO and VAN. Twenty-six percent of the clinical isolates (19 of 72) were highly resistant to MXF (MIC > or = 16 microg/ml). Fourteen of these 19 strains contained nucleotide changes resulting in amino acid substitutions at position 83 in the gyrA protein. Resistant strains selected in vitro did not contain mutations at that position. These findings indicate that resistance to MXF in a majority of cases may be due to amino acid substitution in the gyrA gene. PMID:11451695

  14. Spectrophotometric Determination of Gemifloxacin Mesylate, Moxifloxacin Hydrochloride, and Enrofloxacin in Pharmaceutical Formulations Using Acid Dyes

    Ayman A. Gouda

    2014-01-01

    Full Text Available Simple, rapid, and extractive spectrophotometric methods were developed for the determination of some fluoroquinolones antibiotics: gemifloxacin mesylate (GMF, moxifloxacin hydrochloride (MXF, and enrofloxacin (ENF in pure forms and pharmaceutical formulations. These methods are based on the formation of ion-pair complexes between the basic drugs and acid dyes, namely, bromocresol green (BCG, bromocresol purple (BCP, bromophenol blue (BPB, bromothymol blue (BTB, and methyl orange (MO in acidic buffer solutions. The formed complexes were extracted with chloroform and measured at 420, 408, 416, 415, and 422 nm for BCG, BCP, BPB, BTB, and MO, respectively, for GMF; at 410, 415, 416, and 420 nm for BCP, BTB, BPB, and MO, respectively, for MXF; and at 419 and 414 nm for BCG and BTB, respectively, in case of ENF. The analytical parameters and their effects are investigated. Beer’s law was obeyed in the ranges 1.0–30, 1.0–20, and 2.0–24 μg mL−1 for GMF, MXF, and ENF, respectively. The proposed methods have been applied successfully for the analysis of the studied drugs in pure forms and pharmaceutical formulations. Statistical comparison of the results with the reference methods showed excellent agreement and indicated no significant difference in accuracy and precision.

  15. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin.

    Govendir, M; Hansen, T; Kimble, B; Norris, J M; Baral, R M; Wigney, D I; Gottlieb, S; Malik, R

    2011-01-10

    Rapidly growing mycobacteria (RGM) cause infections in cats and dogs which require prolonged antibacterial medication for resolution. In Australia, pathogens from the Mycobacterium fortuitum and Mycobacterium smegmatis clusters are responsible for most of the RGM infections in cats and dogs. As fluoroquinolones are often recommended for treating such infections, 14 M. fortuitum isolates, 51 isolates from the M. smegmatis cluster and 2 M. mageritense isolates, collected from feline and canine patients, underwent susceptibility testing to the second generation fluoroquinolones ciprofloxacin and enrofloxacin and the newer generation fluoroquinolone moxifloxacin. Using microbroth dilution, the MIC(90) of ciprofloxacin, enrofloxacin, and moxifloxacin that inhibited growth of M. fortuitum isolates were 0.500, 0.250 and 0.063 μg/mL respectively. For the M. smegmatis cluster isolates the corresponding MIC(90) was 0.500, 0.250 and 0.125 μg/mL respectively. E-test results showed similar trends but MICs were lower than those determined by microbroth dilution. Additionally, moxifloxacin was administered to 10 clinically normal cats (50mg per cat, once daily for 4 days). The plasma moxifloxacin concentration 2h after the last dose was determined by liquid chromatography as 2.2 ± 0.6 μg/mL. The plasma concentration at 2h:MIC(90) ratios for moxifloxacin for M. fortuitum and M. smegmatis cluster was 34.9 and 17.6 respectively which exceeded the recommended threshold of 10, indicating that moxifloxacin has good theoretical efficacy for treatment of those M. fortuitum and M. smegmatis infections in cats and dogs that have become refractory to other antibacterial drug classes. PMID:20619975

  16. A validated HPTLC method for estimation of moxifloxacin hydrochloride in tablets.

    Dhillon, Vandana; Chaudhary, Alok Kumar

    2010-10-01

    A simple HPTLC method having high accuracy, precision and reproducibility was developed for the routine estimation of moxifloxacin hydrochloride in the tablets available in market and was validated for various parameters according to ICH guidelines. moxifloxacin hydrochloride was estimated at 292 nm by densitometry using Silica gel 60 F254 as stationary phase and a premix of methylene chloride: methanol: strong ammonia solution and acetonitrile (10:10:5:10) as mobile phase. Method was found linear in a range of 9-54 nanograms with a correlation coefficient >0.99. The regression equation was: AUC = 65.57 × (Amount in nanograms) + 163 (r(2) = 0.9908). PMID:23781417

  17. Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

    Ferro, Beatriz E; Srivastava, Shashikant; Deshpande, Devyani; Pasipanodya, Jotam G; van Soolingen, Dick; Mouton, Johan W; van Ingen, Jakko; Gumbo, Tawanda

    2016-06-01

    Current regimens used to treat pulmonary Mycobacterium abscessus disease have limited efficacy. There is an urgent need for new drugs and optimized combinations and doses. We performed hollow-fiber-system studies in which M. abscessus was exposed to moxifloxacin lung concentration-time profiles similar to human doses of between 0 and 800 mg/day. The minimum bactericidal concentration and MIC were 8 and 2 mg/liter, respectively, in our M. abscessus strain, suggesting bactericidal activity. Measurement of the moxifloxacin concentrations in each hollow-fiber system revealed an elimination rate constant (kel) of 0.11 ± 0.05 h(-1) (mean ± standard deviation) (half-life of 9.8 h). Inhibitory sigmoid maximal effect (Emax) modeling revealed that the highest Emax was 3.15 ± 1.84 log10 CFU/ml on day 3, and the exposure mediating 50% of Emax (EC50) was a 0- to 24-h area under the concentration time curve (AUC0-24)-to-MIC ratio of 41.99 ± 31.78 (r(2) = 0.99). The EC80 was an AUC0-24/MIC ratio of 102.11. However, no moxifloxacin concentration killed the bacteria to burdens below the starting inoculum. There was regrowth beyond day 3 in all doses, with replacement by a resistant subpopulation that had an MIC of >32 mg/liter by the end of the experiment. A quadratic function best described the relationship between the AUC0-24/MIC ratio and the moxifloxacin-resistant subpopulation. Monte Carlo simulations of 10,000 patients revealed that the 400- to 800-mg/day doses would achieve or exceed the EC80 in ≤12.5% of patients. The moxifloxacin susceptibility breakpoint was 0.25 mg/liter, which means that almost all M. abscessus clinical strains are moxifloxacin resistant by these criteria. While moxifloxacin's efficacy against M. abscessus was poor, formal combination therapy studies with moxifloxacin are still recommended. PMID:27067317

  18. Stability indicating HPLC method for simultaneous determination of moxifloxacin hydrochloride and ketorolac tromethamine in pharmaceutical formulations

    Syed Naeem Razzaq; Islam Ullah Khan; Muhammad Ashfaq; Irfana Mariam

    2012-01-01

    A simple, RP-HPLC method was established for determining moxifloxacin and ketorolac in pharmaceutical formulations. Moxifloxacin, ketorolac and their degradation products were separated using C8 column with methanol and phosphate buffer pH 3.0 (55:45 v/v) as the mobile phase. Detection was performed at 243 nm using a diode array detector. The method was validated using ICH guidelines and was linear in the range 20-140 µg mL-1 for both analytes. Good separation of both the analytes and their d...

  19. A Meta-analysis of Sequential Intravenous/Oral Moxifloxacin Monotherapy for Treatment of Skin and Skin Structure Infections.

    Chu, Y; Qu, J; Qu, L-Y; Luo, Y-F; Jiang, M-Y

    2015-12-01

    Moxifloxacin is widely recognized for the treatment of bacterial infections of the respiratory tract such as community acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis. However, the use of moxifloxacin for skin infections is much valued in recent years. This study is to compare the clinical efficacy and safety of moxifloxacin monotherapy among adults with skin and skin structure infections. The meta-analysis of RCTs is conducted by searching Medline, Embase, Pubmed and the Cochrane Library. 6 RCTs, involving a total of 2608 patients, were included in the meta-analysis. English and Chinese language papers were reviewed. The results of the meta-analysis showed that the moxifloxacin monotherapy has similar clinical cure rate, bacteriological success rates and mortality compared with the control group. The drug-related adverse of moxifloxacin was significantly higher than that in the control group, although the overall incidence of adverse events, serious adverse events, and serious drug-related adverse events were similar between the compared treatment groups. Through this meta-analysis, we can draw a conclusion that moxifloxacin monotherapy has similar effectiveness and relative safety as other recommended antibiotics for the treatment of SSSIs. At the same time, it possesses the superior bacteria eradication rate. The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for other recommended antibiotic therapy. PMID:26070015

  20. Response of Gardnerella vaginalis biofilm to 5 days of moxifloxacin treatment.

    Swidsinski, Alexander; Dörffel, Yvonne; Loening-Baucke, Vera; Schilling, Johannes; Mendling, Werner

    2011-02-01

    Polymicrobial communities are often recalcitrant to antibiotics. We tested whether the polymicrobial Gardnerella vaginalis biofilm can be eradicated with moxifloxacin. Twenty women with bacterial vaginosis were treated with 400 mg moxifloxacin for 5 days. The changes in the occurrence and proportions of Gardnerella, Atopobium and Lactobacillus spp. were assessed using FISH. The bacterial biofilm was investigated using desquamated epithelial cells of spontaneously voided urine and sections of vaginal biopsies. Fifteen of 20 women showed a significant and sustained clinical response to moxifloxacin according to Amsel and Nugent criteria. The concentrations of adherent bacteria decreased significantly. The incidence and proportion of Atopobium declined sustainably. The proportions of Lactobacillus in the biofilm mass increased following therapy. Initially, Gardnerella was the main component of the polymicrobial biofilm. Following treatment, Gardnerella was not accessible to FISH in the urine and vaginal samples of 75% of all women. Ten to 12 weeks after the end of therapy, Gardnerella biofilm was cumulatively present in 40%. This was not due to newly acquired disease, but due to reactivation of the persisting, but biochemically inactive biofilm. Despite clear clinical efficacy, and initially definite suppression of the biofilm, moxifloxacin was, similar to metronidazole, not able to eradicate the Gardnerella vaginalis biofilm in all patients. PMID:20955467

  1. Synthesis and evaluation of 99mTc-moxifloxacin, a potential infection specific imaging agent

    To synthesize and evaluate a 99mTc labeled fluroquinolone, moxifloxacin as a potential bacteria specific infection imaging agent. A radiolabeling formulation including moxifloxacin, [MoxicipTM injection, Cipla] (4 mg), sodium pertechnetate and stannous chloride (5 μg) gave the best radiolabeling efficiency and moderately stable labeled 99mTc moxifloxacin. Quality control analysis was performed by ITLC. Rats and rabbit with infectious intramuscular lesions induced in either thigh with E. Colli were used for studying biodistribution and scintigraphic imaging of the labeled product. Imaging of an infected thigh of a rabbit was performed with a γ-camera at various intervals. A good radiolabeling efficiency (90-95%) was obtained within 5 min. No purification of the labeled product was done. Labeled product retained its radiochemical purity upto 85% even at 3 h. Scintigraphy showed uptake in infectious lesions at 30 min after injection, which remains constant upto 3 h study. Abscess-to-muscle ratios were 1.60, 1.62, 1.74 and 1.75 at 30 min, 1, 2 and 3 h, respectively. Thus, 99mTc moxifloxacin, a new potential radiopharmaceutical has been developed for infection imaging agent.

  2. Effect of moxifloxacin administration on pharmacokinetics of tolfenamic acid in rats

    Satish D. Patel

    2011-08-01

    Full Text Available Pharmacokinetics of tolfenamic acid as a single drug (4 mg/kg, intramuscularly and its co-administration with moxifloxacin (5 mg/kg, intramuscularly in wistar rats were studied. The plasma drug concentration of tolfenamic acid was assayed by LC-MS/MS. Following intramuscular administration of tolfenamic acid as single drug and in combination with moxifloxacin in male rats, the mean values of observed peak plasma drug concentration (Cmax, area under plasma drug concentration-time curve (AUC(0-¥ , volume of distribution (Vz, half-life (t½ and clearance (Cl were 4111.44 ± 493.15 and 3837.69 ± 351.83 ng/ml, 20280.77 ± 3501.67 and 15229.18 ± 678.80 ng.h/ml, 822.17 ± 115.38 and 1249.64 ± 139.52 ml, 2.59 ± 0.16 and 3.27 ± 0.32 hr, and 218.39 ± 25.47 and 265.18 ± 11.36 ml/hr, respectively. The peak plasma drug concentration (Cmax was significantly higher in female rats compared to male rats. The volume of distribution (Vz of the drug was significantly higher (P < 0.05 in moxifloxacin-treated male rats compared to female rats. Concomitant administration of moxifloxacin may alter the disposition of tolfenamic acid in male rats.

  3. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort

    Majcher-Peszynska, Jolanta; Sass, Marko; Schipper, Sora; Czaika, Viktor; Gussmann, Andreas; Lobmann, Ralf; Mundkowski, Ralf G.; Luebbert, Christoph; Kujath, Peter; Ruf, Bernhard R.; Koch, Horst; Schareck, Wolfgang; Klar, Ernst; Drewelow, Bernd

    2010-01-01

    Abstract Objectives Physiological changes occurring in patients with diabetes may affect the pharmacokinetics and penetration of antimicrobial agents into peripheral tissue. We examined the pharmacokinetics and the penetration of moxifloxacin into perinecrotic tissue of diabetic foot lesions in patients with diabetic foot infections (DFI). Patients and methods Adult patients suffering from type 2 diabetes ...

  4. Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis

    Alffenaar, J. W. C.; van Altena, R.; Bokkerink, H. J.; Luijckx, G. J.; van Soolingen, D.; Aarnoutse, R. E.; van der Werf, T. S.

    2009-01-01

    Moxifloxacin cerebrospinal fluid (CSF) penetration was evaluated by obtaining full plasma and CSF time concentration curves for 4 patients with tuberculous meningitis. The geometric mean ratio of the areas under the curve for CSF to plasma were 0.82 (range, 0.70-0.94) at 400 mg once per day and 0.71

  5. Synthesis and evaluation of {sup 99m}Tc-moxifloxacin, a potential infection specific imaging agent

    Chattopadhyay, Sankha [Radiopharmaceuticals Laboratory, Board of Radiation and Isotope Technology, Variable Energy Cyclotron Centre, 1/AF, Bidhan Nagar, Kolkata 700 064 (India)], E-mail: sankha@veccal.ernet.in; Saha Das, Sujata [Radiopharmaceuticals Laboratory, Board of Radiation and Isotope Technology, Variable Energy Cyclotron Centre, 1/AF, Bidhan Nagar, Kolkata 700 064 (India); Chandra, Susmita; De, Kakali; Mishra, Mridula [Nuclear Medicine Department, Indian Institute of Chemical Biology, Kolkata (India); Ranjan Sarkar, Bharat; Sinha, Samarendu; Ganguly, Shantanu [Regional Radiation Medicine Centre, Variable Energy Cyclotron Centre, Kolkata (India)

    2010-02-15

    To synthesize and evaluate a {sup 99m}Tc labeled fluroquinolone, moxifloxacin as a potential bacteria specific infection imaging agent. A radiolabeling formulation including moxifloxacin, [Moxicip{sup TM} injection, Cipla] (4 mg), sodium pertechnetate and stannous chloride (5 {mu}g) gave the best radiolabeling efficiency and moderately stable labeled {sup 99m}Tc moxifloxacin. Quality control analysis was performed by ITLC. Rats and rabbit with infectious intramuscular lesions induced in either thigh with E. Colli were used for studying biodistribution and scintigraphic imaging of the labeled product. Imaging of an infected thigh of a rabbit was performed with a {gamma}-camera at various intervals. A good radiolabeling efficiency (90-95%) was obtained within 5 min. No purification of the labeled product was done. Labeled product retained its radiochemical purity upto 85% even at 3 h. Scintigraphy showed uptake in infectious lesions at 30 min after injection, which remains constant upto 3 h study. Abscess-to-muscle ratios were 1.60, 1.62, 1.74 and 1.75 at 30 min, 1, 2 and 3 h, respectively. Thus, {sup 99m}Tc moxifloxacin, a new potential radiopharmaceutical has been developed for infection imaging agent.

  6. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery

    De Smet, Julie; Colin, Pieter; De Paepe, Peter; Ruige, Johannes; Batens, Helene; Van Nieuwenhove, Yves; Vogelaers, Dirk; Blot, Stijn; Van Bocxlaer, Jan; Van Bortel, Luc M.; Boussery, Koen

    2012-01-01

    Objectives: Roux-en-Y gastric bypass surgery is the most commonly performed procedure for the treatment of morbid obesity. This anatomical alteration may affect the absorption and consequently the bioavailability of oral drugs. This study aims to investigate the oral bioavailability of moxifloxacin

  7. Evaluation of moxifloxacin for the treatment of tuberculosis : 3 years of experience

    Pranger, A. D.; van Altena, R.; Aarnoutse, R. E.; van Soolingen, D.; Uges, D. R. A.; Kosterink, J. G. W.; van der Werf, T. S.; Alffenaar, J. W. C.

    2011-01-01

    Moxifloxacin (MFX) is a powerful second-line anti-tuberculosis (TB) agent, but the optimal dose has not yet been established and long-term safety data are scarce. We retrospectively reviewed the medical charts of TB patients treated at the Tuberculosis Centre Beatrixoord, University Medical Centre G

  8. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis.

    Alffenaar, J.W.C.; Altena, R. van; Bokkerink, H.J.; Luijckx, G.J.R.; Soolingen, D. van; Aarnoutse, R.E.; Werf, T.S. van der

    2009-01-01

    Moxifloxacin cerebrospinal fluid (CSF) penetration was evaluated by obtaining full plasma and CSF time concentration curves for 4 patients with tuberculous meningitis. The geometric mean ratio of the areas under the curve for CSF to plasma were 0.82 (range, 0.70-0.94) at 400 mg once per day and 0.71

  9. Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis

    Pranger, Arianna D.; Kosterink, Jos G. W.; van Altena, Richard; Aarnoutse, Rob E.; van der Werf, Tjip S.; Uges, Donald R. A.; Alffenaar, Jan-Willem C.

    2011-01-01

    Background: Moxifloxacin (MFX) is a potent drug for multidrug resistant tuberculosis(TB) treatment and is also useful if first-line agents are not tolerated. Therapeutic drug monitoring may help to prevent treatment failure. Obtaining a full concentration-time curve of MFX for therapeutic drug monit

  10. 莫西沙星控制结核病复发的效果分析%Analysis of the effect of moxifloxacin on tuberculosis recurrence

    王秀丽; 汪远红; 梁肇和

    2012-01-01

    目的 分析初治结核病人强化期使用莫西沙星可减少结核病复发.方法 对2005年1月至2006年12月200例初治肺结核病人随机分为两组,每组100例,初治强化期二个月Ⅰ组用药HREZ,Ⅱ组在用HREZ基础上加用莫西沙星0.4g,每天一次,巩固期六个月均为HR,观察5年病人的复发率.结果 Ⅰ组病人100例5年内复发18例,复发率为18%,Ⅱ组病人100例5年内复发2例,复发率为2%.结论 初治病人强化期治疗使用莫西沙星能有效地控制结核病人的复发.%Objective To analyze the effects of moxifloxacin on tuberculosis recurrence patients initially treated in intensive stage. Method 200 pulmonary tuberculosis patients initially treated from January 2005 to December 2006 were randomly divided into two groups, 100 cases in each group. In the intensive period of two months, group Ⅰ received 11REZ, while group Ⅱ received moxifloxacin 0. 4g qd based on the treatment of groupⅠ In consolidation period of six months, two groups all received 11REZ. Relapse rate of 5 years was observed in two groups. Result 18 cases recurred in group Ⅰ , and relapse rate of 5 years was 18% ; 2 cases recurred in group Ⅰ , and relapse rate of 5 years was 2% . Conclusion Moxifloxacin can effectively control the recurrence of tuberculosis patients initially treated in intensive stage.

  11. In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis

    Andreas Weber; Wolfgang Huber; Klaus Kamereck; Philipp Winkle; Petra Voland; Hans Weidenbach; Roland M Schmid; Christian Prinz

    2008-01-01

    AIM:To analyze the in vitro activity of moxifioxacin and piperacillin/sulbactam against pathogens isolated from patients with acute cholangitis.METHODS:In this prospective study a total of 65 patients with acute cholangitis due to biliary stone obstruction (n = 7),benign biliary stricture (n =16),and malignant biliary stricture (n = 42) were investigated with regard to spectrum of bacterial infection and antibiotic resistance.Pathogens were isolated from bile cultures in all study patients.In 22 febrile patients,blood cultures were also obtained.In vitro activity of moxifloxacin and piperacillin/sulbactam was determined by agar diffusion.RESULTS:Thirty-one out of 65 patients had positive bile and/or blood cultures.In 31 patients,63 isolates with 17 different species were identified.The predominant strains were Enterococcus species (26/63),Ecoli (13/63) and Klebsiella species (8/63).A comparable in vitro activity of moxifloxacin and piperacillin/sulbactam was observed for E.coli and Klebsiella species.In contrast,Enterococcus species had higher resistances towards moxifloxacin.Overall bacteria showed antibiotic resistances in vitro of 34.9% for piperacillin/sulbactam and 36.5% for moxifloxacin.CONCLUSION:Enterococcus species,E.coli andKlebsiella species were the most common bacteria isolated from bile and/or blood from patients with acute cholangitis.Overall,a mixed infection with several species was observed,and bacteria showed a comparable in vitro activity for piperacillin/sulbactam and moxifloxacin.

  12. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.

    Ruslami, R.; Ganiem, A.R.; Dian, S.; Apriani, L.; Achmad, T.H.; Ven, A.J.A.M. van der; Borm, G.F.; Aarnoutse, R.E.; Crevel, R. van

    2013-01-01

    BACKGROUND: Intensified antibiotic treatment might improve the outcome of tuberculous meningitis. We assessed pharmacokinetics, safety, and survival benefit of several treatment regimens containing high-dose rifampicin and moxifloxacin in patients with tuberculous meningitis in a hospital setting. M

  13. [Status of the lipid peroxidation system in the tissues of rats following a 7-day flight on the Kosmos-1667 biosatellite].

    Delenian, N V; Markin, A A

    1989-01-01

    Rats flown for 7 days on Cosmos-1667 were for the first time used to measure antioxidative enzymes (superoxide dismutase, glutathione peroxidase, glutathione reductase, catalase), lipid peroxidation products (diene conjugates, malonic dialdehyde, Schiff bases) and tocopherol. Enhanced lipid peroxidation in the heart was completely compensated by activation of antioxidative enzymes. The content of all lipid peroxidation products measured in the liver increased; this was accompanied by a decrease of glutathione peroxidase and an increase of superoxide dismutase activities. It is suggested that lipid peroxidation was activated in response to altered gravity. PMID:2586059

  14. Efficacy and Safety of Intravenous Moxifloxacin Versus Cefoperazone with Azithromycin in the Treatment of Community Acquired Pneumonia

    XU Shuyun; XIONG Shengdao; XU Yongjian; LIU Jin; LIU Huiguo; ZHAO Jianping; XIONG Weining

    2006-01-01

    To compare the efficacy, safety, and tolerability of intravenous moxifloxacin with those of a commonly used empirical antibiotic regimen, cefoperazone and azithromycin in the treatment of community acquired pneumonia (CAP) in adult patients requiring initial parenteral therapy, 40 patients with CAP were divided into two groups, a moxifloxacin group (n=20) and a control group(n=20), which were treated for 7 to 14 days. The patients in the moxifloxacin group were intravenously given 400 mg of moxifloxacin (AveloxR) once a day. Patients in the control group were administered 2.0 g of cefoperazone twice a day and azithromycin 0.5 g once a day. Clinical, bacteriological, and laboratory examinations were performed before the treatment, and at the end of the treatment. Our results showed that there was no significant difference in the clinical efficacy rate between two treatment groups at end of therapy (90 % for moxifloxacin, 95 % for cefoperazone plus azithromycin) (P>0.05). The bacteriologic eradication rate at the end of treatment was 90 % in the moxifloxacin group and 80 % in the cefoperazone-plus-azithromycin group, whereas there was no significant difference between the two groups (P>0.05). In addition, both drugs were well-tolerated in this trial, with the number of drug-related adverse events being comparable. It is concluded that moxifloxacin is an effective and well-tolerated treatment for CAP and was equivalent to the commonly used empirical treatment of cefoperazone plus azithromycin. Moxifloxacin is likely to offer clinicians an alternative for reliable empirical CAP treatment in the face of increasing antibiotic resistance.

  15. Comparison of aqueous humour concentration after single high dose versus multiple administration of topical moxifloxacin in rabbits

    Monika Chopra; Rehan, H. S.; Rachna Gupta; Ahmad, F. J.; M D Tariq; Gupta, L. K.

    2014-01-01

    For the prevention of postoperative ocular infections prophylactic topical antibiotics are routinely used. Studies evaluating comparative difference between single dose versus multiple dose administration on aqueous humour concentration of moxifloxacin are lacking. This study compared the aqueous humour concentration of moxifloxacin following its topical administration in rabbit eyes with two dose regimens. Twelve albino rabbits were divided into two groups. In group-1, two drops were adminis...

  16. Comparative evaluation of aqueous and plasma concentration of topical moxifloxacin alone and with flurbiprofen in patients of cataract surgery

    Sujash Halder; Kanchan Kumar Mondal; Supreeti Biswas; Tapan Kumar Mandal; Bakul Kumar Dutta; Mithilesh Haldar

    2013-01-01

    Objectives: To determine the aqueous and plasma concentrations of moxifloxacin administered topically alone and with flurbiprofen in patients undergoing cataract surgery. Materials and Methods: A total of 50 subjects scheduled for routine cataract surgery were randomly allocated to two groups (n = 25 each). Group-1 patients were treated with topical moxifloxacin alone: One drop 6 times/day for 3 days before surgery and one drop 4 times on the day of surgery: Group-2 patients were treated ...

  17. Comparison of aqueous humour concentration after single high dose versus multiple administration of topical moxifloxacin in rabbits

    Monika Chopra

    2014-01-01

    Full Text Available For the prevention of postoperative ocular infections prophylactic topical antibiotics are routinely used. Studies evaluating comparative difference between single dose versus multiple dose administration on aqueous humour concentration of moxifloxacin are lacking. This study compared the aqueous humour concentration of moxifloxacin following its topical administration in rabbit eyes with two dose regimens. Twelve albino rabbits were divided into two groups. In group-1, two drops were administered thrice (total six drops at 2 min intervals, in both the eyes; in group-2, two drops of moxifloxacin were administered three times a day for three days and also two h before aqueous humour collection i.e. on fourth day. Mean aqueous humour concentrations were calculated and compared using Student′s ′t′ test and P<0.05 was considered significant. Moxifloxacin concentration in aqueous humour in group-1 was 23.79 μg/ml and in group-2 was 42.08 μg/ml. Both dosing regimens produced substantially higher aqueous concentrations than the known minimum inhibitory concentration for most bacteria. Moxifloxacin concentration in aqueous humour with multiple instillations is significantly higher than single instillation (P<0.05, which is adequate to cover ciprofloxacin-resistant gram-negative bacteria. Repeated topical moxifloxacin administration achieved significantly higher aqueous humour concentrations than single administration.

  18. Comparative evaluation of aqueous and plasma concentration of topical moxifloxacin alone and with flurbiprofen in patients of cataract surgery

    Sujash Halder

    2013-01-01

    Full Text Available Objectives: To determine the aqueous and plasma concentrations of moxifloxacin administered topically alone and with flurbiprofen in patients undergoing cataract surgery. Materials and Methods: A total of 50 subjects scheduled for routine cataract surgery were randomly allocated to two groups (n = 25 each. Group-1 patients were treated with topical moxifloxacin alone: One drop 6 times/day for 3 days before surgery and one drop 4 times on the day of surgery: Group-2 patients were treated with topical moxifloxacin as in Group-1 and with topical flurbiprofen: One drop 4 times/day for 3 days before and on the day of surgery. The interval between two drugs was 30 min for last 3 days and 15 min on the day of surgery. Last dose was administered 1 h before aqueous humor and blood sampling for both the groups. The antibiotic concentration in aqueous humor and plasma were determined by using high performance liquid chromatography. Results: The mean concentration of moxifloxacin in aqueous humor was 1.71 ± 0.82 mg/ml in Group-1 and 2.39 ± 1.34 mg/ml in Group-2. Concentrations of moxifloxacin in aqueous humor were significantly higher in Group-2 than that of Group-1. Conclusion: Flurbiprofen may increase the concentration of moxifloxacin in aqueous humor.

  19. Comparative Efficacy and Safety of Moxifloxacin and Clindamycin in the Treatment of Odontogenic Abscesses and Inflammatory Infiltrates: a Phase II, Double-Blind, Randomized Trial▿

    Cachovan, Georg; Böger, Rainer H.; Giersdorf, Ina; Hallier, Olaf; Streichert, Thomas; Haddad, Munif; Platzer, Ursula; Schön, Gerhard; Wegscheider, Karl; Sobottka, Ingo

    2010-01-01

    Moxifloxacin penetrates well into oromaxillary tissue and covers the causative pathogens that show an increasing resistance to standard antibiotics. Clinical reports suggest that moxifloxacin may be effective for the treatment of odontogenic infections that can lead to serious complications. The objective of this prospective, randomized, double-blind, multicenter study was to compare the efficacies and safeties of moxifloxacin and clindamycin for the medical treatment of patients with gingiva...

  20. Disposition kinetics of long acting moxifloxacin following intravenous administration in Sheep

    Chirag M. Modi

    Full Text Available Aim: The objective of the present study was to study the disposition kinetics and dosage regimens of long acting moxifloxacin following intravenous administration at the dose rate of 7.5 mg/kg-1 b. wt. in six male sheep and to calculate dosage regimens of the same in sheep. Materials and Methods: The study was conducted using six healthy male sheep. Long acting Moxifloxacin solution (10 % moxifloxacin in solution with L- arginine, N-butyl alcohol and benzyl alcohol was injected in jugular vein and periodical blood samples were collected from contra-lateral jugular vein in test tubes containing 30-50 IU heparin (anticoagulant at 0.083 (5 min, 0.166 (10 min, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72 and up to 96 h post administration of drug. Drug concentration in plasma was determined using High Performance Liquid Chromatography (HPLC with Fluorescence Detector. The blood concentrations versus time data were analyzed using software. Results: After single dose intravenous administration of long acting moxifloxacin the plasma concentration of 0.016 ± 0.001 μg/ml-1 was maintained for up to 72 h. Distribution half-life (t and elimination half-life (t were 1.637 ± 0.053 h, and 1/2 1/2 12.130 ± 0.202 h, following IV administration. The mean values of apparent volume of distribution V 5.436 ± 0.135 L/kg-1 d(area as well as mean residence time 10.02 ± 4.787 minute were detected with IV administration. Conclusion: The long acting Moxifloxacin @ the dose 7.5 mg/kg IV maintains the effective therapeutic concentration in the plasma of sheep for up to 72 hours. The long acting Moxifloxacin at this dose rate can be used to treat sensitive bacteria causing infectious diseases in sheep. [Vet World 2012; 5(9.000: 517-521

  1. Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium

    Bermudez, Luiz E.; Inderlied, Clark B.; Kolonoski, Peter; Petrofsky, Mary; Aralar, Priscilla; Wu, Martin; Young, Lowell S.

    2001-01-01

    Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 μg/ml. In addition, U937 macrophage monolayers infected with MAC strain 101 (serovar 1) were treated with moxifloxacin (0.25 to 8 μg/ml) daily, and the number of intracellular bacteria was quantitated after 4 days. Moxifloxacin showed inhibitory activity at 0.5 μg/ml and higher. To assess the activity of moxifloxacin containing regimens i...

  2. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: Long-term results of Phase III clinical trial

    Purpose: To update 5-year results of a previously published study on special 7-days-a-week fractionation continuous accelerated irradiation (CAIR) for head-and-neck cancer patients. Methods and Materials: One hundred patients with squamous cell carcinoma of head and neck in Stage T2-4N0-1M were randomized between two definitive radiation treatments: accelerated fractionation 7 days a week including weekends (CAIR) and conventional 5 days a week (control). Hence the overall treatment time was 2 weeks shorter in CAIR. Results: Five-year local tumor control was 75% in the CAIR group and 33% in the control arm (p < 0.00004). Tumor-cure benefit corresponded with significant improvement in disease-free survival and overall survival rates. Confluent mucositis was the main acute toxicity, with the incidence significantly higher in CAIR patients than in control (respectively, 94% vs. 53%). When 2.0-Gy fractions were used, radiation necrosis developed in 5 patients (22%) in the CAIR group as a consequential late effect (CLE), but when fraction size was reduced to 1.8 Gy no more CLE occurred. Actuarial 5-year morbidity-free survival rate was similar for both treatments. Conclusions: Selected head-and-neck cancer patients could be treated very effectively with 7-days-a-week radiation schedule with no compromise of total dose and with slight 10% reduction of fraction dose (2 Gy-1.8 Gy), which article gives 1 week reduction of overall treatment time compared with standard 70 Gy in 35 fractions over 47-49 days. Although this report is based on the relatively small group of patients, its results have encouraged us to use CAIR fractionation in a standard radiation treatment for moderately advanced head-and-neck cancer patients

  3. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD

    Miravitlles, Marc

    2007-01-01

    Bacteria are isolated in more than 50% of exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD). The most prevalent respiratory pathogens include Gram-positive (Streptococcus pneumoniae) and Gram-negative (Haemophilus influenzae, Moraxella catarrhalis) microorganims. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against respiratory pathogens, including atypicals and those resistant to most common antibiotics. The bi...

  4. Validated spectrophotometric methods for the estimation of moxifloxacin in bulk and pharmaceutical formulations

    Motwani, Sanjay K.; Chopra, Shruti; Ahmad, Farhan J.; Khar, Roop K.

    2007-10-01

    New, simple, cost effective, accurate and reproducible UV-spectrophotometric methods were developed and validated for the estimation of moxifloxacin in bulk and pharmaceutical formulations. Moxifloxacin was estimated at 296 nm in 0.1N hydrochloric acid (pH 1.2) and at 289 nm in phosphate buffer (pH 7.4). Beer's law was obeyed in the concentration range of 1-12 μg ml -1 ( r2 = 0.9999) in hydrochloric acid and 1-14 μg ml -1 ( r2 = 0.9998) in the phosphate buffer medium. The apparent molar absorptivity and Sandell's sensitivity coefficient were found to be 4.63 × 10 4 l mol -1 cm -1 and 9.5 ng cm -2/0.001 A in hydrochloric acid; and 4.08 × 10 4 l mol -1 cm -1 and 10.8 ng cm -2/0.001 A in phosphate buffer media, respectively indicating the high sensitivity of the proposed methods. These methods were tested and validated for various parameters according to ICH guidelines. The detection and quantitation limits were found to be 0.0402, 0.1217 μg ml -1 in hydrochloric acid and 0.0384, 0.1163 μg ml -1 in phosphate buffer medium, respectively. The proposed methods were successfully applied for the determination of moxifloxacin in pharmaceutical formulations (tablets, i.v. infusions, eye drops and polymeric nanoparticles). The results demonstrated that the procedure is accurate, precise and reproducible (relative standard deviation moxifloxacin in different dosage forms and dissolution studies.

  5. Anstieg der Clostridium difficile-assoziierten Diarrhoe nach Einsatz von Moxifloxacin

    Günther, Claudia

    2010-01-01

    The Clostridium-difficile associated diarrhea has shown a rising incidence in recent years. This has a dramatic medial and economical impact. The main cause for the disease is a recent antibiotic therapy. There have been numerous studies which have established certain antibiotics most potent for causing colitis, eg. Cephalosporins of group II an III, clindamycin and ciprofloxacin. Moxifloxacin was introduced as a new flourochinolon a few years ago. With a high bioavailability it has s...

  6. Reproductive and Developmental Effects of Moxifloxacin on Female Mice and Embryos

    Hanaa M. Roshdy

    2004-12-01

    Full Text Available Moxifloxacin (Avelox® is a fluoroquinolone antibiotic with a broad spectrum of activity and bactericidal action. Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative organisms. The safe use of moxifloxacin in human pregnancy has not been established. In order to evaluate the genotoxic and embryo toxic effects of (Avelox® during pregnancy, Avelox was administrated orally to female mice with doses (8.7, 17 and 26 mg/kg/day from 1 to 17 days of pregnancy. Caesarean sections were completed on gestation day 18 and complete fetal examinations and cytogenetic analysis were conducted. Decreases in the fetal body weights and increases in the external visceral and skeletal anomalies were found in all doses of (8.7, 17 and 26 mg Avelox compared to the controls. Cytogenetic analysis in mothers and embryos revealed that all the tests doses produced chromosomal aberrations and micronuclei (MN formations in a dose dependent manner compared to the controls. These results indicate that Avelox has a maternal and embryotoxic effects on the female mice and their embryos when administered with a recommended and above the recommended dose during pregnancy.

  7. Synthesis and in vitro Antimycobacterial Activity of Moxifloxacin Methylene and Ethylene Isatin Derivatives

    FENG Lian-shun; LIU Ming-liang; WANG Shuo; CHAI Yun; LI Su-jie; GUO Hui-yuan

    2012-01-01

    A series of novel moxifloxacin methylene and ethylene isatin derivatives with remarkable improvement in lipophilicity,compared to the parent moxifloxacin,was designed,synthesized and characterized by 1H NMR,MS and HRMS.These derivatives were initially evaluated for their in vitro antimycobacterial activity against M.smegmatis CMCC 93202.Compounds 3a-3f,5a,5f and 5j were chosen for the further evaluation of their in vitro activity against Mycobacterium tuberculosis(MTB) H37Rv ATCC 27294 and MDR-MTB 09710.All the target compounds[minimum inhibitory concentration(M1C):0.39->16 μg/mL] were far more active than rifampin(MIC:2.0->256 μg/mL),but less active than moxifloxacin(MIC:0.1-1.0 μg/mL) against the three tested strains.The most active compounds 3a and 3c were found to be 2-64 fold more potent than isoniazid and rifampin against M.smegmatis CMCC 93202,2 fold more potent than rifampin against MTB H37Rv ATCC 27294,and 16->64 fold more potent than ethambutol,isoniazid and rifampin against MDR-MTB 09710.

  8. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors

    Sun Tieying; Sun Li; Wang Rongmei; Ren Xiaoping; Sui Dong-jiang; Pu Chun; Ren Yajuan

    2014-01-01

    Background Community-acquired pneumonia (CAP) is a common infectious disease throughout the world and the incidence continues to grow as the population ages.Aspiration is an important pathogenic mechanism for pneumonia in the elderly and the management of patients with community-acquired pneumonia with aspiration factors is a major medical problem.Our study aimed to assess whether moxifloxacin in comparison to levofloxacin plus metronidazole are effective and safe in the treatment of community-acquired pneumonia with aspiration factors.Methods In this prospective,multicenter,open-label,randomized controlled trial,77 patients with mild-to-moderate community-acquired pneumonia with aspiration factors were enrolled and randomly assigned to receive moxifloxacin or levofloxacin plus metronidazole.The primary efficacy variables were clinical outcomes in evaluable patients at a follow-up visit 7 to 14 days after the end of therapy.Results Seven days after the end of therapy a clinical cure was achieved for 76.7% (23 of 37) of efficacy-evaluable patients in the moxifloxacin group and 51.7% (15 of 40) of patients in the levofloxacin plus metronidazole group.There was a significant difference between the two groups (x2=4.002,P <0.05).Bacteriological success rates were similar in the moxifloxacin group (93.3%) and levofloxacin plus metronidazole group (96.4%),there was no significant difference between the two groups (P >0.05).The overall adverse event rate was 10.8% (4/37) in the moxifloxacin group versus 17.5% (7/40) in the levofloxacin plus metronidazole group,there was no significant difference between the two groups (P>0.05).No serious adverse events were observed.Conclusions Moxifloxacin is effective and safe for treatment of community-acquired pneumonia with aspiration factors.And the regimen of moxifloxacin monotherapy is more convenient compared with levofloxacin plus metronidazole.

  9. In Vitro Activities of Moxifloxacin against 900 Aerobic and Anaerobic Surgical Isolates from Patients with Intra-Abdominal and Diabetic Foot Infections

    Edmiston, Charles E.; Krepel, Candace J.; Seabrook, Gary R.; Somberg, Lewis R.; Nakeeb, Atilla; Cambria, Robert A.; Towne, Jonathan B.

    2004-01-01

    The in vitro activities of moxifloxacin, ciprofloxacin, levofloxacin, gatifloxacin, imipenem, piperacillin-tazobactam, clindamycin, and metronidazole against 900 surgical isolates were determined using NCCLS testing methods. Moxifloxacin exhibited good to excellent antimicrobial activity against most aerobic (90.8%) and anaerobic (97.1%) microorganisms, suggesting that it may be effective for the treatment of polymicrobial surgical infections.

  10. Moxifloxacin and Azithromycin but not Amoxicillin Protect Human Respiratory Epithelial Cells against Streptococcus pneumoniae In Vitro when Administered up to 6 Hours after Challenge

    Ulrich, Martina; Albers, Cordula; Möller, Jan-Georg; Dalhoff, Axel; Korfmann, Gisela; Künkele, Frank; Döring, Gerd

    2005-01-01

    We determined the protective effect of moxifloxacin, azithromycin, and amoxicillin against Streptococcus pneumoniae infection of respiratory cells. Moxifloxacin and azithromycin effectively killed intracellular S. pneumoniae strains and protected respiratory epithelial cells significantly even when given 6 h after S. pneumoniae challenge. Amoxicillin was less effective.

  11. Biopsy Specimens Obtained 7 Days After Starting Chemoradiotherapy (CRT) Provide Reliable Predictors of Response to CRT for Rectal Cancer

    Suzuki, Toshiyuki [Department of Surgery, Tokai University School of Medicine, Kanagawa (Japan); Sadahiro, Sotaro, E-mail: sadahiro@is.icc.u-tokai.ac.jp [Department of Surgery, Tokai University School of Medicine, Kanagawa (Japan); Tanaka, Akira; Okada, Kazutake; Kamata, Hiroko; Kamijo, Akemi [Department of Surgery, Tokai University School of Medicine, Kanagawa (Japan); Murayama, Chieko [Department of Clinical Pharmacology, Tokai University School of Medicine, Kanagawa (Japan); Akiba, Takeshi; Kawada, Shuichi [Department of Radiology, Tokai University School of Medicine, Kanagawa (Japan)

    2013-04-01

    Purpose: Preoperative chemoradiation therapy (CRT) significantly decreases local recurrence in locally advanced rectal cancer. Various biomarkers in biopsy specimens obtained before CRT have been proposed as predictors of response. However, reliable biomarkers remain to be established. Methods and Materials: The study group comprised 101 consecutive patients with locally advanced rectal cancer who received preoperative CRT with oral uracil/tegafur (UFT) or S-1. We evaluated histologic findings on hematoxylin and eosin (H and E) staining and immunohistochemical expressions of Ki67, p53, p21, and apoptosis in biopsy specimens obtained before CRT and 7 days after starting CRT. These findings were contrasted with the histologic response and the degree of tumor shrinkage. Results: In biopsy specimens obtained before CRT, histologic marked regression according to the Japanese Classification of Colorectal Carcinoma (JCCC) criteria and the degree of tumor shrinkage on barium enema examination (BE) were significantly greater in patients with p21-positive tumors than in those with p21-negative tumors (P=.04 and P<.01, respectively). In biopsy specimens obtained 7 days after starting CRT, pathologic complete response, histologic marked regression according to both the tumor regression criteria and JCCC criteria, and T downstaging were significantly greater in patients with apoptosis-positive and p21-positive tumors than in those with apoptosis-negative (P<.01, P=.02, P=.01, and P<.01, respectively) or p21-negative tumors (P=.03, P<.01, P<.01, and P=.02, respectively). The degree of tumor shrinkage on both BE as well as MRI was significantly greater in patients with apoptosis-positive and with p21-positive tumors than in those with apoptosis-negative or p21-negative tumors, respectively. Histologic changes in H and E-stained biopsy specimens 7 days after starting CRT significantly correlated with pathologic complete response and marked regression on both JCCC and tumor

  12. Growth Recovery of Lemna gibba and Lemna minor Following a 7-Day Exposure to the Herbicide Diuron.

    Burns, Mitchell; Hanson, Mark L; Prosser, Ryan S; Crossan, Angus N; Kennedy, Ivan R

    2015-08-01

    In agricultural catchments, aquatic ecosystems can experience a pulse exposure to pesticides. Following such exposure, non-target organisms that are not extirpated may recover. This paper investigates the potential of two duckweed species (Lemna minor and Lemna gibba) to recover from a 7-day exposure to different concentrations (0.4-208 µg L(-1)) of the herbicide diuron. There was significant inhibition in the growth and biomass after the initial 7-day exposure (e.g. frond number EC50=59.2 and 52.2 µg L(-1) for L. minor and L. gibba, respectively). Following transfer to clean media, recovery (the highest concentration yielding no significant difference in the effect endpoint from the control) was observed for all effects endpoints at concentrations ranging 60-111 µg L(-1) for L. minor and 60-208 µg L(-1) for L. gibba. These results suggest that recovery is possible for primary producers at environmentally relevant concentrations considered significant in ecological risk assessment. PMID:26067703

  13. EPR characteristics of free radicals in DOPA-melanin-moxifloxacin complexes at ambient level of UVA radiation

    Beberok, Artur; Zdybel, Magdalena; Pilawa, Barbara; Buszman, Ewa; Wrześniok, Dorota

    2014-01-01

    EPR studies pointed out that o-semiquinone free radicals with g-values 2.0038-2.0040 take part in moxifloxacin-melanin complex formation. The process contributed to increase in free radicals concentration in nonirradiated complexes. This effect was observed for the complexes with 1 × 10-4 M, 1 × 10-3 M and 4 × 10-3 M drug concentrations. UV irradiation contributed to decrease in free radicals concentration in DOPA-melanin complexes with moxifloxacin, besides the complexes with the drug concentration of 1 × 10-4 M. The strongest decrease was observed for DOPA-melanin-moxifloxacin complexes with the drug concentration of 1 × 10-3 M. Homogeneous broadening of EPR lines, strong dipolar interactions and slow spin-lattice relaxation processes characterized all the tested melanin samples.

  14. Correlation between GyrA Substitutions and Ofloxacin, Levofloxacin, and Moxifloxacin Cross-Resistance in Mycobacterium tuberculosis

    Willby, Melisa; Sikes, R. David; Malik, Seidu; Metchock, Beverly

    2015-01-01

    The newer fluoroquinolones moxifloxacin (MXF) and levofloxacin (LVX) are becoming more common components of tuberculosis (TB) treatment regimens. However, the critical concentrations for testing susceptibility of Mycobacterium tuberculosis to MXF and LVX are not yet well established. Additionally, the degree of cross-resistance between ofloxacin (OFX) and these newer fluoroquinolones has not been thoroughly investigated. In this study, the MICs for MXF and LVX and susceptibility to the critical concentration of OFX were determined using the agar proportion method for 133 isolates of M. tuberculosis. Most isolates resistant to OFX had LVX MICs of >1 μg/ml and MXF MICs of >0.5 μg/ml. The presence of mutations within the gyrA quinolone resistance-determining regions (QRDR) correlated well with increased MICs, and the level of LVX and MXF resistance was dependent on the specific gyrA mutation present. Substitutions Ala90Val, Asp94Ala, and Asp94Tyr resulted in low-level MXF resistance (MICs were >0.5 but ≤2 μg/ml), while other mutations led to MXF MICs of >2 μg/ml. Based on these results, a critical concentration of 1 μg/ml is suggested for LVX and 0.5 μg/ml for MXF drug susceptibility testing by agar proportion with reflex testing for MXF at 2 μg/ml. PMID:26100699

  15. Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

    Jacobsen, F; Fisahn, C; Sorkin, M; Thiele, I; Hirsch, T; Stricker, I; Klaassen, T; Roemer, A; Fugmann, B; Steinstraesser, L

    2011-05-01

    Wound infection is a common risk for patients with chronic nonhealing wounds, causing high morbidity and mortality. Currently, systemic antibiotic treatment is the therapy of choice, despite often leading to several side effects and the risk of an insufficient tissue penetration due to impaired blood supply. If systemically delivered, moxifloxacin penetrates well into inflammatory blister fluid, muscle, and subcutaneous adipose tissues and might therefore be a possible option for the topical treatment of skin and infected skin wounds. In this study, topical application of moxifloxacin was investigated in comparison to mupirocin, linezolid, and gentamicin using a porcine wound infection and a rat burn infection model. Both animal models were performed either by an inoculation with methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa. Wound fluid, tissue, and blood samples were taken, and bacterial counts as well as the moxifloxacin concentration were determined for a 14-day follow-up. A histological comparison of the rat burn wound tissues was performed. Both strains were susceptible to moxifloxacin and gentamicin, whereas mupirocin and linezolid were effective only against MRSA. All antibiotics showed efficient reduction of bacterial counts, and except with MRSA, infected burn wounds reached bacterial counts below 10(5) CFU/g tissue. Additionally, moxifloxacin was observed to promote wound healing as determined by histologic analysis, while no induction of bacterial resistance was observed during the treatment period. The use of topical antibiotics for the treatment of infected wounds confers many benefits. Moxifloxacin is therefore an ideal candidate, due to its broad antibacterial spectrum, its high efficiency, and its potential to promote wound healing. PMID:21343458

  16. Efficacy of Topically Delivered Moxifloxacin against Wound Infection by Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus▿

    Jacobsen, F.; Fisahn, C.; Sorkin, M.; Thiele, I.; Hirsch, T.; Stricker, I.; Klaassen, T.; Roemer, A.; Fugmann, B.; Steinstraesser, L.

    2011-01-01

    Wound infection is a common risk for patients with chronic nonhealing wounds, causing high morbidity and mortality. Currently, systemic antibiotic treatment is the therapy of choice, despite often leading to several side effects and the risk of an insufficient tissue penetration due to impaired blood supply. If systemically delivered, moxifloxacin penetrates well into inflammatory blister fluid, muscle, and subcutaneous adipose tissues and might therefore be a possible option for the topical treatment of skin and infected skin wounds. In this study, topical application of moxifloxacin was investigated in comparison to mupirocin, linezolid, and gentamicin using a porcine wound infection and a rat burn infection model. Both animal models were performed either by an inoculation with methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa. Wound fluid, tissue, and blood samples were taken, and bacterial counts as well as the moxifloxacin concentration were determined for a 14-day follow-up. A histological comparison of the rat burn wound tissues was performed. Both strains were susceptible to moxifloxacin and gentamicin, whereas mupirocin and linezolid were effective only against MRSA. All antibiotics showed efficient reduction of bacterial counts, and except with MRSA, infected burn wounds reached bacterial counts below 105 CFU/g tissue. Additionally, moxifloxacin was observed to promote wound healing as determined by histologic analysis, while no induction of bacterial resistance was observed during the treatment period. The use of topical antibiotics for the treatment of infected wounds confers many benefits. Moxifloxacin is therefore an ideal candidate, due to its broad antibacterial spectrum, its high efficiency, and its potential to promote wound healing. PMID:21343458

  17. Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.

    Ferrándiz, M J; Martín-Galiano, A J; Arnanz, C; Zimmerman, T; de la Campa, A G

    2016-01-01

    We studied the transcriptomic response of Streptococcus pneumoniae to the fluoroquinolone moxifloxacin at a concentration that inhibits DNA gyrase. Treatment of the wild-type strain R6, at a concentration of 10× the MIC, triggered a response involving 132 genes after 30 min of treatment. Genes from several metabolic pathways involved in the production of pyruvate were upregulated. These included 3 glycolytic enzymes, which ultimately convert fructose 6-phosphate to pyruvate, and 2 enzymes that funnel phosphate sugars into the glycolytic pathway. In addition, acetyl coenzyme A (acetyl-CoA) carboxylase was downregulated, likely leading to an increase in acetyl-CoA. When coupled with an upregulation in formate acetyltransferase, an increase in acetyl-CoA would raise the production of pyruvate. Since pyruvate is converted by pyruvate oxidase (SpxB) into hydrogen peroxide (H2O2), an increase in pyruvate would augment intracellular H2O2. Here, we confirm a 21-fold increase in the production of H2O2 and a 55-fold increase in the amount of hydroxyl radical in cultures treated during 4 h with moxifloxacin. This increase in hydroxyl radical through the Fenton reaction would damage DNA, lipids, and proteins. These reactive oxygen species contributed to the lethality of the drug, a conclusion supported by the observed protective effects of an SpxB deletion. These results support the model whereby fluoroquinolones cause redox alterations. The transcriptional response of S. pneumoniae to moxifloxacin is compared with the response to levofloxacin, an inhibitor of topoisomerase IV. Levofloxacin triggers the transcriptional activation of iron transport genes and also enhances the Fenton reaction. PMID:26525786

  18. Safety of prophylactic intracameral moxifloxacin ophthalmic solution after cataract surgery in patients with penetrating keratoplasty

    Osman; Sevki; Arslan; Ceyhun; Arici; Mustafa; Unal; Erdogan; Cicik; Mehmet; Serhat; Mangan; Eray; Atalay

    2014-01-01

    AIM:To determine the safety of prophylactic intracameral moxifloxacin after cataract surgery in patients with penetrating keratoplasty(PKP).METHODS:In this retrospective study of consecutive patients who had phacoemulsification cataract surgery after PKP, were treated with intracameral moxifloxacin0.5% ophthalmic solution(0.5 mg/0.1 mL). The main outcome measures were anterior chamber reaction, best corrected visual acuity(BCVA), corneal endothelial cell count(ECC), and central corneal thickness(CCT).RESULTS:Fifty-five patients were recruited(26 males,29 females). The mean age was 54.36±4.97y(range 45-64y).All eyes had improved postoperative BCVA. The mean BCVA was 0.25 preoperatively and 0.57 postoperatively,which was statistically significant(P <0.001). One eye had 3+, 7 eyes had 2+, 12 eyes had 1+ and 8 eyes had trace amount of aqueous cells on the first day after surgery. All eyes had no anterior chamber cells at subsequent follow up examinations. Effective phacoemulsification time was 4.33 ±1.01 s. The mean ECC was 2340.20 cells/mm2 preoperatively and 1948.75 cells/mm21 mo postoperatively(P <0.001). The increase of21.09 μm in postoperative pachymetry 1mo after surgery was statistically significant(P <0.001).CONCLUSION:Nountowardeffectswereobservedafter intracameral injection of moxifloxacin(0.5 mg/0.1 mL) in terms of anterior chamber reaction, CCT, ECC, and visual rehabilitation at the conclusion of cataract surgery in patients with PKP.

  19. Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ).

    Goudah, Ayman; Hasabelnaby, Sherifa

    2016-06-01

    Plasma disposition and depletion of moxifloxacin were investigated in Japanese quail ( Coturnix japonica ) after single intravenous, intramuscular, and oral administration of 5 mg/kg and after intramuscular and oral administration of 5 mg/kg q24h for 5 consecutive days, respectively. Drug concentrations in plasma and tissues were measured by high-performance liquid chromatography with fluorescence detection. After intravenous injection, plasma drug concentration-time curves were best described by a 2-compartment open model. The decline in plasma drug concentration was biexponential with half-lives of 0.3 hours and 2.18 hours for distribution and elimination phases, respectively. Steady-state volume of distribution and total body clearance after intravenous administration were estimated to be 1.12 L/kg and 0.41 L/h per kilogram, respectively. After intramuscular and oral administration of moxifloxacin at the same dose, the peak plasma concentrations were 2.14 and 1.94 μg/mL and were obtained at 1.4 and 1.87 hours, respectively, and the elimination half-lives were 2.56 and 1.97 hours, respectively. The systemic bioavailabilities were 92.48% and 87.94%, respectively. Tissue levels after intramuscular and oral administration were highest in liver and kidneys, respectively, and decreased in the following order: plasma, lungs, and muscle. Moxifloxacin concentrations after intramuscular and oral administration were below the detection limit of the assay in tissues and plasma after 120 hours. PMID:27315376

  20. Impact of moxifloxacin on serum free amino acid and cytokines in patients with tuberculosis treated by

    Zhao-Zhi Wang

    2015-01-01

    Objective:To explore the impact of serum free amino acid and cytokines in patients with tuberculosis treated by Moxifloxacin.Methods:Chose 130 cases pulmonary tuberculosis patients,they were divided into observation group and control group according to random number table method, 65 cases in each group, all patients were given tuberculosis standard treatment, and on this basis, patients in control group were given levofloxacin tablets, patients in observation group were given moxifloxacin hydrochloride oral, they were treated for 6 months, compared the serum free amino acid and cytokine interleukin-18 (IL-18), tumor necrosis factor alpha-gamma (TNF-α), interferon (IFN-γ), interleukin-10 (IL-10) between two groups before and after treatment. The serum isoleucine, phenylalanine, threonine, leucine, valine, aspartic acid, glutamic acid and arginine in two groups after were increased significantly than before treatment, the difference was statistically significant, acquired aspartic acid, glutamic acid in observation group after treatment were significantly higher than the control group after treatment, the difference was statistically significant; The serum IL-18, IFN-γ, TNF-α and IL-10 in two groups after treatment were significantly reduced, the difference was statistically significant (P<0.05); the serum IL-18, IFN-γ, TNF-α and IL-10 in observation group after treatment were significantly lower than the control group after treatment, the difference was statistically significant.Conclusion:Compared with levofloxacin, moxifloxacin treatment tuberculosis can improve the patients' serum free amino acid levels, adjust the Th1/Th2 balance.

  1. Gender differences in endocrine responses to posture and 7 days of -6 degrees head-down bed rest

    Vernikos, J.; Dallman, M. F.; Keil, L. C.; O'Hara, D.; Convertino, V. A.

    1993-01-01

    Endocrine regulation of fluids and electrolytes during 7 days of -6 degrees head-down bed rest (HDBR) was compared in male (n = 8) and, for the first time, female (n = 8) volunteers. The subjects' responses to quiet standing for 2 h before and after HDBR were also tested. In both sexes, diuresis and natriuresis were evident during the first 2-3 days of HDBR, resulting in a marked increase in the urinary Na(+)-to-K+ ratio and significant Na+ retention on re-ambulation. After the 1st day of HDBR, plasma renin activity (PRA) was increased relative to aldosterone (Aldo), plasma volume was decreased, and the renal response to Aldo appeared to be appropriate. Circulating levels of arginine vasopressin, cortisol, and ACTH were unchanged during HDBR. Plasma testosterone decreased slightly on day 2 of HDBR in males. The ratio of early morning ACTH to cortisol was lower in females than in males because ACTH was lower in females. Urinary cortisol increased and remained elevated throughout the HDBR in males only. There were no gender differences in the responses to 7 days of HDBR, except those in the pituitary-adrenal system; those differences appeared unrelated to the postural change. The provocative cardiovascular test of quiet standing before and after HDBR revealed both sex differences and effects of HDBR. There were significant sex differences in cardiovascular responses to standing before and after HDBR. Females had greater PRA and Aldo responses to standing before HDBR and larger Aldo responses to standing after HDBR than males.(ABSTRACT TRUNCATED AT 250 WORDS).

  2. RETROSPECTIVE STUDY OF EARLY 0-7 DAYS OUTCOME OF BABIES BORN AFTER ART ASSISTED REPRODUCTIVE TECHNOLOGY

    Priyanka

    2014-10-01

    Full Text Available AIM: Retrospective study of early (0-7 days outcome of babies born after ART (Assisted Reproductive Technology In vitro fertilization (IVF is the fertilization of a woman’s egg and a man’s sperm in a laboratory dish. In vitro means “outside the body.” Fertilization means the sperm has attached to and entered the egg. IVF is a form of assisted reproductive technology (ART. This means special medical techniques are used to help a woman become pregnant. There are five basic steps to IVF- Step 1: Stimulation, also called super ovulation, Step 2: Egg retrieval, Step 3: Insemination and Fertilization, Step 4: Embryo culture, Step 5: Embryo transfer. OBJECTIVE: To study the early (0-7 days outcome of babies born after ART (Assisted Reproductive Technology METHODS: This is a retrospective study conducted in Department of Pediatrics, Mahatma Gandhi Medical College & Hospital, Jaipur between Jan 2009- Jan 2010. Inclusion criteria consists of all IVF babies born at Mahatma Gandhi Medical College & Hospital, Jaipur and exclusion criteria consists of all out born babies and IVF babies delivered at another center. CONCLUSION: There were 54.28% male and 45.72% female babies. Most of the babies were above 1.5 kg (44.28% NBW +45.71% LBW= 89.99%. There were only 5.71% babies born before 32 weeks of gestation. 61.42% were Singleton. Complication rate was low with Respiratory Distress in 10 babies, Sepsis in 4 babies and Jaundice in 22. All were treated successfully. There was no mortality.

  3. Disposition Kinetic of Moxifloxacin following Intravenous, Intramuscular, and Subcutaneous Administration in Goats

    Patel, Harshad B.; Shailesh K. Mody; Patel, Hitesh B.; Patel, Vipul A.; Urvesh D. Patel

    2011-01-01

    The present study was carried out to investigate disposition kinetics of moxifloxacin following single-dose intravenous (i.v.), intramuscular (i.m.), and subcutaneous (s.c.) administration at a dose rate of 5 mg/kg of body weight (b.wt.) in goats. Plasma samples collected after treatments were analyzed for drug concentration using high-performance liquid chromatography (HPLC). After i.v. administration, distribution of the drug was rapid and wide as reflected by high steady-state volume of di...

  4. Effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injections

    Mustafa; Atas; Burhan; Baskan; Ayse; zkse; Fatma; Mutlu; Sarιgüzel; Süleyman; Demircan; Emine; Pangal

    2014-01-01

    AIM:To evaluate the effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injections.METHODS:Seventy-two eyes of 36 patients [36 eyes in control group, 36 eyes in intravitreal injection(IVI) group]were enrolled in the study. All the eyes had at least one IVI and had diabetic macular edema(DME) or age-related macular degeneration(ARMD). Moxifloxacin was prescribed to all the patients four times a day for five days following injection. Conjunctival cultures were obtained from the lower fornix via standardized technique with every possible effort made to minimize contamination from the lids, lashes, or skin. Before the application of any ophthalmic medication, conjunctival cultures were obtained from both eyes using sterile cotton culture. An automated microbiology system was used to identify the growing bacteria and determine antibiotic sensitivity.RESULTS:The bacterial cultures were isolated from 72 eyes of 36 patients, sixteen of whom patients(44.4%)were male and twenty(55.6%) were female. Average age was 68.4 ±9.0(range 50-86). The average number of injections before taking cultures was 3.1+1.0. Forty-eight(66.7%) of 72 eyes had at least one significant organism.There was no bacterial growth in 8(20.5%) of IVI eyes and in 16(44.4%) of control eyes(P =0.03). Of the bacteria isolated from culture, 53.8% of coagulase negative staphylococci(CoNS) in IVI eyes and 47.2%CoNS in control eyes. This difference between IVI eyes and control eyes about bacteria isolated from culture was not statistically significant(P =0.2). Eleven of 25 bacteria(44.0%) isolated from IVI eyes and 11(57.9%) of 19 bacteria isolated from control eyes were resistant to oxacillin. The difference in frequency of moxifloxacine resistance between two groups was not statistically significant(12.0% in IVI eyes and 21.1% in control eyes)(P =0.44). There were no cases of resistance to vancomycin, teicoplanin and linezolid

  5. Efficacy of moxifloxacin & econazole against multidrug resistant (MDR Mycobacterium tuberculosis in murine model

    U D Gupta

    2015-01-01

    Full Text Available Background & objectives: Studies have shown the bactericidal potential of econazole and clotrimazole against Mycobacterium tuberculosis under in vitro and ex vivo conditions along with their synergism with conventional antituberculosis drugs. These molecules were also found to be effective against different multidrug resistant (MDR M. tuberculosis isolates in vitro. Hence the present study was designed to evaluate the in vivo antimycobacterial potential of moxifloxacin and econazole alone and in combination against multidrug resistant tuberculosis (MDR-TB in a mice model. Methods: Mice were infected with 2.5×10 [7] bacilli of MDR strain of M. tuberculosis by aerosol route of infection. After four weeks of infection, chemotherapy was started orally by moxifloxacin 8.0 mg/kg body wt and econazole 3.3 mg/kg alone and in combination, as well as with four first line anti-tuberculosis drugs as a positive control. The animals were sacrificed and the lungs and spleen were excised under aspetic conditions. The tissues were homogenized with sterile normal saline, an aliquot of the homogenate was plated on Middlebrook 7H11 agar supplemented with oleate albumin dextrose catalase (OADC and incubated at 37°C for four weeks. The number of visible and individual colonies were counted. Results: The first line anti-tuberculosis drugs (RIF+INH+EMB+PZA after eight weeks of therapy had no impact as the bacillary load in lungs and spleens remained unchanged. However, econazole, moxifloxacin alone as well as in combination significantly reduced the bacillary load in lungs as well as in spleens of MDR-TB bacilli infected mice. Interpretation & conclusions: Co-administration of the two drugs (econazole and moxifloxacin to MDR-TB strain JAL-7782 infected mice exhibited additive effect, the efficacy of the drugs in combination being higher as compared with ECZ or MOX alone. These results were substantiated by histopathological studies. This study suggests the utility of

  6. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.

    Cafini, Fabio; Alou, Luis; Sevillano, David; Valero, Eva; Prieto, José

    2004-10-01

    Time-kill studies compared the activities of moxifloxacin with those of levofloxacin, azithromycin and amoxicillin-clavulanate against 10 pneumococcal strains with various drug susceptibilities. Three Streptococcus pneumoniae strains were resistant to moxifloxacin: 6, 7 and 2 strains were resistant to levofloxacin, azithromycin and amoxicillin-clavulanate, respectively. Of these, 1 strain was resistant to all antimicrobial agents studied. Moxifloxacin and amoxicillin-clavulanate were bactericidal after 24h at serum Cmax levels against 9 and 8 strains, respectively, while levofloxacin and azithromycin were bactericidal against 3 and 2 strains, respectively. A higher activity was only observed for amoxicillin-clavulanate for logarithmic phase cultures at 1, 4 and 8h compared with stationary phase organisms. Amoxicillin-clavulanate and moxifloxacin were bactericidal at free serum levels (protein unbound) after 24h against 8 and 3 strains, respectively. Moxifloxacin was bactericidal at epithelial lining fluid levels against all strains at 24h, including one moxifloxacin, amoxicillin-clavulanate and azithromycin-resistant strain; lower levels of bactericidal activity was observed for levofloxacin, azithromycin and amoxicillin-clavulanate against 7, 2 and 4 strains, respectively. This demonstrated the importance of moxifloxacin tissue levels. PMID:15380257

  7. Development and characterisation of thermo reversible mucoadhesive moxifloxacin hydrochloride in situ ophthalmic gel

    M Dholakia

    2012-01-01

    Full Text Available A sustain release thermo reversible in situ gel of Moxifloxacin Hydrochloride using mucoadhesive polymer was prepared. Mucoadhesive polymer was used to obtain an ophthalmic delivery system with improved mechanical and mucoadhesive properties that will provide prolong retention time for treatment of ocular diseases. Developed formulations were evaluated for drug-excipient compatibility study, pH, Clarity, Gelation temperature study, Mucoadhesion properties and in-vitro release studies. Drug-excipient compatibility study was performed by FTIR technique.The individual IR spectra of the pure drug and polymers as well as the combination spectra of the drug and polymer were taken, which indicate no interaction between Moxifloxacin and polymers when compared with infrared spectrum of pure drug as all functional group frequencies were present. The values of other parameters obtained were in acceptable range. In vitro release tests revealed that 98% drug was released from the in situ gel containing 0.5% and 1.00% HPMC in 12 hr. provides prolonged release.

  8. Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.

    Wicha, Sebastian G; Haak, Thomas; Zink, Karl; Kees, Frieder; Kloft, Charlotte; Kees, Martin G

    2015-06-01

    The objective of this study was to provide a pharmacokinetic/pharmacodynamic (PK/PD) analysis of moxifloxacin in patients with diabetic foot infections (DFI). The plasma concentration-time courses were determined in 50 DFI patients on day 1 and 3 after intravenous moxifloxacin 400 mg once-daily. A two-compartment population pharmacokinetic model was developed, identifying as covariates total body weight on central and peripheral volume of distribution (V1, V2) and ideal body weight on clearance (CL), respectively. For a 70 kg patient V1 was 68.1 L (interindividual variability, CV: 27.4%), V2 44.6 L, and CL 12.1 L/h (25.6%). Simulations were performed to calculate the probability of target attainment (PTA) for Gram-positive and Gram-negative pathogens with fAUC/MIC targets of ≥30 and ≥100, respectively. PTA was 0.68-1 for susceptible (MIC ≤0.5 mg/L according to EUCAST) Gram-positive, but infected with formally susceptible Gram-negative pathogens close to the EUCAST breakpoint. PMID:25600294

  9. Influence of Moxifloxacin on Hepatic Redox Status and Plasma Biomarkers of Hepatotoxicity and Nephrotoxicity in Rat

    Ayokanmi Ore

    2015-01-01

    Full Text Available Moxifloxacin is a broad spectrum fluoroquinolone antibacterial agent. We examined the hepatic redox status and plasma biomarkers of nephrotoxicity and hepatotoxicity in rat following administration of moxifloxacin (MXF. Twenty-four Wistar rats, 180–200 g, were randomized into four groups (I–IV. Animals in group I (control received 1 mL of distilled water, while animals in groups II, III, and IV received 1 mL each of MXF equivalent to 4 mg/kg b.w., 8 mg/kg b.w., and 16 mg/kg b.w., respectively. After seven days, plasma urea, bilirubin, and creatinine were significantly (P<0.05 elevated in the MXF-treated animals. Activities of alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase were significantly increased in the plasma of MXF-treated animals compared to control. Also plasma total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides increased significantly in the MXF-treated groups relative to control. Moreover, MXF triggered a significant decrease in hepatic catalase, superoxide dismutase, and glutathione-S transferase activities. Likewise, MXF caused a decrease in the hepatic levels of glutathione and vitamin C. A significant increase in hepatic MDA content was also observed in the MXF-treated animals relative to control. Overall, our data suggest that the half-therapeutic, therapeutic, and twice the therapeutic dose of MXF induced nephrotoxicity, hepatotoxicity, and altered hepatic redox balance in rats.

  10. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis.

    Yupin Suputtamongkol

    Full Text Available BACKGROUND: Strongyloidiasis, caused by an intestinal helminth Strongyloides stercoralis, is common throughout the tropics. It remains an important health problem due to autoinfection, which may result in hyperinfection and disseminated infection in immunosuppressed patients, especially patients receiving chemotherapy or corticosteroid treatment. Ivermectin and albendazole are effective against strongyloidiasis. However, the efficacy and the most effective dosing regimen are to be determined. METHODS: A prospective, randomized, open study was conducted in which a 7-day course of oral albendazole 800 mg daily was compared with a single dose (200 microgram/kilogram body weight, or double doses, given 2 weeks apart, of ivermectin in Thai patients with chronic strongyloidiasis. Patients were followed-up with 2 weeks after initiation of treatment, then 1 month, 3 months, 6 months, 9 months, and 1 year after treatment. Combination of direct microscopic examination of fecal smear, formol-ether concentration method, and modified Koga agar plate culture were used to detect strongyloides larvae in two consecutive fecal samples in each follow-up visit. The primary endpoint was clearance of strongyloides larvae from feces after treatment and at one year follow-up. RESULTS: Ninety patients were included in the analysis (30, 31 and 29 patients in albendazole, single dose, and double doses ivermectin group, respectively. All except one patient in this study had at least one concomitant disease. Diabetes mellitus, systemic lupus erythrematosus, nephrotic syndrome, hematologic malignancy, solid tumor and human immunodeficiency virus infection were common concomitant diseases in these patients. The median (range duration of follow-up were 19 (2-76 weeks in albendazole group, 39 (2-74 weeks in single dose ivermectin group, and 26 (2-74 weeks in double doses ivermectin group. Parasitological cure rate were 63.3%, 96.8% and 93.1% in albendazole, single dose oral

  11. Gender differences in endocrine responses to posture and 7 days of 6 deg head down bed rest

    Vernikos, J.; Dallman, M. F.; Keil, L. C.; Ohara, D.; Convertino, V. A.

    1993-01-01

    Endocrine regulation of fluids and electrolytes during seven days of 6 deg head down bed rest (HDBR) was compared in male (n = 8) and, for the first time, female (n = 8) volunteers. The subjects' responses to quiet standing for 2 hr before and after HDBR were also tested. In both sexes, diuresis and natriuresis were evident during the first 2-3 days of HDBR, resulting in a marked increase in the urinary Na/K ratio and significant Na retention on reambulation. After the first day of HDBR, plasma renin activity (PRA) was increased relative to aldosterone, plasma volume was decreased, and the renal response to aldosterone appeared to be appropriate. Circulating levels of arginine vasopressin (AVP), cortisol, and ACTH were unchanged during HDBR. Plasma testosterone decreased slightly on day 2 of HDBR in males. The ratio of AM ACTH to cortisol was lower in females than in males because ACTH was lower in females. Urinary cortisol increased and remained elevated throughout the HDBR in males only. There were no gender differences in the responses to 7 day HDBR, except those in the pituitary-adrenal system; those differences appeared unrelated to the postural change. The provocative cardiovascular test of quiet standing before and after bed rest revealed both sex differences and effects of HDBR. There were significant sex differences in cardiovascular responses to standing, before and after HDBR. Females had greater PRA and aldosterone responses to standing before bedrest and larger aldosterone responses to standing after HDBR than males. Cardiovascular responses to standing before and after bedrest differed markedly: arterial pressure and heart rates increased with standing before HDBR, by contrast, arterial pressure decreased, with greater increases in heart rates after HDBR. In both sexes, all hormonal responses to standing were greater after HDBR. The results show clearly that similar responses to standing as well as to HDBR occur in both sexes, but that females exhibit

  12. Activities of New Antimicrobial Agents (Trovafloxacin, Moxifloxacin, Sanfetrinem, and Quinupristin-Dalfopristin) against Bacteroides fragilis Group: Comparison with the Activities of 14 Other Agents

    Betriu, Carmen; Gómez, María; Palau, M. Luisa; Sánchez, Ana; Picazo, Juan J.

    1999-01-01

    The antimicrobial activities of trovafloxacin, moxifloxacin, sanfetrinem, quinupristin-dalfopristin, and 14 other antimicrobial agents against 218 Bacteroides fragilis group strains were determined. A group of 10 imipenem-resistant strains were also tested. Imipenem, meropenem, and sanfetrinem had the lowest MICs of all of the β-lactams. Quinupristin-dalfopristin inhibited all of the strains at 2 μg/ml. Overall, the MICs of trovafloxacin and moxifloxacin for 90% of the strains tested were 1 a...

  13. In-vitro Wirksamkeit von Moxifloxacin und Linezolid gegen Staphylococcus aureus-, Streptococcus pneumoniae- und Enterococcus spp.-Isolate in Abhängigkeit vom Testmedium und der Keimlokalisation

    Wilhelm, Cornelia

    2004-01-01

    Ziel der vorliegenden Arbeit ist die Untersuchung der zuvor nicht bekannten Beeinflussung der Aktivität von bestimmten Antibiotika durch unterschiedliche Testnährmedien. Zu diesem Zweck wird die Aktivität von Moxifloxacin, Linezolid, Penicillin G, Oxacillin und Cefuroxim gegen Bakterienisolate der Spezies S. aureus, S. pneumoniae, E. faecalis und E. faecium in Bouillon und Blut getestet. Des Weiteren wird die Aktivität von Moxifloxacin und Linezolid gegen intrazellulär in humanen Granulozyten...

  14. Serine-to-Asparagine Substitution in the GyrA Gene Leads to Quinolone Resistance in Moxifloxacin-Exposed Chlamydia pneumoniae

    Rupp, Jan; Gebert, Andreas; Solbach, Werner; Maass, Matthias

    2005-01-01

    Quinolone resistance of Chlamydia pneumoniae has not been described previously. Serial subcultures of C. pneumoniae under increasing moxifloxacin concentrations (0.0125 to 6.4 mg/liter) resulted in a 256-fold MIC increase compared to moxifloxacin-naive strains. GyrA gene sequencing revealed a novel point mutation with a Ser→Asn substitution. Subcultures under rifalazil and macrolides did not alter the respective MICs.

  15. Activation of K+ channels and Na+/K+ ATPase prevents aortic endothelial dysfunction in 7-day lead-treated rats

    Seven day exposure to a low concentration of lead acetate increases nitric oxide bioavailability suggesting a putative role of K+ channels affecting vascular reactivity. This could be an adaptive mechanism at the initial stages of toxicity from lead exposure due to oxidative stress. We evaluated whether lead alters the participation of K+ channels and Na+/K+-ATPase (NKA) on vascular function. Wistar rats were treated with lead (1st dose 4 μg/100 g, subsequent doses 0.05 μg/100 g, im, 7 days) or vehicle. Lead treatment reduced the contractile response of aortic rings to phenylephrine (PHE) without changing the vasodilator response to acetylcholine (ACh) or sodium nitroprusside (SNP). Furthermore, this treatment increased basal O2− production, and apocynin (0.3 μM), superoxide dismutase (150 U/mL) and catalase (1000 U/mL) reduced the response to PHE only in the treated group. Lead also increased aortic functional NKA activity evaluated by K+-induced relaxation curves. Ouabain (100 μM) plus L-NAME (100 μM), aminoguanidine (50 μM) or tetraethylammonium (TEA, 2 mM) reduced the K+-induced relaxation only in lead-treated rats. When aortic rings were precontracted with KCl (60 mM/L) or preincubated with TEA (2 mM), 4-aminopyridine (4-AP, 5 mM), iberiotoxin (IbTX, 30 nM), apamin (0.5 μM) or charybdotoxin (0.1 μM), the ACh-induced relaxation was more reduced in the lead-treated rats. Additionally, 4-AP and IbTX reduced the relaxation elicited by SNP more in the lead-treated rats. Results suggest that lead treatment promoted NKA and K+ channels activation and these effects might contribute to the preservation of aortic endothelial function against oxidative stress. -- Highlights: ► Increased free radicals production ► Increased Na+/K+ ATPase activity ► Promotes activation of the K+ channels and reduced vascular reactivity ► These effects preserve endothelial function against oxidative stress. ► Low concentrations constitute environmental cardiovascular

  16. Comparative efficacy of 3-day and 7-day chemotherapy with twice-daily pivmecillinam in urinary tract infections seen in general practice.

    Richards, H H

    1984-01-01

    In a multi-centre general practice study, 183 females suffering from symptoms of acute urinary tract infection were randomly assigned to receive 400 mg pivmecillinam twice-daily for either 3 or 7 days. The clinical response was equally good in both treatment groups with a mean reduction in symptom scores of 88%. Positive pre-treatment bacteriological cultures were obtained from 48 (36%) of the 134 patients for whom data were complete. Bacteriological cure was achieved in all these patients except for 1 in the 3-day treatment group. Pivmecillinam was well tolerated, with side-effects reported by 7 (7%) patients in the 3-day group and 12 (13%) patients in the 7-day group. One patient in the 3-day group and 2 patients in the 7-day group stopped treatment prematurely due to side-effects. PMID:6499513

  17. Relative efficiencies of the Burkard 7-Day, Rotorod and Burkard Personal samplers for Poaceae and Urticaceae pollen under field conditions

    Peel, Robert George; Kennedy, Roy; Smith, Matt;

    2014-01-01

    differences inter-sampler correction factors may be applied, however for many pollen samplers and pollen taxa such correction factors do not exist and cannot be derived from existing published work. Materials and methods: In this study the relative efficiencies of the Burkard 7-Day Recording Volumetric Spore...... collected during 2010 and 2011-12 respectively. Results: The three devices were found to record significantly different concentrations for both pollen taxa, with the exception of the 7-Day and Rotorod samplers for Poaceae pollen. Under the range of conditions present during the study wind speed was found to...

  18. Moxifloxacin Ophthalmic

    ... as cinoxacin (Cinobac) (not available in the US), ciprofloxacin (Cipro, Ciloxan), enoxacin (Penetrex) (not available in the ... other signs of infection ear pain or fullness rash hives itching difficulty breathing or swallowing swelling of ...

  19. Moxifloxacin Injection

    ... if it becomes available.See the FDA Drug Safety Communication (see http://1.usa.gov/1TdvrCk) for a ... BACKGROUND: The safety issues described in the Drug Safety Communication were also discussed at an FDA Advisory Committee ( ...

  20. Comparative In Vitro Activities of Linezolid, Quinupristin-Dalfopristin, Moxifloxacin, and Trovafloxacin against Erythromycin-Susceptible and -Resistant Streptococci

    Betriu, Carmen; Redondo, Montserrat; Palau, M. Luisa; Sánchez, Ana; Gómez, María; Culebras, Esther; Boloix, Ana; Picazo, Juan J.

    2000-01-01

    The in vitro activities of the new agents linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin were determined and compared with those of penicillin, clindamycin, and four macrolides against 53 erythromycin-resistant Streptococcus pneumoniae, 117 S. pyogenes (64 erythromycin-susceptible and 53 -resistant), and 101 S. agalactiae (53 erythromycin-susceptible and 48 -resistant) isolates. Differentiation of macrolide resistance phenotypes was performed by the double-disk method. ...

  1. Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB

    Lee, Seung Heon; Seo, Kyung-Ah; Lee, Young Min; Lee, Hyun-Kyung; Kim, Je Hyeong; Shin, Chol; Ghim, Jong-Ryul; Shin, Jae-Gook; Kim, Dong hyun

    2015-01-01

    Purpose Low serum concentrations of drugs used to treat multi-drug resistant tuberculosis (MDR-TB) have occasionally been associated with treatment failure. We determined the frequencies of low serum concentrations of anti-MDR-TB drugs, and assessed the effects of these concentrations on 2-month sputum conversion. Materials and Methods The serum levels of moxifloxacin (MF), prothionamide (PTH), and cycloserine (CS) were determined for 89 serum samples by high-pressure liquid chromatography-ta...

  2. Efficacy of Topically Delivered Moxifloxacin against Wound Infection by Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus▿

    Jacobsen, F; Fisahn, C.; Sorkin, M.; Thiele, I.; T. Hirsch; Stricker, I; Klaassen, T.; Roemer, A.; Fugmann, B; Steinstraesser, L.

    2011-01-01

    Wound infection is a common risk for patients with chronic nonhealing wounds, causing high morbidity and mortality. Currently, systemic antibiotic treatment is the therapy of choice, despite often leading to several side effects and the risk of an insufficient tissue penetration due to impaired blood supply. If systemically delivered, moxifloxacin penetrates well into inflammatory blister fluid, muscle, and subcutaneous adipose tissues and might therefore be a possible option for the topical ...

  3. Clostridium difficile with Moxifloxacin/Clindamycin Resistance in Vegetables in Ohio, USA, and Prevalence Meta-Analysis

    Alex Rodriguez-Palacios; Sanja Ilic; LeJeune, Jeffrey T.

    2014-01-01

    We (i) determined the prevalence of Clostridium difficile and their antimicrobial resistance to six antimicrobial classes, in a variety of fresh vegetables sold in retail in Ohio, USA, and (ii) conducted cumulative meta-analysis of reported prevalence in vegetables since the 1990s. Six antimicrobial classes were tested for their relevance as risk factors for C. difficile infections (CDIs) (clindamycin, moxifloxacin) or their clinical priority as exhaustive therapeutic options (metronidazole...

  4. Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model▿

    Poissy, Julien; Aubry, Alexandra; Fernandez, Christine; Lott, Marie-Catherine; Chauffour, Aurelie; Jarlier, Vincent; Farinotti, Robert; Veziris, Nicolas

    2010-01-01

    The prevalence of extensively drug-resistant tuberculosis (XDR-TB), defined as TB that is resistant to isoniazid, rifampin, fluoroquinolones, and aminoglycosides, is rising worldwide. The extent of Mycobacterium tuberculosis resistance to fluoroquinolones depends on the mutation in the DNA gyrase, the only target of fluoroquinolones. The MIC of moxifloxacin, the most active fluoroquinolone against M. tuberculosis, may be lower than its peak serum level for some ofloxacin-resistant strains of ...

  5. Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery

    Bucci, Frank A; Nguimfack, Ines Teuma; Fluet, Angel T

    2016-01-01

    Purpose The objective of this study was to compare the pharmacokinetics of levofloxacin 1.5% and moxifloxacin hydrochloride 0.5% ophthalmic solutions in aqueous humor after multiple doses prior to cataract surgery. Methods Ninety-eight eyes underwent cataract surgery and met the requirements of PK analysis. Eligible eyes were randomly assigned in a 1:1 ratio to receive levofloxacin or moxifloxacin prior to cataract surgery and were randomized into one of four sampling time points (ie, 1, 2, 4, and 6 hour post-last dose). Randomization was investigator and laboratory-masked. Three days prior to cataract surgery, each patient instilled one drop of the assigned study medication into the operative eye four times daily. One aqueous humor specimen was collected from the eye at the randomized time point. Aqueous humor specimens were assayed for drug concentration using a validated liquid chromatography and tandem mass spectrometer. Results Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0–6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0–6 6.1, 3.8 μg·min/ml, P<0.001 respectively). No treatment-emergent adverse events were reported. Conclusion Significantly greater drug exposures were attained in aqueous humor following the administration of levofloxacin 1.5% than moxifloxacin 0.5% ophthalmic solution. Achieving considerable higher drug concentration in the aqueous humor with levofloxacin 1.5% may demonstrate a greater potential for bacterial eradication. PMID:27194905

  6. In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans

    Ji, Baohong; Lefrançois, Sébastien; Robert, Jerome; Chauffour, Aurélie; Truffot, Chantal; Jarlier, Vincent

    2006-01-01

    Seven antimicrobials were tested in vitro against 29 clinical isolates of Mycobacterium ulcerans. R207910 demonstrated the lowest MIC50 and MIC90, followed by moxifloxacin (MXF), streptomycin (STR), rifampin (RIF), amikacin (AMK), linezolid (LZD), and PA-824. All but PA-824 demonstrated an MIC90 significantly less than the clinically achievable peak serum level. Administered as monotherapy to mice, RIF, STR, AMK, MXF, R207910, and LZD demonstrated some degree of bactericidal activity, whereas...

  7. 莫西沙星引起QT间期异常延长%Abnormal QT interval prolongation associated with moxifloxacin

    郑策; 甄健存

    2011-01-01

    One 87-year-old man with a history of atrial fibrillation and coronary heart disease for more than 20 years, was intravenously given 400 mg of moxifloxacin once daily for suspected lung infection. On the second day of moxifloxacin administration, the patient developed dyspnea and dizziness, and electrocardiogram showed prolongation of the QTc interval to 489 ms, which was 54 ms longer than the value at the time of admission (435 ms). Moxifloxacin was promptly withdrawn. Eight hours later, the QTc interval was 442 ms, which was close to the baseline range, and had no abnormal change during the therapy time.%1例87岁男性患者,房颤、冠心病史20余年,因怀疑肺部感染静脉用莫西沙星400 mg,qd.次日,患者出现胸闷、头晕,心电图显示QTc489ms,较入院时的435ms延长了54ms.立即停用莫西沙星,8h后,QTc442ms,接近入院时水平,以后均未有异常改变.

  8. Effects of a mouthwash with chlorine dioxide on oral malodor and salivary bacteria: a randomized placebo-controlled 7-day trial

    Ohnuki Mari

    2010-02-01

    Full Text Available Abstract Background Previous research has shown the oxidizing properties and microbiological efficacies of chlorine dioxide (ClO2. Its clinical efficacies on oral malodor have been evaluated and reported only in short duration trials, moreover, no clinical studies have investigated its microbiological efficacies on periodontal and malodorous bacteria. Thus, the aim of this study was to assess the inhibitory effects of a mouthwash containing ClO2 used for 7 days on morning oral malodor and on salivary periodontal and malodorous bacteria. Methods/Design A randomized, double blind, crossover, placebo-controlled trial was conducted among 15 healthy male volunteers, who were divided into 2 groups. Subjects were instructed to rinse with the experimental mouthwash containing ClO2 or the placebo mouthwash, without ClO2, twice per day for 7 days. After a one week washout period, each group then used the opposite mouthwash for 7 days. At baseline and after 7 days, oral malodor was evaluated with Organoleptic measurement (OM, and analyzed the concentrations of hydrogen sulfide (H2S, methyl mercaptan (CH3SH and dimethyl sulfide ((CH32S, the main VSCs of human oral malodor, were assessed by gas chromatography (GC. Clinical outcome variables included plaque and gingival indices, and tongue coating index. The samples of saliva were microbiologically investigated. Quantitative and qualitative analyses were performed using the polymerase chain reaction-Invader method. Results and Discussion The baseline oral condition in healthy subjects in the 2 groups did not differ significantly. After rinsing with the mouthwash containing ClO2 for 7 days, morning bad breath decreased as measured by the OM and reduced the concentrations of H2S, CH3SH and (CH32S measured by GC, were found. Moreover ClO2 mouthwash used over a 7-day period appeared effective in reducing plaque, tongue coating accumulation and the counts of Fusobacterium nucleatum in saliva. Future research is

  9. Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire

    Barrea, Luigi; Macchia, Paolo Emidio; Tarantino, Giovanni; Di Somma, Carolina; Pane, Elena; Balato, Nicola; Napolitano, Maddalena; Colao, Annamaria; Savastano, Silvia

    2015-01-01

    Background Western dietary pattern is included among the environmental dietary factors involved in the pathogenesis of psoriasis. Nutritional data collection methods and gender differences might affect the association between diet and psoriasis. The 7-day food records is considered the “gold standard” of self-administered food frequency questionnaires. In this study, we evaluated the differences in the dietary intake, anthropometric measurements and cardio-metabolic risk profile in a group of...

  10. Comparing a 7-day diary vs. 24 h-recall for estimating fluid consumption in overweight and obese Mexican women

    Hernández-Cordero, Sonia; López-Olmedo, Nancy; Rodríguez-Ramírez, Sonia; Barquera-Cervera, Simón; Rivera-Dommarco, Juan; Popkin, Barry

    2015-01-01

    Background High intake of sugar-sweetened beverages (SSB) is linked to increased weight, energy intake, and diabetes. Even though the increasing interest on beverages and water intake, there are few dietary tools carefully validated. The purpose of this paper is to compare a fluid intake 7-day diary against a 24-h recall questionnaire to estimate the fluid consumption in overweight and obese women participating in a randomized controlled trial in Mexico. Methods This cross-sectional study exp...

  11. Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)

    Kuijper Ed J; Ablij Hans C; Delfos Nathalie M; Wattel-Louis G Hanke; Koster Ted; Leyten Eliane MS; Elzevier Henk W; Assendelft Willem JJ; van't Wout Jan W; van Nieuwkoop Cees; Pander Jan; Blom Jeanet W; Spelt Ida C; van Dissel Jaap T

    2009-01-01

    Abstract Background Current guidelines on the management of urinary tract infection recommend treating febrile urinary tract infection or acute pyelonephritis with antimicrobials for at least 14 days. Few randomized trials showed the effectiveness of treatment durations of 5 to 7 days but this has only been studied in young previously healthy women. Methods/Design A randomized placebo-controlled double-blind multicenter non-inferiority trial in which 400 patients with community acquired febri...

  12. Levofloxacin plus Metronidazole Administered Once Daily versus Moxifloxacin Monotherapy against a Mixed Infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model

    Hermsen, Elizabeth D.; Hovde, Laurie B.; Sprandel, Kelly A.; Rodvold, Keith A.; Rotschafer, John C.

    2005-01-01

    Moxifloxacin has been suggested as an option for monotherapy of intra-abdominal infections. Recent data support the use of a once-daily metronidazole regimen. The purpose of this study was to investigate the activity of levofloxacin (750 mg every 24 h [q24h]) plus metronidazole (1,500 mg q24h) compared with that of moxifloxacin (400 mg q24h) monotherapy in a mixed-infection model. By using an in vitro pharmacodynamic model in duplicate, Escherichia coli and Bacteroides fragilis were exposed t...

  13. Simultaneous determination of moxifloxacin and ofloxacin in physiological fluids using high performance liquid chromatography with ultraviolet detection.

    Khan, Fahim Ullah; Nasir, Fazli; Iqbal, Zafar; Khan, Ismail; Shahbaz, Naila; Hassan, Muhammad; Ullah, Farhad

    2016-04-01

    A novel, sensitive and validated RP-HPLC-UV method was developed for simultaneous determination of moxifloxacin and ofloxacin using timolol maleate as internal standard in physiological fluids. Different experimental parameters were optimized and validated according to international guidelines. Complete separation of the analytes was achieved with Kromasil 100-5C18 analytical column (250mm×4.6mm×5μm), methanol and 0.05% trifloroacetic acid (TFA) (38:62v/v) were used as mobile phase, pumped at flow rate of 1.1ml/min in isocratic phase, column oven temperature maintained at 45°C and detection wavelength of 290nm. Protein precipitation method was applied to extract the drugs from human plasma and bovine aqueous humor samples using methanol as precipitating solvent. This method is linear in concentration range of 0.018-100μg/ml for moxifloxacin and 0.014-20μg/ml for ofloxacin. The recoveries of the method were 97.52 and 97.39% in human plasma for MX and OFN respectively, while in aqueous humor 94.48% for MX. The LOD values in plasma were found to be 10.0 and 8.00ng/ml for MX and OFN respectively, while their respective LOQ values were 18.0 and 14ng/ml. In aqueous humor the LOD and LOQ for MX were 16.0 and 24ng/ml respectively. In future, this method will be used to study the pharmacokinetic profile of moxifloxacin and ofloxacin in biological fluids and pharmaceutical products. PMID:26970846

  14. Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.

    Carman, Robert J; Genheimer, Christopher W; Rafii, Fatemeh; Park, Miseon; Hiltonsmith, Megan F; Lyerly, David M

    2009-12-01

    To characterize the extent and diversity of moxifloxacin resistance among Clostridium difficile isolates recovered during a predominantly Anaerobe Reference Unit (ARU) ribotype 027-associated nosocomial outbreak of antibiotic associated diarrhea we measured the susceptibility of 34 field isolates and 6 laboratory strains of C. difficile to moxifloxacin. We ribotyped the isolates as well as assaying them by PCR for the metabolic gene, gdh, and the virulence genes, tcdA, tcdB, tcdC, cdtA and cdtB. All the laboratory isolates, including the historical ARU 027 isolate Cd196, were susceptible to moxifloxacin (or=16 microg/mL (high resistance). We sequenced the quinolone resistance determining regions of gyrA (position 71-460) and gyrB (position 1059-1448) from two susceptible laboratory strains, all five isolates with moderate resistance and two highly resistant isolates. Two highly resistant isolates (Pitt 40, ribotype ARU 027 and Pitt 33, ribotype ARU 001) had the same C245T (Thr(82)Delta Ile) mutation. No other changes were seen. Amplification with primer pairs specific for the C245T mutant gyrA and for the wild type gene respectively confirmed all 16 highly resistant ARU 027 isolates, as well as the highly resistant isolates from other ribotypes, had the C245T mutation and that the mutation was absent from all other isolates. Among the five isolates with moderate resistance we found combinations of mutations within gyrA (T128A, Val(43)Delta Asp and G349T, Ala(117)Delta Ser) and gyrB (G1276A, Arg(426)Delta Asn). The G1396A (Glu(466)Delta Lys) mutation was not associated with increased resistance. PMID:19818865

  15. Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin

    Rudolph S Wagner

    2010-01-01

    Full Text Available Rudolph S Wagner1, David B Granet2, Steven J Lichtenstein3, Tiffany Jamison4, Joseph J Dajcs4, Robert D Gross5, Paul Cockrum41New Jersey Medical School, Newark, NJ, USA; 2Ratner Children’s Eye Center, University of California – San Diego, La Jolla, CA, USA; 3University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA; 4Alcon Research, Ltd, Fort Worth, TX, USA; 5Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USAPurpose: To compare the kinetics and speed of kill of Streptococcus pneumoniae and Haemophilus influenzae on exposure to three topical ophthalmic antibiotic solutions.Materials and methods: Bacterial conjunctivitis isolates of S. pneumoniae and H. influenzae were exposed to 1:1000 dilutions of moxifloxacin 0.5%, tobramycin 0.3%, gentamicin 0.3%, and water (control. At 15, 30, 60, 120, and 180 minutes after exposure, aliquots were collected, cells were cultured, and viable cell counts were determined using standard microbiological methods.Results: Moxifloxacin achieved 99.9% kill (3-log reduction at approximately 2 hours for S. pneumoniae and at 15 minutes for H. influenzae. Tobramycin and gentamicin did not achieve 3-log reduction of S. pneumoniae during the 180-minute study period. An increase in bacterial growth was noted for these isolates. Gentamicin took more than 120 minutes to achieve the 3-log reduction of H. influenzae and tobramycin did not reach the 3-log reduction of this pathogen during the 180-minute study period.Conclusion: Moxifloxacin killed S. pneumoniae and H. influenzae in vitro faster than tobramycin and gentamicin, suggesting its potential clinical benefit as a first-line treatment for bacterial conjunctivitis to minimize patient symptoms and to limit the contagiousness of the disease.Keywords: kinetics of kill, bacterial conjunctivitis, in vitro, Streptococcus pneumoniae, Haemophilus influenzae, fluoroquinolones, aminoglycosides

  16. Characterisation of patients receiving moxifloxacin for acute bacterial rhinosinusitis in clinical practice: results from an international, observational cohort study.

    Ralph Mösges

    Full Text Available We conducted a prospective, non-controlled, multi-centre Phase IV observational cohort study of patients with acute bacterial rhinosinusitis who were treated with moxifloxacin in clinical practice in 19 countries in Asia Pacific, Europe and the Middle East. With the data collected we evaluated the presentation and course of the current disease episode, particularly in terms of the principal clinical signs and symptoms of acute rhinosinusitis and diagnostic procedures. A final assessment of moxifloxacin therapy was made to evaluate the impact of the sinusitis episode on activities of daily life and on sleep disturbance, and to evaluate the clinical outcome of treatment. A total of 7,090 patients were enrolled, of whom 3909 (57.6% were included in the valid for clinical outcome and safety population. Regional differences were observed in the main symptoms of acute rhinosinusitis and, according to several characteristics, disease episodes appeared to be more severe in patients in Europe than in the Asia Pacific or Middle East regions. The sinusitis episode impacted on daily living for mean (SD periods of 3.6 (3.2, 4.6 (3.9 and 3.1 (3.0 days and disturbed sleep for 3.6 (3.2, 4.6 (3.9 and 3.1 (3.0 nights in the Asia Pacific, Europe and Middle East regions, respectively. With moxifloxacin treatment, the mean (SD time to improvement of symptoms was 3.0 (1.5, 3.4 (1.6 and 3.2 (1.5 days, and the time to resolution of symptoms was 4.8 (2.6 days, 5.7 (2.4 days and 5.5 (2.5 days, in the Asia Pacific, Europe and Middle East regions, respectively. In conclusion, acute rhinosinusitis remains a substantial health burden with significant impact on patients' quality of life, and there are differences between global regions in the clinical presentation, diagnosis and clinical course of disease episodes. Moxifloxacin was an effective and well-tolerated treatment option in the overall population.ClinicalTrials.gov Identifier: NCT00930488.

  17. Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis

    Benson Alice

    2006-04-01

    Full Text Available Abstract Background Acute bacterial sinusitis (ABS is a common infection in clinical practice. Data on time to bacteriologic eradication after antimicrobial therapy are lacking for most agents, but are necessary in order to optimize therapy. This was a prospective, single-arm, open-label, multicenter study to determine the time to bacteriologic eradication in ABS patients (maxillary sinusitis treated with moxifloxacin. Methods Adult patients with radiologically and clinically confirmed ABS received once-daily moxifloxacin 400 mg for 10 days. Middle meatus secretion sampling was performed using nasal endoscopy pre-therapy, and repeated on 3 consecutive days during treatment. Target enrollment was 30 bacteriologically evaluable patients (pre-therapy culture positive for Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis and evaluable cultures for at least Day 2 and Day 3 during therapy visits, including at least 10 each with S. pneumoniae or H. influenzae. Results Of 192 patients enrolled, 42 were bacteriologically evaluable, with 48 pathogens isolated. Moxifloxacin was started on Day 1. Baseline bacteria were eradicated in 35/42 (83.3% patients by day 2, 42/42 (100% patients by day 3, and 41/42 (97.6% patients by day 4. In terms of individual pathogens, 12/18 S. pneumoniae, 22/23 H. influenzae and 7/7 M. catarrhalis were eradicated by day 2 (total 41/48; 85.4%, and 18/18 S. pneumoniae and 23/23 H. influenzae were eradicated by day 3. On Day 4, S. pneumoniae was isolated from a patient who had negative cultures on Days 2 and 3. Thus, the Day 4 eradication rate was 47/48 (97.9%. Clinical success was achieved in 36/38 (94.7% patients at the test of cure visit. Conclusion In patients with ABS (maxillary sinusitis, moxifloxacin 400 mg once daily for 10 days resulted in eradication of baseline bacteria in 83.3% of patients by Day 2, 100% by Day 3 and 97.6% by Day 4.

  18. A comparative study of moxifloxacin and levofloxacin in treating AECOPD%莫西沙星与左氧氟沙星治疗AECOPD的对比研究

    周凤丽; 黄静; 李洪涛; 张文先; 朱家馨; 张天托

    2011-01-01

    目的 观察莫西沙星注射液治疗慢性阻塞性肺疾病急性发作(AECOPD)的疗效、副作用和具体用药方法。方法 收集住院的AECOPD患者113例,随机分成两组,分别以莫西沙星和左氧氟沙星(对照组)治疗,比较两组治疗后的疗效、细菌清除率及对预后指标(FEV1、呼吸困难、6min步行距离)的改善率及药物副作用;同时将莫西沙星治疗组随机分为持续静脉滴注组和静滴加口服序贯治疗组,比较两组治疗后的疗效、细菌清除率及对预后指标(FEV1、呼吸困难、6min步行距离)的改善率。结果 莫西沙星治疗组的临床有效率(77.78%)、细菌清除率(81.48%)及对三项预后指标的改善率(82.54%、73.02%、69.84%)均高于左氧氟沙星组,而药物副作用发生率两组相当。莫西沙星持续治疗组与序贯治疗组比较,临床有效率、细菌清除率及对三项预后指标的改善率均无明显差异。结论 莫西沙星用于治疗AECOPD优于左氧氟沙星,且持续静滴给药治疗AECOPD与序贯给药比较无优势,从经济学角度,应推荐序贯给药治疗。%Objective To observe the curative effects and side effects and administration of moxifloxacin injection when used to treat acute explosion chronic obstructive pulmonary disease(AECOPD). Methods 113 hospitalized patients of AECOPD were collected and randomizedly divided into two groups and were treated with moxifloxacin or levofloxacin respectivly. The efficacy rates, bacteriums eradication rates and the side effects of two groups were compared. And the improvement rates of FEV1 or walking distance of 6min or dyspnea were also compared. Besides, the patients of AECOPD treated with moxifloxacin were randomizedly divided into two groups and treated with moxifloxacin injections continuously or moxifloxacin injections and tables sequently respetively. Similarly, the differents were compared between the two groups. Results The efficacy

  19. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori

    Antonio Francesco Ciccaglione; Luigina Cellini; Laurino Grossi; Leonardo Marzio

    2012-01-01

    AIM:To compare triple therapy vs quadruple therapy for 10 d as first-line treatment of Helicobacterpylori (H.pylori) infection.METHODS:Consecutive H.pylori positive patients never treated in the past for this infection were randomly treated with triple therapy of pantoprazole (PAN) 20 mg bid,amoxicillin (AMO) 1 g bid and moxifloxacin (MOX) 400 mg bid for 10 d (PAM) or with quadruple therapy of PAN 20 mg bid,AMO 1 g bid,MOX 400 mg bid and bismuth subcitrate 240 mg bid for 10 d (PAMB).All patients were found positive at 13 C-Urea breath test (UBT) performed within ten days prior to the start of the study.A successful outcome was confirmed with an UBT performed 8 wk after the end of treatment.x2 analysis was used for statistical comparison.Per protocol (PP) and intention-to-treat (ITT) values were also calculated.RESULTS:Fifty-seven patients were enrolled in the PAM group and 50 in the PAMB group.One patient in each group did not return for further assessment.Eradication was higher in the PAMB group (negative:46 and positive:3) vs the PAN group (negative:44 and positive:12).The H.pylori eradication rate was statistically significantly higher in the PAMB group vs the PAM group,both with the PP and ITT analyses (PP:PAMB 93.8%,PAM 78.5%,P < 0.02; ITT:PAMB 92%,PAM 77.1%,P <0.03).CONCLUSION:The addition of bismuth subcitrate can be considered a valuable adjuvant to triple therapy in those areas where H.pylori shows a high resistance to fluoroquinolones.

  20. Bacterial degradation of moxifloxacin in the presence of acetate as a bulk substrate.

    Carvalho, M F; Maia, A S; Tiritan, M E; Castro, P M L

    2016-03-01

    Fluoroquinolones constitute a group of emerging pollutants and their occurrence in different environmental compartments is becoming object of increasing public concern due to their ecotoxicological effects and the potential to develop resistant bacteria. This study aimed to investigate the biodegradation of moxifloxacin (MOX), for which studies in the literature are very scarce. An activated sludge (AS) consortium and three bacterial strains able to degrade fluoroaromatic compounds - strains F11, FP1 and S2 - were tested. Biodegradation studies were conducted using acetate as a bulk carbon source. Strain F11 showed the highest biodegradation capacity, being able to completely consume and dehalogenate 7.5 μM of the target antibiotic when daily co-supplemented with acetate present as a readily degradable organic substrate in wastewaters. MOX could be used by strain F11 as a sole nitrogen source but the presence of an external nitrogen source in the culture medium was essential for complete biodegradation. Strain F11 was capable of completely consuming MOX in a range between 2 and 11 μM, although stoichiometric fluoride release was not obtained for the highest tested concentration. The antibacterial activity of residual MOX and of the metabolic products potentially resultant from the biodegradation process was investigated by agar diffusion tests, demonstrating that MOX biodegradation is associated with the elimination of the antibacterial properties of the target antibiotic and of the produced metabolites, which is an important result, as the activity of antibiotics and/or their metabolites in the environment, even at low levels, may lead to the development of resistant bacterial strains. Overall, the results obtained in this study suggest that strain F11 is a promising microorganism for the treatment of waters contaminated with MOX, where it could be used for bioaugmentation/bioremediation purposes. To the best of our knowledge, this is the first study reporting

  1. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments

    Cai, Xuejiu; Zhao, Jin; Cui, Junchang

    2016-01-01

    Background The optimal therapy for infections caused by Stenotrophomonas maltophilia (S. maltophilia) has not yet been established. The objective of our study was to evaluate the efficacy of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, polymyxin E, chloramphenicol, and ceftazidime against clinical isolated S. maltophilia strains by susceptibility testing and carried out time-kill experiments in potential antimicrobials. Methods The agar dilution method was used to test susceptibility of nine candidate antimicrobials, and time-killing experiments were carried out to evaluate the efficacy of SXT, minocycline, tigecycline, moxifloxacin, levofloxacin, and ceftazidime both alone and in combinations at clinically relevant antimicrobial concentrations. Results The susceptibility to SXT, minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, chloramphenicol, polymyxin E, and ceftazidime were 93.8%, 95.0%, 83.8%, 80.0%, 76.3%, 76.3%, 37.5%, 22.5%, and 20.0% against 80 clinical consecutively isolated strains, respectively. Minocycline and tigecycline showed consistent active against 22 SXT-resistant strains. However, resistance rates were high in the remaining antimicrobial agents against SXT-resistant strains. In time-kill experiments, there were no synergisms in most drug combinations in time-kill experiments. SXT plus moxifloxacin displayed synergism when strains with low moxifloxacin MICs. Moxifloxacin plus Minocycline and moxifloxacin plus tigecycline displayed synergism in few strains. No antagonisms were found in these combinations. Overall, compared with single drug, the drug combinations demonstrated lower bacterial concentrations. Some combinations showed bactericidal activity. Conclusions In S. maltophilia infections, susceptibility testing suggests that minocycline and SXT may be considered first-line therapeutic choices while tigecycline, moxifloxacin, levofloxacin

  2. Development and validation of sensitive kinetic spectrophotometric method for the determination of moxifloxacin antibiotic in pure and commercial tablets

    Ashour, Safwan; Bayram, Roula

    2015-04-01

    New, accurate, sensitive and reliable kinetic spectrophotometric method for the assay of moxifloxacin hydrochloride (MOXF) in pure form and pharmaceutical formulations has been developed. The method involves the oxidative coupling reaction of MOXF with 3-methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate (MBTH) in the presence of Ce(IV) in an acidic medium to form colored product with lambda max at 623 and 660 nm. The reaction is followed spectrophotometrically by measuring the increase in absorbance at 623 nm as a function of time. The initial rate and fixed time methods were adopted for constructing the calibration curves. The linearity range was found to be 1.89-40.0 μg mL-1 for initial rate and fixed time methods. The limit of detection for initial rate and fixed time methods is 0.644 and 0.043 μg mL-1, respectively. Molar absorptivity for the method was found to be 0.89 × 104 L mol-1 cm-1. Statistical treatment of the experimental results indicates that the methods are precise and accurate. The proposed method has been applied successfully for the estimation of moxifloxacin hydrochloride in tablet dosage form with no interference from the excipients. The results are compared with the official method.

  3. 1 case Moxifloxacin-induced abnormal taste%莫西沙星致味觉异常1例

    许世伟

    2013-01-01

    A 31-year-old man patient with upper respiratory tract infection was given moxifloxacin hydrochloride tablet 0.4g qd po. Two hours later, He felt bitter and abnormal taste, He felt bitter and abnormal taste;on the fourth day, on the fourth day, he took moxifloxacin for some reason and the same symptom appeared again. Finally he decided not to take any again. The adverse effect faded away. He turned to cefpodoxime proxetil tablets. No adverse effect occurred this time.%  1例31岁男性患者,因上呼吸道感染给予盐酸莫西沙星片口服0.4g/次,一日1次.2小时后出现口苦、味觉异常等变化,3天后消失;第4天患者自行再次服用莫西沙星片后又出现味觉异常表现,停用后改为头孢泊肟酯片后未出现味觉异常.

  4. 莫西沙星的严重不良反应及其防范%Severe Adverse Drug Reactions Induced by Moxifloxacin and Their Prevention

    陈晨钟; 史道华

    2011-01-01

    目的:提示临床高度关注莫西沙星的不良反应.方法:检索我院不良反应监测系统,对其中莫西沙星产生的3例严重不良反应报告进行分析.结果:3例莫西沙星严重不良反应中,暴发性肝衰竭1例,经抢救无效死亡;过敏性休克2例,经抢救未产生严重后果.结论:临床应重视莫西沙星严重不良反应的危害性.%OBJECTIVE: To prompt the adverse drug reactions (ADR) of moxifloxacin should be paid high attention to clinic.METHODS: Retrieved from ADR reporting and monitoring system of our hospital, 3 serious ADR cases induced by moxifloxacin were analyzed. RESULTS: Among 3 serious ADR cases induced by moxifloxacin, one case developed fulminant hepatic failure leading to death after rescue, and other 2 patients with anaphylactic shock was recovered without severe consequence after rescue.CONCLUSION:Great importance should be attached to ADR induced by moxifloxacin in the clinic.

  5. Susceptibilities of Mycobacterium marinum to Gatifloxacin, Gemifloxacin, Levofloxacin, Linezolid, Moxifloxacin, Telithromycin, and Quinupristin-Dalfopristin (Synercid) Compared to Its Susceptibilities to Reference Macrolides and Quinolones

    Bråbäck, Martin; Riesbeck, Kristian; Forsgren, Arne

    2002-01-01

    The susceptibility pattern of Mycobacterium marinum was determined. Quinupristin-dalfopristin and telithromycin were less active than clarithromycin. Linezolid showed good antimicrobial activity at clinically achievable concentrations. Gatifloxacin, levofloxacin, and moxifloxacin displayed activities similar to those of ciprofloxacin. Gemifloxacin was less active. The Etest method showed variable agreement with the reference method.

  6. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study

    Dunbar Lala M

    2005-05-01

    Full Text Available Abstract Background Community-acquired pneumonia (CAP remains a major cause of morbidity and mortality throughout the world. Telithromycin (a new ketolide has shown good in vitro activity against the key causative pathogens of CAP, including S pneumoniae resistant to penicillin and/or macrolides. Methods The efficacy and safety of telithromycin 800 mg orally once daily for 7 days in the treatment of CAP were assessed in an open-label, multicenter study of 442 adults. Results Of 149 microbiologically evaluable patients, 57 (9 bacteremic had Streptococcus pneumoniae. Of the 57 S pneumoniae pathogens isolated in these patients, 9 (2 bacteremic were penicillin- or erythromycin-resistant; all 57 were susceptible to telithromycin and were eradicated. Other pathogens and their eradication rates were: Haemophilus influenzae (96%, Moraxella catarrhalis (100%, Staphylococcus aureus (80%, and Legionella spp. (100%. The overall bacteriologic eradication rate was 91.9%. Of the 357 clinically evaluable patients, clinical cure was achieved in 332 (93%. In the 430 patients evaluable for safety, the most common drug-related adverse events were diarrhea (8.1% and nausea (5.8%. Conclusion Telithromycin 800 mg once daily for 7 days is an effective and well-tolerated oral monotherapy and offers a new treatment option for CAP patients, including those with resistant S pneumoniae.

  7. Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients

    Arama, Stefan Sorin; Tiliscan, Catalin; Negoita, Cristina; Croitoru, Alexandru; Arama, Victoria; Mihai, Carmen Marina; Pop, Florinel

    2016-01-01

    Objective. This study compared the eradication rates of of Helicobacter pylori (HP) infection by a 7-day and 14-day anti-HP regimen. Materials and Methods. An open, randomized, prospective study was performed to evaluate the response to anti-HP treatment in adult HP-positive patients following a 7-day course (Regimen A) of a proton pump inhibitor in association with clarithromycin and amoxicillin compared to a 14-day course (Regimen B). Gastric biopsies were performed at baseline and two months after anti-HP treatment. Results. Seventy-eight patients aged 18–64 years (28 males, 50 females) diagnosed with HP infection were included. Fifty-two (66.7%) patients received Regimen B and 26 (33.3%) Regimen A. The overall eradication rate was 70.5%. Better treatment response (p duodenal lesions in both regimens. Younger patients ≤35 years had a better response to Regimen B. Better treatment response was seen in women, urban residents, and those with tertiary level of education in both groups. Conclusion. 14-day anti-HP regimen offered a significant better overall eradication of HP in study population. PMID:26858750

  8. A validated stability-indicating high performance liquid chromatographic method for moxifloxacin hydrochloride and ketorolac tromethamine eye drops and its application in pH dependent degradation kinetics

    Jayant B Dave

    2013-01-01

    Full Text Available Background and Aim: A fixed dose combination of moxifloxacin hydrochloride and ketorolac tromethamine is used in ratio of 1:1 as eye drops for the treatment of the reduction of post operative inflammatory conditions of the eye. A simple, precise, and accurate High Performance Liquid Chromatographic (HPLC method was developed and validated for determination of moxifloxacin hydrochloride and ketorolac tromethamine in eye drops. Materials and Methods: Isocratic HPLC separation was achieved on a ACE C 18 column (C 18 (5 μm, 150 mm×4.6 mm, i.d. using the mobile phase 10 mM potassium di-hydrogen phosphate buffer pH 4.6-Acetonitrile (75:25 v/v at a flow rate of 1.0 mL/min. The detection was performed at 307 nm. Drugs were subjected to acid, alkali and neutral hydrolysis, oxidation and photo degradation. Moreover, the proposed HPLC method was utilized to investigate the pH dependent degradation kinetics of moxifloxacin hydrochloride and ketorolac tromethamine in buffer solutions at different pH values like 2.0, 6.8 and 9.0. Results and Conclusion: The retention time (t R of moxifloxacin hydrochloride and ketorolac tromethamine were 3.81±0.01 and 8.82±0.02 min, respectively. The method was linear in the concentration range of 2-20 μ/mL each for moxifloxacin hydrochloride and ketorolac tromethamine with a correlation coefficient of 0.9996 and 0.9999, respectively. The method was validated for linearity, precision, accuracy, robustness, specificity, limit of detection and limit of quantitation. The drugs could be effectively separated from different degradation products and hence the method can be used for stability analysis. Different kinetics parameters like apparent first-order rate constant, half-life and t 90 (time for 90% potency left were calculated.

  9. Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.

    Chien, Jung-Yien; Chien, Shun-Tien; Chiu, Wei-Yih; Yu, Chong-Jen; Hsueh, Po-Ren

    2016-08-01

    It is unclear whether the use of moxifloxacin (MFX), a newer synthetic fluoroquinolone, results in better outcomes in patients with ofloxacin (OFX)-resistant multidrug-resistant tuberculosis (MDR-TB). During the period from April 2006 to December 2013, a total of 2,511 patients with culture-confirmed tuberculosis (TB) were treated at a TB referral hospital in southern Taiwan. Of the 2,511 patients, 325 (12.9%) had MDR-TB, and of those 325 patients, 81 (24.9%) had OFX-resistant MDR-TB and were included in the study. Among the 81 patients with OFX-resistant MDR-TB, 50 (61.7%) were successfully treated and 31 (38.3%) had unfavorable outcomes, including treatment failure (n = 25; 30.9%), loss to follow-up (n = 2; 2.5%), and death (n = 4; 4.9%). Patients treated with MFX had a significantly higher rate of treatment success (77.3% versus 43.2%; odds ratio [OR] = 4.46, 95% confidence interval [CI] = 1.710 to 11.646, P = 0.002) than patients not treated with MFX, especially among those infected with MFX-susceptible isolates (40.7%) or isolates with low-level resistance to MFX (28.4%). Multivariate logistic regression analysis showed that treatment with MFX (adjusted odds ratio = 6.54, 95% CI = 1.44 to 29.59, P = 0.015) was the only independent factor associated with treatment success. Mutation at codon 94 in the gyrA gene was the most frequent mutation (68.0%) associated with high-level MFX resistance. Multivariate Cox proportional hazards regression analysis showed that treatment with MFX was also an independent factor associated with early culture conversion (hazard ratio = 3.12, 95% CI = 1.48 to 6.54, P = 0.003). Our results show that a significant proportion of OFX-resistant MDR-TB isolates were susceptible or had low-level resistance to MFX, indicating that patients with OFX-resistant MDR-TB benefit from treatment with MFX. PMID:27216062

  10. Randomized clinical trial on 7-day continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity

    The purpose of the study was to evaluate tumour and normal tissues 3-year response to 7-day-a-week continuous accelerated irradiation (CAIR) compared to a conventional treatment (5 days per week) in a randomized trial. One hundred patients with squamous cell carcinoma of the head and neck in stage T2-4-N0-1M0 were entered into the trial between December 1, 1993 and June 30, 1996. Dose per fraction of 2.0 Gy (to the end of 1994), and 1.8 Gy (since January 1, 1995) was the same in both arms and delivered once a day at regular 24-h intervals to total dose in the range of 66-72 Gy (depending on tumour stage). The only difference was overall treatment time being 5 weeks in the CAIR and 7 weeks in control arm. Actuarial 3-year local tumour control was 82% in the CAIR and 37% in the control group (P < 0.0001) with reduction in local recurrence rate of 83%. Actuarial 3-year overall survival was 78 and 32% (P < 0.0001), respectively. Confluent mucositis was significantly more severe and lasted longer in the CAIR than in control arm. After 2.0 Gy fractions five of 23 patients (22%) in the CAIR developed early necroses over a period of 2-4 months of follow-up which can be considered as a consequential to severe protracted acute mucosal reactions (CLE). For this reason dose per fraction was lowered to 1.8 Gy and the CLE was not observed again until now. Thus the overall rate of CLE decreased to 10%. The gain in tumour control is likely the effect of shortening of overall treatment time by 14 days and regular continuous dose delivery during the whole course of radiation therapy including weekends. A 7-day schedule produces more severe acute mucosal reactions lasting longer than in conventional fractionation, however tolerable by patients. Relatively high rate (22%) of CLE in the 7-day arm observed during the first year of the study was eliminated by decreasing dose per fraction from 2.0 Gy to 1.8 Gy

  11. Continuous 7-Days-A-Week External Beam Irradiation in Locally Advanced Cervical Cancer: Final Results of the Phase I/II Study

    Purpose: To evaluate the feasibility and efficacy of definitive continuous 7-days-a-week pelvic irradiation without breaks between external beam radiotherapy and brachytherapy in locally advanced cervical cancer. Methods and Materials: Between November 1998 and December 1999, 30 patients with International Federation of Obstetrics and Gynecology Stage IIB or IIIB cervical cancer were included in a prospective Phase I/II study of continuous 7-days-a-week pelvic irradiation, to the total Manchester point B dose of 40.0–57.6 Gy. The first 13 patients (Group A) were given a daily tumor dose of 1.6 Gy, and the remaining 17 patients (Group B) were given 1.8 Gy. One or two immediate brachytherapy applications (point A dose 10–20 Gy, each) were performed in 28 cases. Results: Two patients did not complete the irradiation because of apparent early progression of disease during the irradiation. Eleven of the 28 evaluable patients (39%; 45% and 35% in Groups A and B, respectively) completed their treatment within the prescribed overall treatment time. Acute toxicity (including severe European Organisation for Research and Treatment of Cancer/Radiation Therapy Oncology Group Grade 3 and 4 effects in 40%) was experienced by 83% of patients and resulted in unplanned treatment interruptions in 40% of all patients (31% and 47% of patients in Groups A and B, respectively). Severe intestinal side effects occurred in 31% and 41% of Patients in Groups A and B, respectively (p = 0.71). The 5-year overall survival probability was 33%. Cancer recurrence occurred in 63% of patients: 20% inside and 57% outside the pelvis. Cumulative incidence of late severe bowel and urinary bladder toxicity at 24 months was 15%. Conclusion: Continuous irradiation in locally advanced cervical cancer is associated with a high incidence of severe acute toxicity, resulting in unplanned treatment interruptions. Late severe effects and survival after continuous radiotherapy do not substantially differ from

  12. [b][/b]Relative efficiencies of the Burkard 7-Day, Rotorod and Burkard Personal samplers for Poaceae and Urticaceae pollen under field conditions

    Robert Peel

    2014-11-01

    Full Text Available [b]Introduction[/b]. In aerobiological studies it is often necessary to compare concentration data recorded with different models of sampling instrument. Sampler efficiency typically varies from device to device, and depends on the target aerosol and local atmospheric conditions. To account for these differences inter-sampler correction factors may be applied, however for many pollen samplers and pollen taxa such correction factors do not exist and cannot be derived from existing published work. [b]Materials and methods.[/b] In this study, the relative efficiencies of the Burkard 7-Day Recording Volumetric Spore Trap, the Sampling Technologies Rotorod Model 20, and the Burkard Personal Volumetric Air Sampler were evaluated for Urticaceae and Poaceae pollen under field conditions. The influence of wind speed and relative humidity on these efficiency relationships was also assessed. Data for the two pollen taxa were collected during 2010 and 2011–2012, respectively. [b]Results[/b]. The three devices were found to record significantly different concentrations for both pollen taxa, with the exception of the 7-Day and Rotorod samplers for Poaceae pollen. Under the range of conditions present during the study, wind speed was found to only have a significant impact on inter-sampler relationships involving the vertically-orientated Burkard Personal sampler, while no interaction between relative efficiency and relative humidity was observed. [b]Conclusions[/b]. Data collected with the three models of sampler should only be compared once the appropriate correction has been made, with wind speed taken into account where appropriate.

  13. Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer

    Purpose: To evaluate the normal tissue reactions and loco-regional control rates (LRC) in patients treated with 7-days-a-week postoperative continuous irradiation (p-CAIR) compared to conventionally fractionated 5-days-a-week postoperative radiotherapy (CF). Materials/methods: Between 2001 and 2004, 279 patients with high-risk squamous cell cancer of the larynx (158 pts.) or cancer of the oral cavity/oropharynx (121 pts.) were enrolled. They were stratified according to the primary cancer site (larynx vs. others) and the treating center and randomized to receive 63 Gy in fractions of 1.8 Gy given 5-days-a-week (140 pts: CF) or 7-days-a-week (139 pts: p-CAIR). Results: The acute and late toxicity was considered acceptable, although the proportion of patients with confluent mucositis was higher in p-CAIR compared to CF (60.0 vs. 33.3%). The actuarial 3-year LRC were 64 vs. 70% for CF and p-CAIR, respectively, p = 0.32. A statistically significant improvement in 3-year LRC in p-CAIR arm appeared in a subset of the patients with cancer of the oropharynx/oral cavity (74% p-CAIR vs. 53% CF, p = 0.02). By contrast, there was no improvement in LRC in a subset of the patients with cancer of the larynx (p = 0.46). Conclusion: An improvement in LRC attributable to acceleration of postoperative radiotherapy appeared restricted to the patients with cancer of the oropharynx/oral cavity. In patients with cancer of the larynx acceleration of postoperative radiotherapy did not have any beneficial effect

  14. Intracameral cefuroxime and moxifloxacin used as endophthalmitis prophylaxis after cataract surgery: systematic review of effectiveness and cost-effectiveness

    Linertová R

    2014-08-01

    Full Text Available Renata Linertová,1,2 Rodrigo Abreu-González,3 Lidia García-Pérez,1,2 Marta Alonso-Plasencia,3 Luis Mateo Cordovés-Dorta,4 José Augusto Abreu-Reyes,4 Pedro Serrano-Aguilar2,5 1Fundación Canaria de Investigación y Salud (FUNCIS, Santa Cruz de Tenerife, Spain; 2Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC, Madrid, Spain; 3Ophthalmology Service, University Hospital Ntra Sra de La Candelaria, Santa Cruz de Tenerife, Spain; 4Ophthalmology Service, University Hospital of Canary Islands, La Laguna, Spain; 5HTA Unit, Canary Health Service, Santa Cruz de Tenerife, Spain Abstract: Postoperative endophthalmitis is one of the most serious potential complications of ocular lens surgery. Its incidence can be reduced by means of antibiotic prophylaxis. Although the prophylactic use of intracameral cefuroxime has been extended, other drugs, such as moxifloxacin, have arisen as alternatives. We performed a systematic literature review on the effectiveness and efficiency of intracameral cefuroxime and moxifloxacin for the prophylaxis of postoperative endophthalmitis after cataract surgery. Several bibliographic databases were searched up to October 2010 and were updated up to January 2013. Outcomes were the onset of endophthalmitis after surgery and the cost-effectiveness ratio of using both antibiotic prophylaxis alternatives. The following were included: a clinical trial reported in two papers, six observational studies, and an economic evaluation. All studies assessed cefuroxime compared with another antibiotic prophylaxis or no prophylaxis. The only randomized controlled trial performed by the European Society of Cataract and Refractive Surgery found that intracameral cefuroxime is significantly more effective than not using prophylaxis or the use of a topical antibiotic. The observational studies support these results. The economic evaluation compared different prophylaxis regimens and concluded that intracameral

  15. Al3+-MXFX体系的紫外特性及莫西沙星的测定%UV characteristic of Al3+-moxifloxacin and determination of moxifloxacin tablets

    朱红梅; 席会平; 龚文琪

    2009-01-01

    目的:建立Al3+增敏,紫外分光光度法测定莫西沙星(Moxifloxacin,MXFX)的含量.方法:基于在pH=6.0的缓冲溶液中,铝(Ⅲ)对莫西沙星的吸光度有显著的增敏作用,建立了铝(Ⅲ)增敏,紫外分光光度法快速测定莫西沙星的新方法.结果:将该方法用于MXFX片剂的测定,样品平均回收率为97.70%,RSD=2.68%,检出限为0.01542μg/ml.结论:该方法简便、快捷、准确.

  16. Radiosynthesis and biological evaluation of the 99mTc-tricarbonyl moxifloxacin dithiocarbamate complex as a potential Staphylococcus aureus infection radiotracer

    In the present investigation, radiosynthesis of the 99mTc-tricarbonyl moxifloxacin dithiocarbamate complex (99mTc(CO)3-MXND) and its biological evaluation in male Wister rats (MWR) artificially infected with Staphylococcus aureus (S. aureus) was assessed. The 99mTc(CO)3-MXND complex was radiochemically examined in terms of stability in saline and in serum and biologically its in-vitro binding with S. aureus and percent absorption in MWR models. Radiochemically the 99mTc(CO)3-MXND complex showed more than 90% stability in saline up to 240 min and in serum 14.95% undesirable species was appeared within 16 h. In-vitro the 99mTc(CO)3-MXND complex showed saturated binding with S. aureus. In MWR artificially infected with live S. aureus the complex showed about six fold higher uptakes in the infected muscle as compared to the normal muscle. However, insignificant change in the uptake of 99mTc(CO)3-MXND complex in the infected and inflamed or normal muscle was observed in the MWR infected with heat killed S. aureus. The 99mTc(CO)3-MXND complex disappeared from the circulatory system and appeared in the urinary system within 60-90 min followed by excretion through normal route of urinary system. Based on the elevated and stable radiochemical succumb in saline, serum, saturated in-vitro binding with S. aureus and higher accumulation in the target organ of the MWR, we recommend the 99mTc(CO)3-MXND complex for radio-localization of the infection induced by S. aureus in human.

  17. Radiosynthesis and biological evaluation of the {sup 99m}Tc-tricarbonyl moxifloxacin dithiocarbamate complex as a potential Staphylococcus aureus infection radiotracer

    Shah, Syed Qaiser, E-mail: ssqaiser2002@yahoo.co [Nuclear Medicine Research Laboratory (NMRL), University of Peshawar, Peshawar, KPK (Pakistan); Khan, Muhammad Rafiullah [Phytopharmaceutical and Neutraceuticals Research Laboratory (PNRL), University of Peshawar, Peshawar, KPK (Pakistan)

    2011-04-15

    In the present investigation, radiosynthesis of the {sup 99m}Tc-tricarbonyl moxifloxacin dithiocarbamate complex ({sup 99m}Tc(CO){sub 3}-MXND) and its biological evaluation in male Wister rats (MWR) artificially infected with Staphylococcus aureus (S. aureus) was assessed. The {sup 99m}Tc(CO){sub 3}-MXND complex was radiochemically examined in terms of stability in saline and in serum and biologically its in-vitro binding with S. aureus and percent absorption in MWR models. Radiochemically the {sup 99m}Tc(CO){sub 3}-MXND complex showed more than 90% stability in saline up to 240 min and in serum 14.95% undesirable species was appeared within 16 h. In-vitro the {sup 99m}Tc(CO){sub 3}-MXND complex showed saturated binding with S. aureus. In MWR artificially infected with live S. aureus the complex showed about six fold higher uptakes in the infected muscle as compared to the normal muscle. However, insignificant change in the uptake of {sup 99m}Tc(CO){sub 3}-MXND complex in the infected and inflamed or normal muscle was observed in the MWR infected with heat killed S. aureus. The {sup 99m}Tc(CO){sub 3}-MXND complex disappeared from the circulatory system and appeared in the urinary system within 60-90 min followed by excretion through normal route of urinary system. Based on the elevated and stable radiochemical succumb in saline, serum, saturated in-vitro binding with S. aureus and higher accumulation in the target organ of the MWR, we recommend the {sup 99m}Tc(CO){sub 3}-MXND complex for radio-localization of the infection induced by S. aureus in human.

  18. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy.

    Estebanez, A; Pascual, R; Gil, V; Ortiz, F; Santibáñez, M; Pérez Barba, C

    2009-12-01

    The purpose of this paper was to compare the efficacy of a single dose of 3 g of fosfomycin to that of a 7-day regimen of amoxicillin-clavulanate in the treatment of asymptomatic bacteriuria during pregnancy. A randomised, prospective, interventional, analytical, longitudinal study was undertaken, in which the efficacy of two antibiotic regimens (one short and the other long) in the treatment of pregnant women with asymptomatic bacteriuria is compared. One hundred and nine patients were randomly assigned to two groups: 56 were treated with amoxicillin-clavulanate and 53 with fosfomycin. The two groups were similar in terms of co-morbidity, treatments received during pregnancy, obstetric, gynaecological and surgical history and laboratory data. The efficacy of the two regimens was similar and the eradication rate was over 80% in both groups (P = 0.720) (relative risk [RR] 1.195, 95% confidence interval [CI]: 0.451-3.165). The number of reinfections was greater in the amoxicillin-clavulanate group (P = 0.045). The secondary effects were lower in the fosfomycin group (P = 0.008). There were no significant differences in the number of persistences (P = 0.39), development of symptomatic urinary infections (P = 0.319) or recurrences (P = 0.96). Treatment with a single dose of fosfomycin is as effective as the standard course of treatment with amoxicillin-clavulanate and may be preferable due to its simpler administration and the smaller number of reinfections. PMID:19768649

  19. An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite®

    Granet, David; Lichtenstein, Steven J; Onofrey, Bruce; Katz, James A

    2007-01-01

    This subject-masked, randomized, active and placebo-controlled study compared subjects’ perceptions of two antibiotic ophthalmic drops. One hundred and twenty-five healthy volunteers received two of the following solutions: moxifloxacin 0.5% ophthalmic solution (Vigamox®, Alcon Laboratories, Inc., Ft Worth, TX, USA), azithromycin 1% in DuraSite® (AzaSite™, Inspire Pharmaceuticals, Inc., Durham, NC, USA), or Tears Naturale II® (Alcon Laboratories, Inc., Ft. Worth, TX, USA) in contralateral eye...

  20. Choice of baseline in a multiple-dose thorough QT study (TQTS – effect on analysis of moxifloxacin-induced QTc prolongation

    B Tyl, S Azzam, E Reinbolt

    2009-12-01

    Full Text Available B Tyl1, S Azzam2, E Reinbolt2, N Blanco1, J Olbertz3, W Wheeler11MDS Pharma Services, Centralized Cardiac Services, Baillet-en-France, France; 2MDS Pharma Services, Early Clinical Research, Lincoln (Nebraska, USA; 3MDS Pharma Services, Early Clinical Research, Phoenix (Arizona, USABackground: The primary endpoint of a thorough QT study (TQTS is the change from baseline in QT corrected (QTc measured on electrocardiograms (ECG tracings. It has been suggested that during a crossover study, the time-matched or predose baseline could be recorded. The choice of method for baseline ECG collection may influence the results and the cost of the TQTS.Objective: The objective of our study was to compare the collection of a time-matched baseline before each period (TMEACH, an average of all the time-matched baseline (TMMEAN, a time-matched baseline before period 1 (TMP1 and a predose baseline (PDEACH on QT interval prolongation induced by moxifloxacin, in a 30 subjects, 5 arm cross-over TQTS.Results: Moxifloxacin induced a similar significant increase in QT corrected using Fridericia’s formula (QTc (lower limit of the confidence interval excluded 5 ms at all time-points between 0.5 hours and 12 hours with all baseline methods. TMEACH was associated with a lower within subject variability (SD 5.59 ms than TMMEAN and TMP1 (5.90 and 6.90 ms, respectively. PDEACH was associated with the highest variability (7.41 ms.Conclusion: The collection of ECG tracings during a full baseline day before each period was associated with the lowest variability. However, the two more cost effective designs (TMP1 and PDEACH were sufficient, in this small TQTS, to significantly detect moxifloxacin.Keywords: thorough QT study, QT correction, baseline, design, superimposed representative complex, moxifloxacin

  1. Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy▿

    Shandil, Radha K.; Jayaram, Ramesh; Kaur, Parvinder; Gaonkar, Sheshagiri; Suresh, B. L.; Mahesh, B. N.; Jayashree, R.; Nandi, Vrinda; Bharath, Sowmya; V. Balasubramanian

    2006-01-01

    Members of the fluoroquinolone class are being actively evaluated for inclusion in tuberculosis chemotherapy regimens, and we sought to determine the best in vitro and pharmacodynamic predictors of in vivo efficacy in mice. MICs for Mycobacterium tuberculosis H37Rv were 0.1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX]). The unbound fraction in the presence of murine serum was concentration dependent for MXF, OFX, SPX, and CIP. In...

  2. Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin.

    Lismond, Ann; Tulkens, Paul M; Mingeot-Leclercq, Marie-Paule; Courvalin, Patrice; Van Bambeke, Françoise

    2008-09-01

    Antibiotic efflux is observed in both eukaryotic and prokaryotic cells, modulating accumulation and resistance. The present study examines whether eukaryotic and prokaryotic fluoroquinolone transporters can cooperate in the context of an intracellular infection. We have used (i) J774 macrophages (comparing a ciprofloxacin-resistant cell line overexpressing an MRP-like transporter with wild-type cells with basal expression), (ii) Listeria monocytogenes (comparing a clinical isolate [CLIP21369] displaying ciprofloxacin resistance associated with overexpression of the Lde efflux system with a wild-type strain [EGD]), (iii) ciprofloxacin (substrate of both Lde and MRP) and moxifloxacin (nonsubstrate), and (iv) probenecid and reserpine (preferential inhibitors of MRP and Lde, respectively). The ciprofloxacin MICs for EGD were unaffected by reserpine, while those for CLIP21369 were decreased approximately fourfold (and made similar to those of EGD). Neither probenecid nor reserpine affected the moxifloxacin MICs against EGD or CLIP21369. In dose-response studies (0.01x to 100x MIC) in broth, reserpine fully restored the susceptibility of CLIP21369 to ciprofloxacin (no effect on EGD) but did not influence the activity of moxifloxacin. In studies with intracellular bacteria, reserpine, probenecid, and their combination increased the activity of ciprofloxacin in wild-type and ciprofloxacin-resistant macrophages in parallel with an increase in ciprofloxacin accumulation in macrophages for EGD and an increase in accumulation and decrease in MIC (in broth) for CLIP21369. Moxifloxacin accumulation and intracellular activity were consistently not affected by the inhibitors. A bacterial efflux pump may thus actively cooperate with a eukaryotic efflux transporter to reduce the activity of a common substrate (ciprofloxacin) toward an intracellular bacterial target. PMID:18573933

  3. Mental disorders attributed to moxifloxacin in an elderly patient%莫西沙星致高龄患者精神异常

    谭喜莹

    2011-01-01

    1例87岁女性患者,因胸闷、心慌加重伴喘息、咯痰给予莫西沙星0.4g、1次/d口服,1d后改为莫西沙星0.4 g、1次/d静脉滴注.第3天患者出现烦躁、谵语、神志模糊,应答不切题,夜间症状加重.停用莫西沙星,并给予地西泮肌内注射,2d后上述症状消失.%A 87-year-old female patient received moxifloxacin 0.4 g once daily orally for increasing chest tightness and palpitation with short of breath and expectoration. One day later, her regimen was changed to an Ⅳ infusion of moxifloxacin 0.4 g once daily. On day 3, the patient experienced agitation, delirium, confusion, and irrelevant speech. And her symptoms aggravated at that night. Moxifloxacin was discontinued and IM diazepam was given. Two days later, the above-mentioned symptoms subsided.

  4. Effect of chick weight, geometric mean diameter and sodium level in prestarter diets (1 to 7 days on broiler perfomance up to 21 days of age

    AML Ribeiro

    2004-12-01

    Full Text Available Seven hundred and twenty Ross 308 chicks were raised in a controlled environment room, distributed in a factorial design with 3 hatching chick weights (37, 40 and 44 g, 3 geometric mean diameter (GMD (0.561; 0.783 and 0.997 mm and 4 total sodium levels (Na (0.12; 0.24; 0.36 and 0.48% in the pre-starter diet (1 to 7 days. From 8 to 21 days (d one single basal diet was used for all treatments. The thirty seven-gram chicks had the smallest yolk sack weight at 4d, smallest body weight (BW and feed intake (FI at 7d and 21d, but the same feed conversion (FC than the other groups of hatching weight. Chicks receiving diet with intermediate GMD had the greatest BW and FI at 7d, but at 21d this effect was no longer seen. The diet with finest particle size resulted in birds with the smallest gizzard weight at 7d. The 0.12%Na diet was statistically different from the other Na levels, resulting in chicks at 7d with the worst FC and lowest body weights. At 21d, BW still was the lowest for this group of chicks. Birds with 0.48%Na produced more watery excreta and less dry matter in the carcass at 7d. Water consumption (C H2O was influenced linearly by chick weight up to 0.36%Na level. In the 0.48%Na level, 40 and 44 g chicks had similar C H2O, which was different from 37-g chicks. For best performance, Na values were set from 0.31 to 0.48%. The three studied factors influenced quality of pre-starter diet and consequently chick performance.

  5. Intravenous moxifloxacin in routine hospital treatment of respiratory tract infections in China: results of a multicenter, noninterventional study

    Chen R

    2011-04-01

    Full Text Available Rongchang Chen1, Wenjiang Ma2, Xuezhong Yu3, Xinmin Liu4, Jihong Zhu5, Hong Liang6, Xiaomei Wu7, Tao Guo81State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, China; 2Respiratory Department, The First Affiliated Hospital of Medical School of Zhejiang University, China; 3Emergency Department, Peking Union Medical College Hospital, China; 4Geriatric Department, Peking University First Hospital, China; 5Emergency Department, Peking University People's Hospital, China; 6Respiratory Department, Huadong Hospital Affiliated to Fudan University, China; 7Respiratory Department, The Second Affiliated Hospital of Harbin Medical University, China; 8Hematology Department, Wuhan Union Hospital, ChinaObjective: To investigate the effectiveness, safety, and tolerability of moxifloxacin (MXF (intravenous [IV] or sequential therapy [IV followed by oral] under daily treatment conditions in a large number of patients with respiratory tract infections.Design: Patients with a diagnosis of respiratory tract infection should be treated with MXF IV and/or tablets 400 mg once daily for a duration at the physician's discretion. For each patient, the physician documented data at an initial visit and at the end of therapy (EOT visit and/or, in the case of sequential therapy, an interim visit when the patient switched to oral treatment.Results: A total of 1953 patients treated with MXF were documented and were valid for an effectiveness and safety evaluation. An improvement was observed in 98.1% (n = 1911/1949 of patients treated with MXF. Recovery was documented in 89.9% (n = 1754/1951 of the patients. At the EOT visit, severity of infection was assessed to be "relieved" or at least "improved" in 96.5% (n = 1873/1940 of the patients. Physicians assessed overall effectiveness as "good" or "very good" in 93.3% (n = 1822/1953 of all patients. The physicians' overall tolerability rating was "very good" or "good" in 93.5% (n

  6. 莫西沙星与左氧氟沙星治疗社区获得性肺炎的对比分析%Clinical analysis on efficacy of moxifloxacin and levofloxacin in treatment of community acquired pneumonia

    宋雪梅

    2013-01-01

    Objective To explore the efficacy of moxifloxacin and levofloxacin in treatment of community acquired pneumonia. Methods The clinical data of patients with community acquired pneumonia were collected, and they were divided into moxifloxacin group ( 30 cases ) and levofloxacin group ( 30 cases ). Results The duration for disappearance of coughing, defervescent time, normalized time for blood routine examination , and time for X - ray lung shadow apparent absorption > 50% in patients of moxifloxacin group were lower than those of patients in levofloxacin group, the total effectiveness rate of clinical cure in patients of moxifloxacin group was higher than that of patients in levofloxacin group. The rate of bacterial clearance in patients of moxifloxacin group was better than that of patients in levofloxacin group, and their difference was statistically significant ( P 50%时间均低于左氧氟沙星组,莫西沙星组细菌清除率和临床治疗总有效率均明显优于左氧氟沙星组,差异均有统计学意义(P<0.05).结论 莫西沙星治疗社区获得性肺炎临床症状改善明显,效果优于左氧左氧氟沙星,值得临床推广应用.

  7. Cytotoxic effects in 3T3-L1 mouse and WI-38 human fibroblasts following 72 hour and 7 day exposures to commercial silica nanoparticles

    The potential toxic effects in murine (3T3-L1) and human (WI-38) fibroblast cell lines of commercially available silica nanoparticles (NPs), Ludox CL (nominal size 21 nm) and CL-X (nominal size of 30 nm) were investigated with particular attention to the effect over long exposure times (the tests were run after 72 h exposure up to 7 days). These two formulations differed in physico-chemical properties and showed different stabilities in the cell culture medium used for the experiments. Ludox CL silica NPs were found to be cytotoxic only at the higher concentrations to the WI-38 cells (WST-1 and LDH assays) but not to the 3T3-L1 cells, whereas the Ludox CL-X silica NPs, which were less stable over the 72 h exposure, were cytotoxic to both cell lines in both assays. In the clonogenic assay both silica NPs induced a concentration dependent decrease in the surviving fraction of 3T3-L1 cells, with the Ludox CL-X silica NPs being more cytotoxic. Cell cycle analysis showed a trend indicating alterations in both cell lines at different phases with both silica NPs tested. Buthionine sulfoximine (γ-glutamylcysteine synthetase inhibitor) combined with Ludox CL-X was found to induce a strong decrease in 3T3-L1 cell viability which was not observed for the WI-38 cell line. This study clearly indicates that longer exposure studies may give important insights on the impact of nanomaterials on cells. However, and especially when investigating nanoparticle effects after such long exposure, it is fundamental to include a detailed physico-chemical characterization of the nanoparticles and their dispersions over the time scale of the experiment, in order to be able to interpret eventual impacts on cells. -- Highlights: ► Ludox CL silica NPs are cytotoxic to WI-38 fibroblasts but not to 3T3-L1 fibroblasts. ► Ludox CL-X silica NPs are cytotoxic to both cell lines. ► In clonogenic assay both silica NPs induce cytotoxicity, higher for CL-X silica. ► Cell cycle analysis shows

  8. Activation of K{sup +} channels and Na{sup +}/K{sup +} ATPase prevents aortic endothelial dysfunction in 7-day lead-treated rats

    Fiorim, Jonaina, E-mail: nanafiorim@hotmail.com [Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, ES (Brazil); Ribeiro Júnior, Rogério Faustino, E-mail: faustino43@oi.com.br [Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, ES (Brazil); Azevedo, Bruna Fernades, E-mail: brunafernandes.azevedo@gmail.com [Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, ES (Brazil); Simões, Maylla Ronacher, E-mail: yllars@hotmail.com [Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, ES (Brazil); Padilha, Alessandra Simão, E-mail: ale_spadilha@yahoo.com.br [Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, ES (Brazil); Stefanon, Ivanita, E-mail: ivanita@pq.cnpq.br [Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, ES (Brazil); Alonso, Maria Jesus, E-mail: mariajesus.alonso@urjc.es [Departamento de Ciencias de la Salud III, Universidad Rey Juan Carlos, Alcorcón (Spain); Salaices, Mercedes, E-mail: mercedes.salaices@uam.es [Departamento de Farmacología, Universidad Autónoma de Madrid, Instituto de Investigación Hospital Universitario La Paz (IdiPaz) (Spain); Vassallo, Dalton Valentim, E-mail: daltonv2@terra.com.br [Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, ES (Brazil)

    2012-07-01

    Seven day exposure to a low concentration of lead acetate increases nitric oxide bioavailability suggesting a putative role of K{sup +} channels affecting vascular reactivity. This could be an adaptive mechanism at the initial stages of toxicity from lead exposure due to oxidative stress. We evaluated whether lead alters the participation of K{sup +} channels and Na{sup +}/K{sup +}-ATPase (NKA) on vascular function. Wistar rats were treated with lead (1st dose 4 μg/100 g, subsequent doses 0.05 μg/100 g, im, 7 days) or vehicle. Lead treatment reduced the contractile response of aortic rings to phenylephrine (PHE) without changing the vasodilator response to acetylcholine (ACh) or sodium nitroprusside (SNP). Furthermore, this treatment increased basal O{sub 2}{sup −} production, and apocynin (0.3 μM), superoxide dismutase (150 U/mL) and catalase (1000 U/mL) reduced the response to PHE only in the treated group. Lead also increased aortic functional NKA activity evaluated by K{sup +}-induced relaxation curves. Ouabain (100 μM) plus L-NAME (100 μM), aminoguanidine (50 μM) or tetraethylammonium (TEA, 2 mM) reduced the K{sup +}-induced relaxation only in lead-treated rats. When aortic rings were precontracted with KCl (60 mM/L) or preincubated with TEA (2 mM), 4-aminopyridine (4-AP, 5 mM), iberiotoxin (IbTX, 30 nM), apamin (0.5 μM) or charybdotoxin (0.1 μM), the ACh-induced relaxation was more reduced in the lead-treated rats. Additionally, 4-AP and IbTX reduced the relaxation elicited by SNP more in the lead-treated rats. Results suggest that lead treatment promoted NKA and K{sup +} channels activation and these effects might contribute to the preservation of aortic endothelial function against oxidative stress. -- Highlights: ► Increased free radicals production ► Increased Na{sup +}/K{sup +} ATPase activity ► Promotes activation of the K{sup +} channels and reduced vascular reactivity ► These effects preserve endothelial function against oxidative

  9. Spectrofluorimetric study of the interaction between europium(III) and moxifloxacin in micellar solution and its analytical application

    Kamruzzaman, Mohammad; Alam, Al-Mahmnur; Lee, Sang Hak; Ragupathy, Dhanusuraman; Kim, Young Ho; Park, Sang-Ryoul; Kim, Sung Hong

    2012-02-01

    A sensitive spectrofluorimetric method has been developed for the determination of moxifloxacin (MOX) using europium(III)-MOX complex as a fluorescence probe in the presence of an anionic surfactant, sodium dodecyl benzene sulfonate (SDBS). The fluorescence (FL) intensity of Eu 3+ was enhanced by complexation with MOX at 614 nm after excitation at 373 nm. The FL intensity of the Eu 3+-MOX complex was significantly intensified in the presence of SDBS. Under the optimum conditions, it was found that the enhanced FL intensity of the system showed a good linear relationship with the concentration of MOX over the range of 1.8 × 10 -11-7.3 × 10 -9 g mL -1 with a correlation coefficient of 0.9998. The limit of detection of MOX was found to be 2.8 × 10 -12 g mL -1 with relative standard deviation (RSD) of 1.25% for 5 replicate determination of 1.5 × 10 -8 g mL -1 MOX. The proposed method is simple, offers higher sensitivity with wide linear range and can be successfully applied to determine MOX in pharmaceutical and biological samples with good reproducibility. The luminescence mechanism is also discussed in detail with ultraviolet absorption spectra.

  10. A cross-over study comparing an online versus a paper 7-day food record: focus on total water intake data and participant’s perception of the records

    Monnerie, B.; Tavoularis, L. G.; Guelinckx, I.; Hebel, P.; Boisvieux, T.; Cousin, A.; Le Bellego, L

    2015-01-01

    Purpose To compare (1) fluid, food and nutrient intake obtained with a paper versus an online version of a 7-day food record and (2) user’s acceptability of both versions of the food record. Methods A cross-over study was carried out in 2010 in France. A total of 246 participants aged 18–60 years reported their food and fluid intake using both versions of the 7-day food record, separated by a 7- to 14-day washout period. To help participants in estimating consumed portions, both versions of t...

  11. Moxifloxacin versus Levofloxacin for Acute Exacerbation of Chronic Obstructive Pulmonary Diseases: A Systematic Review%莫西沙星与左氧氟沙星治疗慢性阻塞性肺疾病急性加重期疗效及安全性比较的系统评价

    王小虎; 刘晓菊

    2012-01-01

    of meta-analysis showed that moxifloxacin group was significantly superior to levofloxacin group in the effective rate (OR=3.15, 95%CI 1.80 to 5.49, P<0.000 1). The bacterial clearance rate in moxifloxacin group was also higher than that in the levofloxacin group (OR=2.79, 95%CI 1.30 to 5.97, P=0.008). In addition, adverse effects of moxifloxacin group were less than levofloxacin (OR=0.48, 95%CI 0.24 to 0.98, P=0.04). Conclusion Based on current studies, moxifloxacin is superior to levofloxacin in improving effective rate and bacterial clearance rate, and in lowering side effects when treating AECOPD. Hence it is considerable to use moxifloxacin instead of levofloxacin in the treatment of AECOPD if necessary. Due to the limitation of both quantity and quality of included studies, this conclusion should be further confirmed with more high quality and large sample studies.

  12. 莫西沙星引起不良反应及分析%Adverse reaction and analyse the causes of Moxifloxacin

    罗耀群

    2013-01-01

    Objective To summarize analysis of adverse reactions caused by moxifloxacin, to guide the rational use of clinical. Methods The domestic literature in recent years, the reported adverse reactions of moxifloxacin, summary, analysis and summary. Results The main adverse reactions of gastrointestinal system, central nervous system, cardiovascular system, etc;The elderly are adverse reactions of high-risk groups;Dosage has no significant gender differences, injected more than the oral medicine. Conclusion Moxifloxacin is the fourth generation of new fluoroquinolone antibiotic, by a large number of applications in recent years, adverse reaction is increasingly outstanding, should strengthen the management and reasonable use.%目的总结分析莫西沙星引起的不良反应,以指导临床合理使用。方法查阅近年来国内文献,对报道莫西沙星的不良反应,进行总结、分析、汇总。结果不良反应主要表现为胃肠道系统、心血管系统等;老年人是发生不良反应的高危人群;无明显的的性别差异,给药途径为注射给药多于口服给药。结论莫西沙星是第四代新型氟喹诺酮类抗菌药物,近年来被大量的应用,不良反应日益突出,应加强管理合理使用。

  13. Separation and identification of moxifloxacin impurities in drug substance by high-performance liquid chromatography coupled with ultraviolet detection and Fourier transform ion cyclotron resonance mass spectrometry

    Cai Sheng Wu; Zhi Xin Jia; Bao Ming Ning; Jin Lan Zhang; Song Wu

    2012-01-01

    In this paper,a high-performance liquid chromatography coupled with ultraviolet detection and Fourier transform-ion cyclotron resonance mass spectrometry (HPLC-UV/FTICRMS) method was described for the investigation of impurity profile in moxifloxacin (MOX) drug substance and chemical reference substance.Ten impurities were detected by HPLC-UV,while eight impurities were identified by using the high accurate molecular mass combined with multiple-stage mass spectrometric data and fragmentation rules.In addition,to our knowledge,five impurities were founded for the first time in MOX drug substance.

  14. Evaluation of 99mTcN-moxifloxacin dithiocarbamate, as a potential radiopharmaceutical for scintigraphic localization of infectious foci

    In the current study radio complexation of the moxifloxacin dithiocarbamate (MXND) with technetium-99m (99mTc) using the [99mTc-N]2+ core through legend exchange reaction was explored. The 99mTcN-MXND complex was biologically evaluated as a potential radiopharmaceutical for in vivo scintigraphy using artificially infected male sprague-dawley rats (MSDR) with Staphylococcus aureus (S. aureus). The radiochemistry of the complex was explored in terms of radiochemical purity (RCP), in vitro stability in serum at 37 deg C for 16 h, in vitro binding with S. aureus and biodistribution in artificially infected with S. aureus MSDR. It was observed that the complex showed stability of more than 90% up to 4 h after reconstitution with a maximum RCP value of 97.55 ± 0.42% at 30 min. The complex showed significantly in vitro stability in serum at 37 deg C with an insignificant free species up to 16.50% within 16 h. In vitro saturated binding with S. aureus was noted up to 120 min with maximum value of 73.25% at 90 min of incubation. Almost sixfold uptake was noted in the infected muscle of the MSDR as compared to inflamed and normal muscle. The 97.55 ± 0.42% RCP values, stability in serum with insignificant untagged 16.50% species, 73.25% in vitro binding with S. aureus and sixfold uptake in the target organ posed the 99mTcN-MXND complex as a promising radiopharmaceutical for S. aureus infectious foci. (author)

  15. Redox-Triggered Release of Moxifloxacin from Mesoporous Silica Nanoparticles Functionalized with Disulfide Snap-Tops Enhances Efficacy Against Pneumonic Tularemia in Mice.

    Lee, Bai-Yu; Li, Zilu; Clemens, Daniel L; Dillon, Barbara Jane; Hwang, Angela A; Zink, Jeffrey I; Horwitz, Marcus A

    2016-07-01

    Effective and rapid treatment of tularemia is needed to reduce morbidity and mortality of this potentially fatal infectious disease. The etiologic agent, Francisella tularensis, is a facultative intracellular bacterial pathogen which infects and multiplies to high numbers in macrophages. Nanotherapeutics are particularly promising for treatment of infectious diseases caused by intracellular pathogens, whose primary host cells are macrophages, because nanoparticles preferentially target and are avidly internalized by macrophages. A mesoporous silica nanoparticle (MSN) has been developed functionalized with disulfide snap-tops that has high drug loading and selectively releases drug intracellularly in response to the redox potential. These nanoparticles, when loaded with Hoechst fluorescent dye, release their cargo exclusively intracellularly and stain the nuclei of macrophages. The MSNs loaded with moxifloxacin kill F. tularensis in macrophages in a dose-dependent fashion. In a mouse model of lethal pneumonic tularemia, MSNs loaded with moxifloxacin prevent weight loss, illness, and death, markedly reduce the burden of F. tularensis in the lung, liver, and spleen, and are significantly more efficacious than an equivalent amount of free drug. An important proof-of-principle for the potential therapeutic use of a novel nanoparticle drug delivery platform for the treatment of infectious diseases is provided. PMID:27246117

  16. Synthesis and Structure Characterization of Moxifloxacin Hydrochloride%盐酸莫西沙星的合成及结构解析

    沈小莉; 陈家润

    2015-01-01

    以莫西沙星母核为起始原料,经硼酸酯活化、烃化、酸解三步反应合成了盐酸莫西沙星,通过高分辨质谱(HRMS)、紫外光谱(UV)、红外光谱(IR)、核磁共振氢谱(1 HNMR)、核磁共振碳谱(13 CNMR)、DEPT 谱、氢-氢相关谱(H-H COSY)、NOESY 谱、HSQC 谱、二级高分辨质谱及 XRD 谱确证了盐酸莫西沙星的结构。%Using ethyl 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate as starting material,moxifloxacin hydrochloride was synthesized via a three-step reaction including borate ester ac-tivation,N-alkylation and acidification.The molecular structure of moxifloxacin hydrochloride was characterized by HRMS,UV,IR,1 HNMR,13 CNMR,DEPT,H-H COSY,NOESY,HSQC,two-stage HRMS and XRD.

  17. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections

    Gyssens, I.C.J.; Dryden, M.; Kujath, P.; Nathwani, D.; Schaper, N.; Hampel, B.; Reimnitz, P.; Alder, J.; Arvis, P.

    2011-01-01

    OBJECTIVES: The primary aim of the RELIEF study was to evaluate the efficacy and safety of two sequential intravenous (iv)/oral regimens: moxifloxacin iv/oral versus piperacillin/tazobactam (TZP) iv followed by oral amoxicillin/clavulanate (AMC). PATIENTS AND METHODS: The study had a prospective, ra

  18. Activity of Moxifloxacin against Resistant Staphylococcus Biofilms in Vitro%莫西沙星对耐药葡萄球菌生物膜体外药效学研究

    姜剑伟; 陈向东; 汪辉; 李魁; 范璐; 王素霞

    2015-01-01

    Objective: To investigate the antibacterial effect of moxifloxacin against four strains of clinical resistant Staphylococcus biofilms in vitro. Methods: MIC (minimal inhibitory concentrations), MBIC (minimal biofilm inhibitory concentration) and MBEC (minimal biofilm eradication concentration) were examined by microdilution in broth; the percentages of biofilms formed and the viable cells of biofilms were investigated; and the synergy effects against biofilms were evaluated by a microdilution checkerboard method. Results: Moxifloxacin can eradicat biofilms at the concentration of 16-256 mg·L-1; The biofilms formed significantly decreased when moxifloxacin was at 2×MIC; moxifloxacin at 100×MIC caused significant decrease in viable cells of biofilms; the fractional biofilm inhibitory concentrations (FBICs) of moxifloxacin in combination with topical antibiotic retapamulin were all less than 1.0. Conclusions: Moxifloxacin can inhibit and eradicate clinical resistant Staphylococcus biofilms in vitro; synergy was demonstrated for moxifloxacin in combination with topical antibiotic retapamulin against them.%目的:研究莫西沙星对4株临床耐药葡萄球菌生物膜的体外药效学。方法:采用微量肉汤稀释法测定莫西沙星的最低抑菌浓度(minimal inhibitory concentration,MIC)、最低抑制生物膜浓度(minimal biofilm inhibitory concentration,MBIC)和最低摧毁生物膜浓度(minimal biofilm eradication concentration,MBEC);测定莫西沙星对细菌生物膜形成量以及存活菌的影响;采用微量稀释棋盘法测定莫西沙星与局部用药瑞他帕林的联合抗生物膜效果。结果:莫西沙星在16~256 mg·L-1的范围内可完全摧毁细菌生物膜;2×MIC显著降低生物膜的形成量;100× MIC可显著降低生物膜存活菌数;与瑞他帕林的联合抗生物膜分数(fractional biofilm inhibitory concentration,FBIC)均小于1.0。结论:莫西沙星对4株耐药葡

  19. Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 days

    Johansson, Per Ingemar; Svendsen, M.S.; Salado, J.;

    2008-01-01

    BACKGROUND AND OBJECTIVES: Transfusion based on the Thrombelastograph (TEG) results reduces transfusion requirements in cardiac surgery and in liver transplantation. Taking the pivotal role of thrombin generation in the coagulation process into consideration, the clinical utility of the TEG may, ...

  20. 93例莫西沙星致严重不良反应报告分析%Analysis of 93 Cases of Severe Adverse Drug Reactions Caused by Moxifloxacin

    周冰; 张俊; 张黎明

    2011-01-01

    目的 分析93例莫西沙星致严重不良反应报告,探讨莫西沙星致严重不良反应的特点和规律,为临床安全合理用药提供参考.方法 对2004年1月1日至2009年12月31日,北京市药品不良反应监测中心收到的93例莫西沙星致严重不良反应报告按人群、药品、不良反应情况等方面进行统计、分析.结果 临床使用莫西沙星多数能够按照药品使用说明书使用,少数存在不合理用药现象.结论 使用莫西沙星应严格按药品使用说明书用药,加强用药过程监护,减少药品带来的伤害.%Objective To probe into the general pattern and characteristics of severs ADRs indused by moxifloxacin so as to procide references for clinic retional use of moxifloxacin. Methods A total of 93 cases indused by moxifloxacin received from 2004 to 2009 in Beijing were analyzed statistically. Results The clinical use of moxifloxacin most can defer to the drugs instruction, the minority exists the irreasonabl phenomenon. Conclusion The use of moxifloxacin should strictly accord to the drugs instruction, enhance medication monitoring process, reduce the injury which the drugs bring.

  1. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.

    Mohideen S Jawahar

    Full Text Available BACKGROUND: Shortening tuberculosis (TB treatment duration is a research priority. This paper presents data from a prematurely terminated randomized clinical trial, of 4-month moxifloxacin or gatifloxacin regimens, in South India. METHODS: Newly diagnosed, sputum-positive HIV-negative pulmonary TB patients were randomly allocated to receive gatifloxacin or moxifloxacin, along with isoniazid and rifampicin for 4 months with pyrazinamide for first 2 months (G or M or isoniazid and rifampicin for 6 months with ethambutol and pyrazinamide for first 2 months (C. All regimens were administered thrice-weekly. Clinical and bacteriological assessments were done monthly during treatment and for 24 months post-treatment. The Data and Safety Monitoring Board recommended termination of the trial due to high TB recurrence rates in the G and M regimens. RESULTS: Of 416 patients in intent-to-treat analysis, 6 (5% of 124, 2 (2% of 110 and 2 (2% of 137 patients with drug-susceptible TB in the G, M and C arms respectively had unfavorable response at the end of treatment; during the next 24 months, 17 (15% of 115, 11 (11% of 104 and 8 (6% of 132 patients respectively, had TB recurrence. Of 38 drug-resistant patients 1 of 8 and 3 of 26 in the G and C arms respectively had unfavourable response at the end of treatment; and TB recurrence occurred in 2 of 7 and 2 of 23 patients, respectively. The differences in TB recurrence rates between the G and C arms was statistically significant (p = 0.02. Gastro-intestinal symptoms occurred in 23%, 22% and 9% of patients in the G, M and C arms respectively, but most reactions were mild and manageable with symptomatic measures; 1% required regimen modification. CONCLUSIONS: 4-month thrice-weekly regimens of gatifloxacin or moxifloxacin with isoniazid, rifampicin and pyrazinamide, were inferior to standard 6-month treatment, in patients with newly diagnosed sputum positive pulmonary TB. TRIAL REGISTRATION: Clinical Trials Registry

  2. 莫西沙星治疗慢性盆腔炎临床探讨%Clinical Observation of Moxifloxacin Treatment of Chronic Pelvic Inflammatory Disease

    程金阳

    2015-01-01

    Objective To Study of moxifloxacin in the treatmentof chronic pelvic inflammatory disease treatment effect. MethodWe selected 320 patients with chronic pelvic inflammatory disease in 2013 June --2014 yearinJune I treated patients in Department of gynecology and obstetrics, Were randomly divided into 2 groups with 160 cases in each, The control group was given penicillin combined with metronidazole in treatment, The observation group was given moxifloxacin treatment,Comparative analysis of therapeutic effect and adverse reaction oftwo groups.ResultThe observation group, the total efficiency is 96.3%, The control group the total effective rate was 81.8%, The observation group was significantly better than the control group(P< 0.05);The observation group the incidence of adverse reaction was 2.5%;the controlgroup, the incidence rate of adverse reaction was 10.6%, There was significant difference between two groups (P<0.05).Conclusion Moxifloxacin treatment using can obviously improve the clinical symptoms of patients with chronic pelvic inflammatory disease,And less adverse reaction, It is worth to popularize in the clinical application.%目的:探讨莫西沙星治疗慢性盆腔炎的治疗效果。方法选取2013年6月—2014年6月该妇产科收治的慢性盆腔炎患者320例,随机分为2组各160例,对照组给予青霉素联合甲硝唑治疗,观察组给予莫西沙星治疗,对比分析两组治疗效果和不良反应。结果观察组总有效率为96.3%,对照组总有效率为81.8%,观察组明显优于对照组(P<0.05);观察组不良反应发生率为2.5%;对照组不良反应发生率为10.6%,两组比较差异有统计学意义(P<0.05)。结论慢性盆腔炎患者采用莫西沙星治疗可明显改善患者临床症状,且不良反应少,值得在临床推广应用。

  3. Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis Patients

    Jawahar, Mohideen S.; Banurekha, Vaithilingam V.; Paramasivan, Chinnampedu N.; Rahman, Fathima; Ramachandran, Rajeswari; Venkatesan, Perumal; Balasubramanian, Rani; Selvakumar, Nagamiah; Ponnuraja, Chinnaiyan; Iliayas, Allaudeen S.; Gangadevi, Navaneethapandian P.; Raman, Balambal; Baskaran, Dhanaraj; Kumar, Santhanakrishnan R.; Kumar, Marimuthu M.; Mohan, Victor; Ganapathy, Sudha; Kumar, Vanaja; Shanmugam, Geetha; Charles, Niruparani; Sakthivel, Murugesan R.; Jagannath, Kannivelu; Chandrasekar, Chockalingam; Parthasarathy, Ramavaram T.; Narayanan, Paranji R.

    2013-01-01

    Background Shortening tuberculosis (TB) treatment duration is a research priority. This paper presents data from a prematurely terminated randomized clinical trial, of 4-month moxifloxacin or gatifloxacin regimens, in South India. Methods Newly diagnosed, sputum-positive HIV-negative pulmonary TB patients were randomly allocated to receive gatifloxacin or moxifloxacin, along with isoniazid and rifampicin for 4 months with pyrazinamide for first 2 months (G or M) or isoniazid and rifampicin for 6 months with ethambutol and pyrazinamide for first 2 months (C). All regimens were administered thrice-weekly. Clinical and bacteriological assessments were done monthly during treatment and for 24 months post-treatment. The Data and Safety Monitoring Board recommended termination of the trial due to high TB recurrence rates in the G and M regimens. Results Of 416 patients in intent-to-treat analysis, 6 (5%) of 124, 2 (2%) of 110 and 2 (2%) of 137 patients with drug-susceptible TB in the G, M and C arms respectively had unfavorable response at the end of treatment; during the next 24 months, 17 (15%) of 115, 11 (11%) of 104 and 8 (6%) of 132 patients respectively, had TB recurrence. Of 38 drug-resistant patients 1 of 8 and 3 of 26 in the G and C arms respectively had unfavourable response at the end of treatment; and TB recurrence occurred in 2 of 7 and 2 of 23 patients, respectively. The differences in TB recurrence rates between the G and C arms was statistically significant (p = 0.02). Gastro-intestinal symptoms occurred in 23%, 22% and 9% of patients in the G, M and C arms respectively, but most reactions were mild and manageable with symptomatic measures; 1% required regimen modification. Conclusions 4-month thrice-weekly regimens of gatifloxacin or moxifloxacin with isoniazid, rifampicin and pyrazinamide, were inferior to standard 6-month treatment, in patients with newly diagnosed sputum positive pulmonary TB. Trial Registration Clinical Trials Registry of India

  4. Spectroscopic studies, thermal analyses and biological evaluation of new V(IV), Zr(IV) and U(VI) moxifloxacin complexes

    Sadeek, Sadeek A.; El-Shwiniy, Walaa H.; Zordok, Wael A.; Kotb, Essam

    2011-12-01

    The synthesis and characterization of the new solid complexes [VO(MOX) 2H 2O]SO 4·11H 2O, [ZrO(MOX) 2Cl]Cl·15H 2O and [UO 2(MOX) 3](NO 3) 2·3H 2O formed in the interaction of moxifloxacin (MOX) with VOSO 4·H 2O, ZrOCl 2·8H 2O and UO 2(NO 3) 2·6H 2O in methanol and acetone as a solvents at room temperature were reported. The isolated solid complexes have been characterized with melting points, elemental analysis, molar conductance, magnetic moments studies, spectral (UV-Visible, IR and 1HNMR) as well as thermal analyses (TGA and DTG). The results support the formation of the complexes and indicate that moxifloxacin reacts as a bidentate ligand chelate to the metal ion through the pyridone oxygen and one carboxylato oxygen. The kinetic parameters of thermogravimetric (TGA) and its differential (DTG), such as activation energies, E*, enthalpies, Δ H*, entropies, Δ S* and Gibbs free energies, Δ G*, have been evaluated by using Coats-Redfern (CR) and Horowitz-Metzeger (HM) methods. The proposed structure of the ligand and their complexes were detected by using the density functional theory (DFT) at the B3LYP/CEP-31G level of theory. The bond stretching force constant and length of the U dbnd O for the [UO 2(MOX) 3](NO 3) 2·3H 2O complex were calculated. The antibacterial activity of the free moxifloxacin ligand and their metal complexes have been tested against some selected bacterial strains such as: Streptococcus aureus K1, Bacillus subtilis K22, Brevibacterium otitidis K76, Escherichia coli K32, Pseudomonas aeruginosa SW1 and Klebsiella oxytoca K42. The complexes showed good antibacterial effect to the selected bacterial strains as compared to the free ligand and Zr(IV) complex is very highly significant compared with the other two complexes.

  5. Comparing of moxifloxacin and azythromycin against urogenital chlamydia trachomatis%莫西沙星与阿奇霉素治疗泌尿生殖道沙眼衣原体感染疗效比较

    展小飞; 王树椿; 陈昭; 刘全忠

    2012-01-01

    目的:比较莫西沙星与阿奇霉素两种抗生素治疗泌尿生殖道沙眼衣原体感染的疗效.方法:收集1 671例确诊为泌尿生殖道沙眼衣原体感染并服用莫西沙星或阿奇霉素治疗的患者的临床资料,对两种药物的治愈率进行统计分析.结果:(1)两种药物的病原学治愈率分别是:莫西沙星为83.61%,阿奇霉素为73.28%,但两种抗生素病原学治愈率均有逐年递减的趋势(均P>0.05).(2)临床学治愈率分别是:莫西沙星为74.88%,阿奇霉素为88.91%.结论:莫西沙星的病原学治愈率高于阿奇霉素,而阿奇霉素的临床学治愈率好于莫西沙星.%Objective: To compare the effects of moxifloxacin and azythromycin in treating with urogenital chlamydia trachomatis. Methods: The data of 1 671 patients who were insured to have got urogenital chlamydia trachomatis infection and treated with moxifloxacin or azythromycin were collected and the effects of the two antibiotics were analyzed with descriptive epidemiological method. Results: The etiology cure rate of moxifloxacin was 83.61%, that of azythromycin was 73.28%. What's more, their effects decreased year by year. The clinical cure rate of moxifloxacin was 74.88%, that of azythromycin was 88.91%. Conclusion: The etiology cure rate of moxifloxacin is higher than that of azythromycin, but the clinical cure rate of moxifloxacin is lower than that of azythromycin.

  6. A novel oral preparation of human growth hormone (hGH) is absorbed and increases serum IGF-I levels after 7 days administration to GH-deficient adults

    Laursen, Torben; Mindeholm, Linda; Haemmerle, Sibylle;

    2007-01-01

    Growth hormone deficient (GHD) patients are currently effectively treated with daily subcutaneous (sc) injections of hGH in the evening, but alternative routes would be attractive. An oral formulationulation of hGH, using an amino-caprilic acid derivative (5-CNAC, Emisphere's eligen® technology) as...... carrier has recently been developed. The aim of this study was to determine if this oral formulation of hGH could be absorbed and be bioactive. Eight GHD men (mean age 50 years) receiving sc hGH therapy were withdrawn from therapy for 7 days and then treated for 7 days orally with tablets of HGH191...... (Novartis). Each tablet contained 100 mg of hGH and 200 mg 5-CNAC. One tablet was given at 08 h and 17 h, and two tablets at 22 h to match nocturnal GH secretion. The patients were studied thrice for 24 hours: at day 7 of washout, at days 1 and 7 of treatment. GH peaks were recorded in all patients...

  7. Comparative Activities of Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, Sparfloxacin, and Trovafloxacin and Nonquinolones Linozelid, Quinupristin-Dalfopristin, Gentamicin, and Vancomycin against Clinical Isolates of Ciprofloxacin-Resistant and -Susceptible Staphylococcus aureus Strains

    Jones, Mark E.; Visser, Maarten R.; Klootwijk, Miriam; Heisig, Peter; Verhoef, Jan; Schmitz, Franz-Josef

    1999-01-01

    The activities of eight fluoroquinolones and linezolid, quinupristin-dalfopristin (Synercid), gentamicin, and vancomycin were tested against 96 ciprofloxacin-susceptible and 205 ciprofloxacin-resistant Staphylococcus aureus strains. Overall, clinafloxacin, followed by moxifloxacin and trovafloxacin, was the most active quinolone tested. For all isolates, linezolid and quinupristin-dalfopristin showed activities that were at least comparable to vancomycin, with no cross-resistance to any other...

  8. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections

    Gyssens, Inge C; Dryden, Matthew; Kujath, Peter; Nathwani, Dilip; Schaper, Nicolaas; Hampel, Barbara; Reimnitz, Peter; Alder, Jeff; Arvis, Pierre

    2011-01-01

    Objectives The primary aim of the RELIEF study was to evaluate the efficacy and safety of two sequential intravenous (iv)/oral regimens: moxifloxacin iv/oral versus piperacillin/tazobactam (TZP) iv followed by oral amoxicillin/clavulanate (AMC). Patients and methods The study had a prospective, randomized, double-dummy, double-blind, multicentre design. Patients ≥18 years were prospectively stratified according to complicated skin and skin structure infection (cSSSI) subtype/diagnosis (major ...

  9. Moxifloxacin hydrochloride treatment of respiratory tract infection of 44 cases%盐酸莫西沙星治疗下呼吸道感染44例临床分析

    梁福贵

    2009-01-01

    目的 评价盐酸莫西沙星治疗下呼吸道感染的疗效.方法 88例下呼吸道感染患者随机分为两组,治疗组用盐酸莫西沙星注射液0.4g/次,qd;对照组用左氧氟沙星治疗.疗程均为7~10d.结果 莫西沙星组和左氧氟沙星组临床总有效率分别为93.2%和90.9%,细菌清除率为94.7%和89.5%,两组不良反应少见而轻微.结论 盐酸莫西沙星治疗下呼吸道感染疗效确切,可作为治疗下呼吸道感染的一线用药.%Objective To evaluate the moxifloxacin hydrochloride treatment of respiratory tract infection.Methods 88 cases of respiratory tract infections were, randomly divided into 2 groups, group therapy with moxifloxacin hydrochloride injection 0.4g / times, qd; with the control group. Courses are 7 ~ 10d. Results Moxifloxacin and levofloxacin clinical total effective rate of 93.2 percent and 90.9 percent; bacterial clearance rate 94.7% and 89.5%, two rare and minor side effects. Conclusion Moxifloxacin hydrochloride in the treatment of respiratory tract infection the exact effect can be used as the treatment of lower respiratory tract infection of the first-line drugs.

  10. Clinical Observation of Moxifloxacin in the Treatment of Cerebrovascular Disease Complicating with Aspiration Pneumonia%莫西沙星治疗脑血管病伴吸人性肺炎的临床观察

    刘石磊; 焦雪; 杜娟; 陆思静

    2011-01-01

    OBJECTIVE: To evaluate the efficacy and safety of moxifloxacin in the treatment of cerebrovascular disease complicating with aspiration pneumonia.METHODS: 112 patients with cerebrovascular disease complicating with aspiration pneumonia who were treated with moxifloxacin(0.4 g, qd, iv.gtt) were enrolled in this study.The clinical efficacy and safety were analyzed.RESULTS: The effective rate and curative rate of moxifloxacin therapy were 86 % and 55 %, respectively.The bacterial eradication rate was 77%, and the rate of adverse drug reaction was 7%.CONCLUSION: Moxifloxacin therapy is effective in the treatment of cerebrovascular disease complicating with aspiration pneumonia with few adverse drug reaction.%目的:观察莫西沙星治疗脑血管病伴吸入性肺炎患者的有效性和安全性.方法:选择112例脑血管病伴吸入性肺炎患者,应用莫西沙星(0.4 g,qd,静脉滴注)治疗,观察其临床疗效、安全性.结果:莫西沙星治疗脑血管病患者吸入性肺炎有效率为86%,痊愈率为55%,细菌清除率为77%,不良反应发生率为7%.结论:莫西沙星治疗脑血管病伴吸入性肺炎效果好,不良反应少.